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Abstract 
Prostate cancer (PC) is the most commonly diagnosed disease in the UK which causes 
approximately 10,000 deaths annually. Although an initially effective response to androgen 
deprivation therapy (ADT) occurs in most patients, the tumour normally recurs in a more 
aggressive form of the disease termed castrate resistant PC (CRPC) and is largely untreatable at 
this stage.  In many cases, disease is driven by inappropriate androgen receptor (AR) signalling. It 
is therefore vital to have better understanding of mechanisms that re-activate AR and promote 
ADT resistance in the clinic and hence better treatments for advanced tumour.  
Activation of AR by testosterone is crucial for prostate growth and transformation. Anti-
androgens, the second most common PC therapy after surgery, antagonise ligand binding to the 
receptor and hence deactivate AR signalling. In 2012, enzalutamide, a more potent agents in 
terms of availability to block AR was approved by the FDA and ENA as a second-generation anti-
androgen for clinical usage. Although it demonstrated several advantages over its pervious 
counterpart bicalutamide, response rates of just 50% in CRPC patients and subsequent resistance 
observed in responders has limited its effectiveness. Critically, several lines of evidence from pre-
clinical models and patient samples indicate that one particular resistant mechanism is the 
emergence of AR mutant(s), in part, driven by a specific AR mutation F876L that enables the 
compound to act as an agonist. Importantly, the same mutant was later detected in metastatic 
PC patient had been treated with apalutamide. Evidently, novel therapies emerging into clinical 
treatment of advance disease have the added challenge of being efficacious in the background 
of mutant AR and thus developing model systems to test this is of paramount importance.  
In order to enable more physiological modelling of aberrant ARF876L activity that would highlight 
potentially distinct mechanisms that could be exploited in future therapies, this project aimed to 
generate CRISPR-edited LNCaP and CWR22Rv1 cell lines expressing the enzalutamide-activated 
ARF876L mutant. Meanwhile, a part of project has also focused on generation of a physiologically 
relevant AR rescue/replacement in vitro cell line model (LNCaP- ARF876L cells) which permits 
ability for studying ARF876L directly regulated gene expression profiles by effectively knockdown 
endogenous AR without impacting on the ectopically expressed mutant. Furthermore, by using 
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Illumina Human HT-12 arrays analysing LNCaP-ARF876L cells revealed a comprehensive 
transcriptomic data-set to provide an insight into how an enzalutamide-activated AR mutant can 
drive a distinct gene-set in advanced PC. This is important as it may enable distinct biomarker 
discovery in enzalutamide-resistance disease and has highlighted interplay between the ARF876L 
mutation and the glucocorticoid receptor. Lastly, the LNCaP- ARF876L cell lines was utilised to 
demonstrate that aberrantly-functioning receptor is sensitive to BET inhibitors. In all, the work 
has shown that the ARF876L mutant drives a distinct transcriptional programme to the endogenous 
AR in LNCaP cells and the model can be utilised effectively to indicate sensitivities of the receptor 
to clinically-relevant compounds. 
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1.1.Prostate cancer and treatment.  
The first prostate cancer (PC) case was described as ‘a very rare disease’ in 1853 (Adams J, 1853; 
(Denmeade and Isaacs, 2002).  Remarkably, the same disease 150 years later has become the 
most important health issue among the aging population in the Western world. Globally, PC is 
the second most common cancer, and the third most common cancer in men in developed 
countries (Hassanipour-Azgomi et al., 2016). PC today has become the leading cause of cancer-
associated deaths in men in the UK and accounts for 13% of all cancer deaths in males with over 
10,000 deaths in 2016 (CRUK). 
PC incidence is strongly related to age; with the highest mortality rates being in older men (>70 
years). In the UK between 2014 and 2016, 74% of PC cases was diagnosed in males over the age 
of 75 while only 1% in males under 50 (Figure 1.1). Significantly, PC incidence is expected to 
further increase in the future due to improvements in diagnosis and an increase in the ageing 
population (Divo et al., 2014). 
Figure 1.1 Average Number of Deaths per Year and Age-Specific Mortality Rates (per 100,000 Population, 
2014-2016, UK).  Prostate cancer mortality rates have age specific distribution. Figure taken from CRUK, 
cancer stats, last updated 10/2017.  
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Many factors have been suggested that may relate to higher PC risk, including external 
influences, such as environmental changes and lifestyle (Gann, 2002); and phenotypic factors 
including age, race/ethnicity, family history and genetic alteration. The inherited factors are 
estimated to be responsible for 5–9% of incidences. For instance, risk of developing PC is 5 times 
higher in men with BRCA2 mutations (Cavanagh and Rogers, 2015). Although with extensive 
research, no preventable risk factors have been conclusively linked with PC risk. 
Many patients with the disease have tumours with slow growth that may never cause a problem. 
Others can be cured by treating the tumour within the prostate gland. But in some, the cancer 
spreads to elsewhere in the body, usually to the bones (Yap et al., 2011). Depending on the 
situation, the treatment options for men with PC include: i) expectant management or active 
surveillance; ii) surgery; iii) radiation therapy; iv) cryosurgery (cryotherapy); v) hormone therapy; 
vi) chemotherapy; vii) vaccine treatment and viii) bone-directed treatment (Mohler et al., 2014). 
Most of these treatments are employed individually, although in some cases they may be 
combined. Hormone therapy, for example, is often used in combination with radiation therapy. 
The treatment of choice for PC, however, is more complicated as it takes into account the stage 
and grade of disease, patents’ age and expected life span, or whether patents have other serious 
health conditions (Carroll et al., 2014).  
 
1.2.Androgen sensitivity in prostate cancer.  
Over half a century ago, PC patients diagnosed with local advanced or metastatic disease 
normally died within 1-2 years (Li et al., 2016a). This changed when the role of androgenic activity 
in PC was firstly discovered  in 1941 (Huggins and Clark, 1940).  Two PC research pioneers, 
Huggins and Hodges (1972) found that PC responded to surgical castration therapies. Initially, 
they noticed that reducing androgen levels in patients led to growth arrest of the tumour. By 
monitoring patients’ serum acid-phosphatase levels after surgical castration (orchiectomy) or 
oral estrogen (stilbesterol) administration, they sequentially reported the elimination or down-
regulation of androgen levels can inhibit disseminated prostatic carcinoma growth. Thus, PC was 
concluded as an ‘androgen-sensitive’ disease for the first time (Huggins and Hodges, 2002). Their 
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discovery of hormone dependence in PC brought a new era to cancer treatment. ‘Endocrine-
therapy’ therefore firstly entered into PC therapy history, and to this day, androgen ablation 
remains the most useful PC therapy (Denmeade and Isaacs, 2002).  
Following their important discovery, a wave of androgen-ablation treatments emerged during 
the 1960s, which aimed either to reduce androgen production, or to block androgen functions 
within the target tissues. Those methods have become the predecessor of modern androgen-
deprivation therapy (ADT), that is alternatively known as hormone therapy (Denmeade and 
Isaacs, 2002). 
Today, ADT is the second most common treatment approach, after surgery, for local advanced 
PC (Canalichio et al., 2015). It has three different hormonal approaches: luteinizing hormone-
releasing hormone (LHRH) agonists, orchiectomy, and anti-androgens. Orchiectomy and LHRH 
agonist aim to lower the levels of testosterone or other androgens; while anti-androgens were 
designed to block the action of those hormones. ADT is usually used as first line treatment for 
advanced PC patients where disease is likely extended beyond the prostate gland and into nearby 
tissues. However, there are numerous other settings in which ADT is used.  These include 
administration in the neoadjuvant or adjuvant setting combined with surgery or radiation 
therapy or when there is biochemical recurrence after therapy with curative intent (Suzman and 
Antonarakis, 2014).  
In most of cases, ADT is initially effective. Most patients respond favorably with tumour 
regression and often with reduced expression level of the PC serum biomarker prostate-specific 
antigen (PSA). Unfortunately, androgen deprivation is not sufficient to completely cure 
metastatic tumours (Tsao et al., 2012). After a median time of 18 months, up to 40% of patients 
with definitive local disease and nearly all metastatic patients will eventually have disease 
relapse. 
Tumours re-appear in a more aggressive, androgen-independent form, termed castrate-resistant 
PC (CRPC). Disease is largely lethal at this stage due to patients pre-treated with ADT no longer 
responding to conventional hormonal targeting analogue treatment. Hence resurgence of 
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advanced prostatic tumours represents a major clinical challenge, as therapies for patients at this 
stage are largely ineffective.   
 
 
 
1.3.The androgen-receptor signalling cascade in prostate cancer and castration-
resistant prostate cancer 
In the human body, the main androgens are testosterone and dihydrotestosterone (DHT), the 
latter being the most potent endogenous androgen, most of which is produced from the testes, 
although the adrenal glands also make a small amount. DHT binds to the androgen receptor (AR), 
a member of the nuclear receptor (NR) superfamily (Brinkmann, 2011); specifically the steroid-
hormone receptor family that includes the estrogen receptor (ER), progesterone receptor (PR), 
glucocorticoid receptor (GR) and mineralocorticoid receptor (MR). 
 
The activation of the androgen-AR signalling pathway is indispensable for the differentiation, 
growth and support of male primary sexual characteristics. The signalling axis initiates at early 
stages of embryogenesis (Mateo et al., 2014) to enable development and growth of the prostate, 
which is especially active in adult male reproductive organs, including the prostate in order to 
maintain the male phenotype. The AR-mediated signalling axis also plays an essential role in the 
early stages of PC development:  AR is overexpressed in a large number of localised PC patients 
and leads to an increase in the serum level of PSA (Karantanos et al., 2013). Androgens stimulate 
PC cells to grow hence ablating serum androgen levels or stopping their function in PC cells causes 
tumours to initially shrink (Gomella, 2009). 
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Figure 1.2 The signal transduction pathway of androgen receptor.   Graphic representations of AR action. 
DHT interacts with the AR and releases it from bound heat shock proteins (HSP) enabling N/C-terminal 
interaction and dimerization of the receptor. This exposes a nuclear localization signal (NLS) required for 
interaction with importin-α and nuclear translocation. Inside the nucleus, DNA binding to target genes 
whereby the N/C-terminal interaction is lost (Askew et al., 2012), allowing the recruitment of 
transcriptional co-regulators, such as CREB binding protein (CBP), and p300 that facilitate the recruitment 
of RNA-Polymerase II (RNAP2) to transcribe AR-dependent genes (Brooke et al., 2008) (van de Wijngaart 
et al., 2012). N—N-terminal domain (NTD); D—DNA-binding domain (DBD); L—ligand-binding domain 
(LBD). ARE-androgen response elements. Image adapted from (Brooke et al., 2008).            
 
In vivo, unliganded AR stays in the cytoplasm as a stable protein complex with molecular 
chaperones, including heat shock protein 90 (HSP90) and HSP70 (Figure 1.2). Upon binding its 
ligand, DHT, the receptor undergoes a conformational rearrangement and consequently 
disassociates from the HSPs leading to AR dimerisation and an essential intermolecular 
interaction between the N- and C-termini of the AR. This so called N/C-terminal interaction 
exposes a bi-partite nuclear localisation signal (NLS), which allows translocation of the AR to the 
nucleus (Lange et al., 2007). Post-nuclear translocation, the AR homodimerises, via the DNA 
binding domain (DBD) (Figure 1.2), and subsequently interacts with specific DNA sequences 
within chromatin termed androgen response elements (AREs). Co-regulators are recruited that 
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facilitate the binding of the RNA polymerase II machinery to transcribe AR-dependent genes, 
including PSA, KLK2, and TMPRSS2 (Brooke et al., 2008). 
In addition to androgen-dependent PC, the AR signalling axis remains unexpectedly active in the 
castration-resistant setting regardless of castrate levels of androgen (Karantanos et al., 2013; de 
Oliveira Barros et al., 2014). Comprehensive studies over the past decade have shown that the 
androgen receptor pathway is very often altered in most CRPC samples and promotes the 
concept that persistent AR signalling occurs in most CRPC (Petrylak, 2013) (Lorente and De Bono, 
2014). 
Currently, several resistant mechanisms have been implicated in CRPC (Tan et al., 2015b).  These 
include, but are not limited to: AR gene amplification and/or overexpression; the acquisition of 
AR mutations during ADT; inappropriate AR activation by interleukins, cytokines and growth 
factors; intratumoural androgen synthesis, such as up-regulated transcript levels of enzymes 
involved in androgen synthesis; aberrant AR co-regulator expression, such as cAMP response 
element binding protein (CREB)-binding protein (CBP)/p300 and steroid receptor coregulator-1 
(SRC-1) which facilitate AR binding to DNA. Recently, emerging evidence implicates that therapy-
induced selection of novel AR splice forms, termed AR-variants (AR-Vs), that lack the target site 
of conventional anti-androgen therapies, have a role in CRPC (Dehm and Tindall, 2011).  
The reactivation of AR signalling in most CRPC patients indicates that the AR remains a critical 
factor in treatment-resistant advanced tumours. Most importantly, it suggests that AR remains a 
suitable therapeutic target for advanced PC. In this regard, deciphering aberrant AR regulation 
and function in CRPC is essential for the development of more effective therapies for this fatal 
disease.   
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1.4.The structure of the androgen receptor  
The human AR gene is located on the X chromosome at position Xq11-12 consists of eight exons 
and encodes a 919 amino acid protein (Figure 1.3). Similar to other steroid receptor family 
members, the AR protein contains three major functional domains and several activation 
functional units that control its activity. The AR is composed of an unstructured N-terminal 
transactivation domain (NTD), a highly conserved DNA-binding domain (DBD), a short hinge 
region and a C-terminal ligand-binding domain (LBD) (Tan et al., 2015b).  
Figure 1.3 Functional domains of the androgen receptor.   Scheme of the domain organization of the AR: 
NTD (N-terminal transactivation domain), DBD (DNA binding domain), hinge region (Hinge) and LBD (ligand 
binding domain). Residue numbers above the scheme delineate the domain boundaries. Figure adapted 
from (Tan et al., 2015b). 
 
1.4.1.N-terminal transactivation domain (NTD) 
The N-terminal transactivation domain of AR (AR-NTD) is the least conserved region among all 
NR members (Claessens et al., 2008). AR–NTD corresponds to the first 558 residues encoded by 
exon 1 and spans about 60% of the coding region of the receptor. The activation function 1 (AF-
1) region within the NTD contains the majority of inherent transcriptional activity of the receptor. 
Two overlapping but distinct transcription activation units (TAU), TAU-1 (amino acid residues 
110-485) and TAU-5 (amino acid residues 360-528) are located within AF-1. By deleting either 
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one of the units from AF-1, TAU-1 was revealed to be required for ligand-dependent activation 
of the full length receptor while TAU-5 is important for ligand-independent activity and is capable 
of permitting transactivation for the receptor that lacks the LBD  or in the absence of ligand 
(Bevan et al., 1999). In addition, the NTD of AR also harbors an important motif, FQNLF (residues 
23–27), that facilitates NTD binding to the LBD, enabling the N/C-interaction of the receptor. 
Thus, this short motif is vital for the full transcriptional potential of the AR to be elicited (McEwan, 
2004). 
1.4.2.The DNA-binding Domain (DBD) and hinge region (H) 
The DNA binding domain (DBD) is the most conserved functional domain of the AR. Its genomic 
sequence has up to 80% similarity with corresponding domains in other NR family members, 
including PR and ER.  The AR-DBD consists of three α-helices that are organised into two zinc 
finger modules and a relatively unstructured C-terminal extension. The α-helix in the first zinc-
finger contains 5 amino acid residues (577-GSCKV-581); so-called the proximal (P)-box which 
confers specific sequence recognition of the receptor to 15-bp palindromic target sites within 
androgen responsive elements (AREs) that are located in the promoter and enhancer region of 
androgen-responsive genes.  The second and the third α-helix form the second zinc finger, 
containing a distal (D)-box (596-ASRND-600) that is involved in receptor dimerisation.  A direct 
interaction between the DBD of the receptor and the major groove of DNA is also required for 
recognition of AREs of ligand-activated AR.  Additional contacts with the DNA are made by the C-
terminal extension that is adjacent to the ligand-binding domain (LBD). The DBD also contains 
the first part of a bipartite nuclear localisation signal (NLS) and a non-classical nuclear export 
signal and has also suggested to be involved in nucleo-cytoplasmic shuttling (Lorente and De 
Bono, 2014). 
A part of exon 4 codes for a flexible and poorly conserved hinge region, positioned between 
residues 624–689. The hinge contains the second part of NLS. It also is a target for several post-
translational modifications, including acetylation and methylation, which regulates AR function 
(Coffey et al., 2012) 
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1.4.3.The ligand-binding domain (LBD) 
The ligand-binding domain (LBD) is the most well studied functional domain in the AR. It is 265 
amino acids long (665-919) and encoded by exons 5-8. Unlike the DBD, the AR-LBD shares less 
sequence homology with other NRs; with almost half of the AR-LBD sequence differing from 
other family members (Poujol et al., 2000). The LBD is composed of 11 α-helices, one less than 
other steroid receptors, although the nomenclature remains the same: helices 1-12 with 
omission of helix 2.  Helices 3, 5, 7 and 11 of 12 are of particular importance. Helices 3, 5, 7 and 
11 form a barrel-like structure suitable for hormone binding.  This ligand-binding pocket has an 
important role for AR activity in providing a hydrophobic pocket for binding of testosterone and 
DHT in order to activate the receptor. Upon binding of ligands, the LBD undergoes a 
conformational change in which helix 12 swings round and closes the ligand-binding pocket. This 
rearrangement of helix 12 results in a hydrophobic surface groove (also referred to as the 
coactivator binding pocket) and serves as a docking site for the AF-1 FQNLF motif within the NTD 
(Bourguet et al., 2000; Greschik and Moras, 2003). In addition, the coactivator binding pocket 
also plays a role for determining the preference of transcriptome modulation via mediating co-
regulatory protein interaction (Greschik and Moras, 2003). 
 
1.5.Direct AR-targeting anti-androgens. 
With the recent increasing understanding of the physiology and molecular mechanism of AR 
function in advanced disease, development of direct or indirect AR targeting agents and 
androgen analogues has been a major objective in PC research for improved therapies. Many 
drugs have been developed and are most frequently used in the clinic as daily practice for 
intermediate- and high-risk diseases whether or not within the context of a LHRH agonists.     
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Figure 1.4 Schematic of AR activation and anti-androgens mechanism.   The diagram illustrates the 
mechanism of antiandrogen action. AR-LBD target antiandrogens are competing with AR ligand, the 
endogenous androgens, testosterone or DHT for the same ligand-binding pocket of the receptor and 
ultimately block the activation of AR signalling.  Image taken from (Chen et al., 2009) .  
 
Most anti-androgens are designed to interfere with AR function by competitively inhibiting 
androgen binding to cognate receptors at the target organ. Two types of anti-androgens have 
clinically been used (Chen et al., 2009): the steroidal anti-androgens and the non-steroidal anti-
androgens. Several steroidal anti-androgens includes cyproterone acetate, megestrol acetate, 
and medroxyprogesterone acetate are initially used for androgen blockade in patients. However, 
their clinical use is limited due to severe drawbacks such as hepatotoxicity, interference with 
libido and impotence, cardiovascular side effects and low efficacy. Non-steroidal anti-androgens 
were later developed, which including the first-generation anti-androgens, such as 
hydroxyflutamide, bicalutamide (Casodex), nilutamide, and the second-generation compounds: 
enzalutamide (MDV3100) and apalutamide (ARN-509). Most of the non-steroidal anti-androgens 
have been widely used in combined therapies as they avoid the typical constraints of steroidal 
anti-androgens.  
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In the in vivo scenario, non-steroidal anti-androgens, acting as androgen analogues, compete 
with endogenous DHT for the same ligand-binding pocket of AR and subsequently block the AR 
signalling cascade. As illustrated in Figure 1.4, bicalutamide and enzalutamide disturb the AR 
signalling pathway by binding to the ligand-binding pocket of the AR, which prevents coactivator 
recruitment and abrogating AR-DNA interaction. The novel AR antagonist enzalutamide was first 
introduced in 2009 as a second-generation anti-androgen to patients who had failed first-line 
hormonal therapy (Semenas et al., 2013) (Figure 1.5). In comparison with the ‘classical’ anti-
androgens, such as bicalutamide, enzalutamide does not only block androgen binding, but it also 
inhibits translocation of the AR to the nucleus and impairs AR binding to DNA (Tran et al., 2009). 
With several advantages over bicalutamide, both the US Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) approved enzalutamide for clinical use in patients with 
chemo-resistant CRPC in 2012 (Heck et al., 2012). Another second-generation antiandrogen that 
is related to enzalutamide called apalutamide, has rapidly progressed into Phase I and Phase II 
clinical trials due to its lower side effect and higher efficacy than enzalutamide (Schweizer and 
Antonarakis, 2012). 
Figure 1.5 The molecule structure of first and second-generation anti-androgens. MDV3100- 
enzalutamide, ARN-509-apalutamide. Image was taken form (Mohler et al., 2012). 
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1.6.Acquisition of AR mutation as a mechanism of therapy evasion. 
Unfortunately, although initially being sensitive to anti-androgen therapy, most PC patients will 
relapse; with disease progressing to a refractory, untreatable state. At this stage, tumours either 
become endocrine-therapy resistant during the course of treatment or possesses a small 
population of pre-existing hormone-refractory cells that remain viable in spite of castration level 
of androgen (van de Wijngaart et al., 2012). By selective outgrowth of resistant cells, tumours 
aggressively progress and eventually claim the life of patients.  
Acquisition of genetic changes could contribute to disease progression. In particular, somatic 
mutations in the AR gene is a consistent finding present in metastatic PC, as well as in human PC 
cell lines and xenograft animal models (Koochekpour, 2010). In the clinic, non-synonymous AR 
mutations are rarely detectable in localized or anti-androgen naive patients, but presents in 
around 20% of initial CRPC patients (Beltran et al., 2017). Importantly, AR mutation frequency is 
elevated in androgen-independent PC and are further significantly increased in distant 
metastases of patients following endocrine therapy, which suggests that treatment failure may 
result from PC cells adapting resistance from the selective pressure applied by the therapy. 
 
AR gene sequencing of CRPC patients, has identified 159 AR mutations in PC tissue (last update 
2015, Tan et al. (2015a). Almost 50% of them were found to fall within the LBD (Gottlieb et al., 
2012). These included L701H, H874Y and T877A (Figure 1.6), noticeably, all of which were from 
patients that had been treated with anti-androgens. Further studies found that most of them 
resulted in reduced ligand specificity and hence permitted inappropriate receptor activation by 
binding with adrenal androgens or other steroid metabolites. ARL701H can become active by other 
steroids, including estrogen, cortisone; while ARH874Y can be activated by progesterone. Certain 
LBD mutations are also sufficient to convert AR antagonists to AR agonists. H874Y mutation was 
found in CWR22Rv1 cell lines, and shown to be abnormally activated by Cyproterone Acetate 
(CPA).  
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Figure 1.6 Schematic representation of the human AR with mutation encoding the LBD.  Schematic 
representation of unique mutations in ligand banding domain of the human AR. Highlighting enzalutamide 
resistant mutation F876L in bold.   
 
ART877A mutation, the amino acid substitution of threonine to alanine at codon 877 of the AR 
(Figure 1.6), was the first reported AR mutation and is expressed in the hormone-dependent 
LNCaP human prostate cancer cell line that is derived from a lymph node metastasis (Horoszewicz 
et al., 1980; Veldscholte et al., 1990). ART877A associated with AF-2 have been shown to produce 
a receptor capable of activation by AR antagonists Flutamide.  In the clinic, Taplin et al. (1999)  
have shown that 31% of CRPC patients treated with Flutamide harbored the T877A mutation. 
This substitution enables the anti-androgen Flutamide to act as an agonist and hence patients 
who are refractory to Flutamide therapy regularly express ART877A mutation (Suzuki et al., 1996; 
Monge et al., 2006).   
 
Recently, the crystal structure of ART877A upon binding of DHT has been solved (Figure 1.7 B) (Bohl 
et al., 2007). Upon binding of DHT, the structure of wildtype AR (Figure 1.7 A) and ART877A (Figure 
1.7 B) are essentially identical except at the point of the mutation. However, by substitution of 
alanine for threonine at residue 877, a polar interaction with DHT was lost. As a result, the size 
of the binding pocket is expected to increase compared with wildtype AR, and more space was 
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introduced allowing the accommodation of a larger functional group at this position, such as that 
found in Flutamide (Tan et al., 2015a).  
 
Figure 1.7 Structural representation of ligand binding to wildtype AR and ART877A.  (A) Binding of DHT to 
wildtypeAR. (B) Binding of DHT to the ART877A mutation. Important LBD residues are indicated in blue; the 
ligand is indicated in yellow. Hydrogen bonds are indicated with dotted lines. Figure taken from van de 
Wijngaart, Dubbink et al. (2012). 
 
Another mutation, W741L was later found both in LNCaP and ADT-treated metastatic patient 
sample-derived xenograft tumours which exhibit increased tumour growth and PSA secretion in 
response to bicalutamide (Yoshida et al., 2005).  A stable cell model from Luke Gaughan’s lab 
(O'Neill et al., 2015)  proved robust evidence of ARW741L being a bicalutamide-activated mutant.  
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Clinically, approximately 50% of patients after hormone therapy present with anti-androgen 
withdrawal syndrome (AAWS). This condition is characterised by cancers that grow in the 
presence of anti-androgens and whose growth is attenuated by stopping anti-androgen 
treatment (Paul and Breul, 2000; Sartor et al., 2008). Acquiring somatic mutations in the AR gene 
is likely responsible for the 15–30% of patients that exhibit a withdrawal syndrome after 
cessation of first-generation therapies (Wyatt and Gleave, 2015).  This evidence strongly 
suggested that mutation selection under pressure of anti-androgen treatment contributes, in 
part, to drug resistance. Long-term treatment with the AR antagonists could selectively enable 
outgrowth of tumour cells that are driven by AR mutants that turn anti-androgens from 
antagonists to agonists causing drug resistance.  
 
1.7. ARF876L 
Similar to the bicalutamide-activated ARW741L mutation, a specific AR mutation, F876L within the 
LBD of AR, has been reported that is sufficient to confer partial resistance to enzalutamide and 
apalutamide in vitro and in vivo models of CRPC (Joseph et al., 2013). Importantly, the mutation 
was later detected in plasma DNA of progressive CRPC patients after treatment with 
apalutamide.  
It had been firstly reported that prolonged treatment with enzalutamide in prostate cancer cell 
lines led to the spontaneous emergence of ARF876L that converted enzalutamide into an AR 
agonist (Balbas et al., 2013).  Moreover, structural analysis of the mutated AR showed that F876L 
mutation affects the ligand- binding domain of the AR and is responsible for the switch of 
enzalutamide from antagonist to agonist. Joseph et al. (2013) showed that the F876L mutation 
was sufficient to convey acquired resistance not only to enzalutamide, but also to apalutamide 
in CRPC cell models. A published pre-clinical study (Korpal et al., 2013b) latter confirmed that 
ARF876L-bearing prostate cancer cells are not only resistant to enzalutamide but also dependent 
on the agonist effect of enzalutamide for cellular growth under androgen-deprivation conditions. 
Importantly, the same mutation has been detected in circulating tumour DNA from apalutamide-
treated CRPC patients (Dellis and Papatsoris, 2018).  Taken together, the evidence highlights the 
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selective outgrowth of ARF876L-expressing cells is a clinically relevant mechanism of second-
generation anti-androgen enzalutamide resistance.  
1.8.Alternative AR targeting agents 
It is well accepted that the AR signalling axis remains a suitable therapeutic target for advance PC 
treatment.  However, from the latest studies on enzalutamide resistance and the much earlier 
reports of bicalutamide and flutamide resistance, it is possible that eventually every LBD-
targeting agent will lead to the occurrence of a somatic mutation that causes a switch to agonistic 
activity. Therefore, it seems that the future of AR antagonists lies in the development of 
compounds with alternative targeting sites or impact on another point in the signaling cascade.  
Figure 1.8 The graphic representation of Full-length AR (FL-AR) and AR splice variants (AR-Vs).   (A) 
Graphic representation of Full-length AR (FL-AR). (B) Exon skipping or splicing of cryptic exons (CE) yield C-
terminal truncated AR splice variants (AR-Vs). The splice variants lack the LBD and are constitutively active 
in the absence of ligand. Increased expression of AR-Vs has been identified in castration-resistant prostate 
cancer (CRPC). 
 
In addition, several AR splice variants (AR-Vs) (Figure 1.8 B) have been recently found to be 
expressed in a high proportion of CRPCs; particularly metastatic disease. AR-Vs share an identical 
N-terminal structure to full length AR (FL-AR) with preservation of the NTD and DBD but are 
devoid of some of the hinge region and the entire LBD. Thus, they circumvent the need for ligand 
and are constitutively active transcription factors.  AR-Vs were firstly found in the CWR22Rv1 cell 
line, a castrate-resistant PC cell line derived from the CWR-RD1 xenograft post-castration 
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(Sramkoski et al., 1999; Tepper et al., 2002), suggesting that androgen-ablation selected for these 
ligand-independent isoforms. (Watson et al., 2010) initially reported that the proliferative effects 
of AR-V7 were mediated via full-length AR. Notably, however, convincing evidence from other 
groups (Kobayashi et al., 2013)  have recently shown that AR-Vs alone can drive expression of AR 
target genes. Although additional understanding is required in this area, clearly, constitutive, 
ligand-independent transcriptional activities of these isoforms accelerate the requirement for 
alternative AR targeting sites to inactivate these aberrantly functioning receptors. 
The first question is that whether AR signaling inhibition can be achieved in an LBD-independent 
manner by targeting other critical steps of AR transcriptional pathway instead of hormone 
binding.  For instance, compounds that do not act via the ligand-binding pocket but through other 
sites on the LBD, or other domains of the receptor will be of interest. Furthermore, the 
combination of compounds with a complementary action mechanism could lead to more 
efficient inhibition of AR and thus better control of disease.  
 
1.9.Cross Talk between the AR and Glucocorticoid Receptor (GR) 
At present, an increasing number of studies have focused on revealing the androgenic signalling-
dependent mechanisms of tumor resistance to androgen deprivation and AR antiandrogen 
therapies which mainly includes: AR-mediated progression driven by AR amplification or somatic 
mutations that allow AR activation via nonandrogenic ligands binding (Tan et al., 1997; Romanel 
et al., 2015), as well as expression of constitutively active AR splice variants (Hu et al., 2009). 
Importantly, AR-independent bypass mechanisms of CRPC progression have also been 
hypothesized to play a role, such as activated oncogenic pathways, including PI3K, c-MYC (Carver 
et al., 2011), and the increased expression and activity of another steroid receptor family 
member, the glucocorticoid receptor (GR) (Isikbay et al., 2014). By investigating GR function in 
CRPC, Arora et al. (2013) and (Isikbay et al., 2014) uncovered that GR activity can indeed promote 
prostate cancer progression following AR blockade. GR antagonism has also been suggested as a 
therapeutic strategy for CRPC (Kach et al., 2015). 
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More recently, the GR activation has been reported to contribute to CRPC resistance to various 
therapies including docetaxel (de Bono et al., 2010) and enzalutamide  (Crona and Whang, 2017). 
Clinically, significantly elevated GR levels were found in the bone metastases of PC patients after 
receiving enzalutamide treatment comparing to the  treatment naïve group (Nadal and Bellmunt, 
2016). Importantly, GR expression also correlated with poor prognosis of treatment outcome. In 
vitro, (Arora et al., 2013) demonstrated that increasing GR expression is an alternative 
mechanism for enzalutamide resistance as up-regulated GR expression at both the mRNA and 
protein level in LNCaP cells resistant to the anti-androgens enzalutamide and apalutamide was 
detected. A dependency on GR activation for enzalutamide-driven growth was revealed by 
depleting GR in an enzalutamide-resistant cell line (named LREX) that was derived from an LNCaP 
xenograft refractory to chronic enzalutamide treatment. In addition, global gene expression 
profiling and GR/AR chromatin immunoprecipitation sequencing (ChIP-Seq) analyses in the LREX 
and parental cell lines demonstrated a significant overlap between the transcriptome and 
cistrome of the AR and those of the GR in the LREX’ model. This observation is consistent with 
previous findings which demonstrated a positive role of the forkhead protein, FOXA1 in the 
redistribution of AR and GR in androgen deprived conditions (Yang and Yu, 2015). 
 
GR-mediated resistance in CRPC does not seem to be limited to enzalutamide/ apalutamide. The 
involvement of GR in docetaxel-resistant PC has also been reported. A robust overexpression of 
GR was detected in vitro cultured PC cell line with an acquired docetaxel resistance as well as in 
docetaxel-treated patient’s samples comparing to primary patients tissue (Kroon et al., 2016). 
Additionally, by applying GR antagonists (mifepristone and CPA) in docetaxel-resistant PC cell 
lines, (Kroon et al., 2016)   demonstrated a restoration of sensitivity to docetaxel, supporting a 
role for the GR in docetaxel resistance which further supports the GR is a potential therapeutic 
target in advanced disease. 
 
Given that the activating GR ligands glucocorticoids promote inhibitory effects on 
adrenocorticotropic hormone (ACTH) production, corticosteroids are routinely co-administered 
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with docetaxel and abiraterone in patients receiving chemotherapy (Han et al., 2012). The 
administration of glucocorticoids has been shown to reduce PSA levels in patients due to further 
androgen blockage via interrupting feedback mechanisms in the pituitary gland. However, given 
the aforementioned role of GR in mediating resistance to PC therapies, it may seem 
counterintuitive to administer glucocorticoids for CRPC patients as corticosteroids might 
promote tumour progression in men whose tumours express GR.  Recently, a phase I/II clinical 
trial (NCT 02012296) was initiated to test the treatment of patients with enzalutamide in 
combination either with or without mifepristone to further depict the role of the GR in CRPC 
(Arora et al., 2013). 
 
While improved AR-direct targeted agents have doubtlessly improved survival for prostate 
cancer patients, they are not curative in many cases and resistance eventually occurs in most 
patients who develop CRPC for which limited treatment options exist. Activation of the androgen 
receptor via alternative signalling cascades or activation of the AR target gene signature by a 
different nuclear hormone receptor, such as the GR, provide mechanisms to maintain a pro-
survival phenotype in low androgenic conditions. More studies have demonstrated that GR can 
provide a mechanism of resistance to a number of current PC therapies and GR antagonists may 
provide clinical benefit in patients with CRPC. 
 
1.10.The bromodomain and extra terminal domain (BET) family proteins involves in 
AR-mediated transcriptional programme. 
Recently, by applying massive high-throughput analysis in parallel using hundreds of PC patients’ 
tumour specimens, a comprehensive picture of the genetic alteration landscape that accompany 
cancer evolution in the prostate was revealed (Ruggero et al., 2018). Of note, some crucial players 
in chromatin biology and epigenetic master regulators, mainly including: methyltransferases, 
demethylases, DNA methylation, histone acetylation (HAT), the bromodomain and extra terminal 
domain (BET) bromodomain epigenetic readers and pioneer transcription factors have been 
highlighted to be key alterations in metastatic CRPC and tumours that progress to CRPC upon 
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administration of next-generation anti-androgen therapy (Urbanucci et al., 2017). Thus, 
identifying AR downstream signalling events and investigating the involvement of the epigenetic 
regulation of AR activity may become a new avenue for navigating potential prognostic markers 
and therapeutic targets for CRPC. To that end, in this study, we focus on investigating if two key 
epigenetic regulators, the BET family of bromodomain epigenetic readers proteins and the p300 
histone acetyltransferase as potential therapeutic targets for AR-mediated anti-androgen 
resistance.  
 
Bromodomains (BRDs) are approximately 110 amino acid-containing functional domains with 
conserved sequence, which recognises, principally, acetylated lysines of the N-terminal tails of 
histones (Sanchez and Zhou, 2009). BRDs motif are found in proteins with diverse functions, 
including histone acetyltransferases (HAT), histone methyltransferases (HMT), histone kinases, 
transcriptional modulators, ubiquitin ligases and chromatin re-modellers (Josling et al., 2012). To 
initiate transcriptional regulation, recruitment of BRDs-containing proteins are generally 
required acting as chromatin readers to recognize mono-acetylated histones and trigger 
chromatin remodelling (Josling et al., 2012). BRD-containing proteins have been identified in 
oncogenic rearrangements that lead to highly oncogenic fusion proteins, which have a key role 
in the development of several aggressive types of cancer. Mutations and deregulation of BRDs-
containing proteins are commonly found involving in development of different type of cancer 
(Perez-Salvia and Esteller, 2017). Importantly, 42 known BRDs-containing proteins are found 
presenting genomic alterations in more than half of both local and advanced PC as well as over 
70 percent of neuroendocrine PC (Ruggero et al., 2018). Of particular note, the BRD and extra- 
terminal (BET) subgroup of bromodomain-containing proteins, including BRDT, BRD2, BRD3 and 
in particular BRD4, have been recently proposed to play a role in the progression to drug-resistant 
phenotypes in prostate cancer (Barbieri et al., 2013).  
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Figure 1.9 Domain Architecture of Human BET Proteins.   (A) The functional domain of Brd4 as indicated. 
ET, extra-terminal domain. CTD, C-terminal domain. Isoform B of Brd4 has a unique C terminus, which 
interacts with condensin II complexes (Floyd et al., 2013). (B) The illustration of BRD4 at acetylated docking 
sites resulting mediator complex fusion which initiates a transcriptional programme with strong tumour-
promoting properties. The arrows indicate the breakpoints where the gene transcription occur. The 
positive transcription elongation factor B, PTEFB; RNA polymerase II, RNA Pol II; TSS, transcription start 
site. Figure adapted form (Filippakopoulos and Knapp, 2014). 
 
The BET subfamily is composed of two tandem BRDs in the N-terminus and a recruitment domain 
in the C-terminus (Figure 1.9 A). The conserved BET family includes BRD4, BRD2, BRD3, expressed 
ubiquitously, and BRDT, specifically expressed in the testis (Taniguchi, 2016). The BRD4 protein 
is one of the most characterised BRD-containing subfamily proteins. The dysfunction of BRD4 
proteins was detected to associate with cancer and inflammation (Hongmao, 2016).   
 
To exert its transcriptional modulation, BRD4 firstly recognises acetylated chromatin regions and 
recruits the positive transcription elongation factor B (P-TEFb) to subsequently stimulate RNA 
polymerase II-dependent transcription (Figure 1.9 B). BRD4 is found particularly enriched at 
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enhancer and super-enhancer regions, which strongly stimulates the expression of some 
oncogenes in cancer (Lamoureux et al., 2014). Importantly, BRD4 have been shown to associate 
with transcription factors (TFs) including AR, ER and NFkB, and contribute to aggressive types of 
PC (Urbanucci et al., 2017). Specifically, endogenous BRD4 is found physically interacting with the 
AR-NTD with a high-binding affinity which leads to transcriptional complex assembly at target 
loci, and promotes AR activity and expression of target genes in CRPC (Asangani et al., 2014). In 
addition, a finding by (Zuber et al., 2017) with implications in risk assessment shows that tissue-
specific Single Nucleotide Polymorphism (SNPs) in super-enhancer sequence bound by BRD4 are 
significantly associated with increased prostate cancer incidence. 
 
Moreover, BRD4 is found involved in resistance to anti-androgens.  (Pawar et al., 2018) and 
(Ruggero et al., 2018) found that treatment with the BET inhibitor, JQ1, can effectively re-
sensitise resistant tumours to enzalutamide. JQ-1 works downstream of AR and abrogates 
recruitment of the receptor to cis-regulatory elements resulting in removal of RNA polymerase II 
from AR target genes, to induce apoptosis and down-regulate AR-regulated gene transcription 
(Asangani et al., 2014). An additional small molecule BET inhibitor ABBV-075 has been recently 
shown to inhibit AR-target gene expression by attenuating BRD4 loading at enhancer elements 
of AR target genes while leaving AR protein level unaffected (Faivre et al., 2017). Taken together, 
the evidence suggests that BRD4 proteins could be beneficial targets in the development of new 
therapeutic strategies for antiandrogen resistant PC. In fact, several BET inhibitors (BETi) that 
interrupt BRD4 chromatin recruitment are being assessed in clinical trials for CRPC 
(https://clinicaltrials.gov). Furthermore, resistance mechanisms to these agents have been 
studied in models of PC; a BRD4-independent mechanism identified in a BETi-resistant PC cell line 
whereby reactivation of AR signalling via CDK9-mediated phosphorylation of AR was found to 
drive BETi-resistance (Pawar et al., 2018). Furthermore, as a consequence of reduced expression 
of DNA repair genes in BETi-resistant cells, cells were more highly sensitive to PARP inhibitors 
indicating therapeutic potential of employing combination therapies for treating CRPC. 
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1.11.P300/CBP histone acetylation activity associates with progression of prostate 
cancer.  
For the full activity of the AR to be elicited, and for it to be appropriately regulated once bound 
to target genes, the receptor actively recruits various co-regulator proteins of distinct function 
to target sites within the DNA. Two well characterised AR co-regulators are cAMP response 
element-binding protein (CREB)-binding protein (CBP) and p300 histone acetyltransferase 
(CBP/p300) (Takayama and Inoue, 2013) which function as transcriptional co-activators of the AR 
via inherent histone HAT activity (Legube and Trouche, 2003). 
 
p300 and CBP,  also referred to as CBP/ p300 proteins, share significant sequence homology 
(Kalkhoven, 2004) and  contain several conserved regions that mediate most of the known 
functional activities of the protein (Figure 1.10 A): including a) three cysteine–histidine (CH)-rich 
regions (CH1, -2 and -3); b) the CREB binding site, and c) steroid receptor coactivator-1 interaction 
domain (SID).  In addition, p300 and CBP each contain a HAT domain and a bromodomain that 
binds acetylated lysine. Each domain is connected by long stretches of unstructured linkers which 
are less conserved (Arany et al., 1994). In fact, CBP/p300 are known as functional paralogs and 
their HAT domains show sequence identity of more than 90% (Santer et al., 2011) 
 
The functional involvement of the CBP/ p300 HAT activity has been demonstrated to be 
important in various pathologic processes (Kalkhoven, 2004). One important function of 
CBP/p300 involves chromatin remodelling, hence the two proteins are essential coactivators for 
a substantial number of transcription factors. Moreover, CBP/p300 can bind not only to target 
proteins and regulate DNA binding affinity, transcriptional activation, protein–protein 
interactions, and stability of transcription factors but also to other cellular proteins by acetylation 
(Legube and Trouche, 2003).  
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Recent evidence indicated that the expression of CBP/p300 is commonly altered in different 
types of tumours (Kalkhoven, 2004; Culig, 2016). In cancer, the precise role of p300 and CBP is 
understudied and may depend on the physiological background of the cancers. In addition, 
although the two protein’s functional domains share a high degree of homology similarity, the 
cellular roles of CBP and p300 were found not to be entirely redundant with unique roles in vivo. 
In fact, p300 was suggested to act as canonical tumour suppressor in breast, colorectal, and 
pancreatic cancers as p300 is targeted by viral oncoproteins and the mutated or truncated 
isoform is commonly detected (Santer et al., 2011). In PC, however, the accumulating evidence 
clearly indicated the oncogenic function of p300 and CBP. Initially, overexpression of CBP/p300 
was found associated with the agonistic effects of the anti-androgen hydroxyflutamide in PC cell 
line (Comuzzi et al., 2003). In clinical specimens of PC, the expression of p300 correlates with the 
presence of the AR. CBP/p300 were also found may have induced transcription of androgen-
dependent genes, even in the absence or very low level of AR. (Comuzzi et al., 2004; Debes et al., 
2005; Heemers et al., 2007). Moreover, increased p300 expression upon androgen starvation is 
crucial for cell survival and growth of prostate cancer cells (Heemers et al., 2007). And in nude 
mice, CBP/p300 expression are found augmenting transcription of a subset of growth control 
target gene promoters (Fu et al., 2003). 
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Figure 1.10 Schematic representation CBP/p300 protein Structure of the family and the model of the 
AR–CBP/P300 Transcription Complex.   (A) Linear representation of the CBP/p300 proteins with regions 
and functional domains that are highly conserved between species indicated. CH1,CH2 and CH3 – three 
cysteine/histidine rich regions; KIX - the CREB and MYB interaction domain; BRD-the bromodomain, HAT- 
histone acetyltransferase domain and the p160 binding site (B). Agonist-bound ARs are recruited to both 
the enhancer and the promoter of the PSA gene. This is followed by a coordinated and ordered recruitment 
of p160 proteins, CBP, p300, and RNA polymerase II holoenzyme to form the AR transcription complex. 
 
In PC cells, in the presence of agonist ligand, the AR translocates to the nucleus where it binds 
directly to promoter and enhancer elements of target genes, whereby the CBP/p300 is 
concurrently recruited alongside other co-regulators, including p160-family members and 
p300/CBP-associating factor (pCAF) which can interact with the basal transcriptional machinery 
forming an active transcription complex with RNA polymerase II on the transcription start site 
(TSS) (Figure 1.10 B, also see Figure 1.2 ). The coactivator p300 augments AR activity, in part, via 
its intrinsic HAT activity (Fu et al., 2003). Besides directly acetylating target lysines within histones 
H3 and H4, p300 also directly acetylates the AR at a conserved lysine-rich motif within the hinge 
region (Fu et al., 2003).  By inhibiting p300 HAT activity via a newly developed small molecule 
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p300 HAT inhibitor, C646, decreased cellular proliferation and migration of PC cells were 
observed (Santer et al., 2011). In addition, by employing a novel CBP/p300 bromodomain 
inhibitor, a recent study reported the blockage of prostate cancer growth in vitro and in vivo (Jin 
et al., 2017).   
 
Taken together, these results suggest that BRD4 and CBP/p300 inhibition may be a promising 
approach for the development of new anticancer therapies. Importantly, the requirement of 
BRD4 or CBP/p300 for the activity of the ARF876L mutant in enzalutamide resistance has not yet 
been studied. To exploit this vulnerability, the role of BRD4 and CBP/p300 activity for the 
transcriptional activity of the ARF876L and its target gene expression will be studied in details in 
order to investigate the potential of targeting two co-regulators as a strategy for attenuating AR 
mutant-driven enzalutamide resistance.  
 
 
1.12.The novel gene-editing technology is advancing current study tools.  
In recent years, several advanced genome editing technologies have been developed. Of these 
the zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the 
Clustered Regulatory Interspaced Short Palindromic Repeats (CRISPR)/Cas9 RNA-guided 
endonuclease system are the most widely described (Mahfouz et al., 2014). Each of these 
methodologies takes advantage of restriction enzymes to generate a DNA double stranded break 
(DBS) at a targeted genome location with the direction of homologous binding proteins or RNA 
(LaFountaine et al., 2015). Such targeting is viewed as a significant advancement compared to 
current gene therapy methods that lack such specificity. The precise genome editing methods 
including the TALENs and CRISPR/Cas9 systems have proved to be effective and reliable tools for 
genome engineering in multiple disorders, including in vivo experiments, in mammals and even 
early phase human trials (Vassena et al., 2016). Hence, those technologies were named as the 
methods of the year  'Method of the Year 2011' (2012)  by Nature Methods In 2011.  
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1.13.ZINC finger and TALEN 
Back in early 1996, a zinc finger protein domain, which predominantly recognizes nucleotide 
triplets, was demonstrated for the first time to couple with the FokI endonuclease domain and 
to act as a site-specific nuclease cutting DNA at strictly outlined sites in vitro (Kim et al., 1996). 
The chimeric sequence-specific zinc finger nucleases (ZFNs) have later demonstrated to enable 
targeted mutagenesis and genome editing through directed chromosome cleavage (Figure 1.11 
A) (Kim et al., 1996).  The ZFN-based technology since then has become the basis for editing 
cultured cells, including pluripotent stem cells, plant and animal models (Bibikova et al., 2002; 
Townsend et al., 2009; Nemudryi et al., 2014). However, this method has a number of limitations 
which including the complexity and high cost of protein domains generation for each particular 
genome locus and lack of specificity of target DNA cleavage due to high tolerance of single 
nucleotide substitutions or inappropriate interaction between domains (Nemudryi et al., 2014).  
 
To overcome the disadvantages, a transcription activator-like effectors (TALE) protein that 
contains a modular DNA binding domain was adapted from plant pathogenic bacteria 
(Bogdanove and Voytas, 2011). TALE proteins code with a central DNA binding domain, a nuclear 
localization signal (NLS), and a domain that is responsible for activating target gene transcription 
(Schornack et al., 2006). The DNA-binding domain consist of serval tandem repeats of monomers. 
The recognition specificity of TALE relies on the monomers within the DNA-binding domain as 
each of them binds to one nucleotide in the target nucleotide sequence (Lamb et al., 2013). To 
exert its function in vitro, an artificial DNA-binding domain is required inserting into a 
construction of chimeric TALEN nucleases alongside a nuclear localization signal, half-repeat, N-
terminal domain, and the FokI catalytic domain.  Theoretically, by combining different monomers 
within the DNA-binding domain to construct artificial nucleases, the target of which can be any 
nucleotide sequence. 
47 
 
 
Figure 1.11 Schematic representation of various genome-editing platforms.   (A) Zinc finger nucleases  
form (Mahfouz et al., 2014). 
 
Once in the nucleus (Figure 1.11 B), artificial TALEN nucleases bind to target sites: the TAL effector 
targeting domain direct the catalytic domain of the FokI nuclease function as a fusion protein, as 
a results, the FokI domains located at the C-termini of a chimeric protein dimerise to cause a DSB 
in a spacer sequence. A few drawbacks, however, have been realised with this technology, 
including the size of the actual constructed DNA-binding domains which usually consist of 20–30 
selective monomers each with an approximate size 34 amino acid residues (Bogdanove and 
Voytas, 2011). These constructs are therefore large making delivery into cells challenging. In 
addition, as FokI functions as a dimer, both Zinc finger and TALENs are designed in pairs in order 
finger nucleases (ZFNs) are composed of DNA recognition domains and FokI nuclease catalytic domain fusions.
Each zinc finger in the DNA recognition domains binds three nucleotides. On average three to four zinc fingers
are fused to recognize 9–12 nucleotides. Two ZFNs are required to produce double-strand breaks (DSB) as the
FokI domain requires dimerization to be catalytically active. (B) Transcription activator-like effector nucleases
(TALENs) are composed of TAL central DNA-binding repeat domain and FokI catalytic domain fusions. DNA-
binding specificity is determined by the 12th and 13th hypervariable residues of each repeat [repeat variable
diresidue (RVD)]. Similarly, two TALENs heterodimer binding in a tail-to-tail orientation with proper spacer
length to allow dimerization of the FokI domains are required for activity and DSB formation. Image was adapted
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to bind opposing DNA target sites separated by a spacer, allowing the FokI monomers to come 
together to create a DSB  (Nemudryi et al., 2014).  
1.14.Mechanism and development of CRISPR 
Soon after the discovery of the chimeric TALEN proteins, another genome editing technology, 
CRISPR, elements of which includes a non-coding RNA and a CRISPR associated (Cas) protein, 
were adapted from bacteria which provides acquired immunity against invading foreign DNA via 
RNA-guided DNA cleavage (Nemudryi et al., 2014). In 2013, the CRISPR/Cas system was 
demonstrated for the first time to act as an advanced genetic editing tool in cultured mammalian 
cells (Cong et al., 2013; Jinek et al., 2013; Mali et al., 2013b). Since then, it has rapidly emerged 
as a potentially fast and efficient alternative to ZFNs and TALENs for inducing targeted genetic 
alterations (Gaj et al., 2013).  
In general, CRISPR systems have been classified into 6 distinct types (I ~ VI) according to current 
categorisation of CRISPR–Cas loci (Makarova et al., 2015; Shmakov et al., 2015). Each group 
utilises a unique set of Cas proteins along with CRISPR RNAs (crRNAs) for CRISPR system 
activation (Wright et al., 2016). Every group of CRISPR systems act distinctively:  the type I and 
type III systems employ a large multi-Cas protein complex for crRNA binding and target sequence 
degradation (Wright et al., 2016); in contrast, in the type II CRISPR systems, CRISPR/Cas9, relays 
a single DNA endonuclease, Cas9, to generate double-strand DNA (dsDNA) substrates. Due to its 
simplicity and flexibility, the CRISPR/Cas9 system has been wildly implemented as an exquisitely 
powerful tool for genome manipulation in a wide spectrum of organisms (Hsu et al., 2014).  
Two functional domains, the HNH nuclease domain and RuvC-like domain, are critical for Cas9 
protein activation (Sapranauskas et al., 2011). In addition, a small non-coding RNA, termed trans-
activating crRNA (tracrRNA) is also important for Cas9 recruitment. In the nucleus, tracrRNA base-
pairs with a 20 nucleotide (nt) spacer repeat sequence in the crRNA to form a unique dual-RNA 
hybrid structure (Figure 1.12 A) (Nemudryi et al., 2014). This dual-RNA guide directs Cas9 to cleave 
any DNA containing a complementary target sequence that upstream of protospacer adjacent 
motif (PAM) PAM (5’-NGG-3’, N - any given nucleotides) (Deltcheva et al., 2011; Jinek et al., 2012). 
In the presence of Mg2+ ions (Makarova et al., 2011; Jiang et al., 2013), DNA cleavage occurs 
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with the HNH nuclease domain of the enzyme cutting the DNA strand complementary to crRNA, 
and the RuvC domain cutting the non-complementary one three nucleotides from the PAM site 
(Jinek et al., 2012).  
 
In contrast to the other two site-specific nucleases described above, DNA recognition by the 
CRISPR/Cas9 system is not specified by protein (Chandrasegaran and Carroll, 2016), but rather it 
relies upon complementarity between the target genome and crRNA sequence (Doudna and 
Charpentier, 2014). Currently, instead of two non-coding RNAs, a single chimeric sgRNA that 
combines the crRNA and tracrRNA into a single RNA transcript is often generated to simplify the 
system while retaining fully functional Cas9-mediated sequence-specific DNA cleavage 
(Nemudryi et al., 2014). By replacing the guide RNA sequence (spacer) within the crRNA, the 
simplified two-component CRISPR/Cas9 system can be programmed to target virtually any DNA 
sequence of interest in the genome and further generate a site-specific blunt-ended DSB (Hsu et 
al., 2014).  
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Figure 1.12 Schematic representation of single chimeric sgRNA to introduce double-stranded breaks into the target 
loci and the application of DNA repair pathway  (A) The mechanism of CRIPR/Cas9-mediated genome engineering.   target loci and the application of DNA repair pathway. (A) The mechanism of CRISPR/Cas9–mediated genome engineering.
A Cas9 endonuclease was guided through the synthetic sgRNA or crRNA–tracrRNA structure to almost arbitrary DNA
sequence in the genome via a pre-defined 20-nt guide RNA sequence and subsequently guides Cas9 to introduce a double-
strand break (DSB) in targeted genomic DNA. (B) The mechanism utilizing DNA repair pathway for genetic editing application.
The Cas9 generated- DSB is repaired by host-mediated DNA repair mechanisms. Upon DSB, the error-prone nonhomologous
end joining (NHEJ) pathway is prevalently activated and results random insertions and deletions (indels) or even substitutions
at the DSB site, frequently resulting in the disruption of gene function. In the presence of a donor template containing a
sequence of interest flanked by homology arms, the error-free homology directed repair (HDR) pathway can be initiated to
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CRISPR RNA. Images were adapted form (Nemudryi et al., 2014; Jiang and Doudna, 2017).  
 
The DSB created by Cas9, in turn, activates the cellular DNA repair pathways, which can be 
harnessed to create specific DNA sequence modifications at or close to the break site (Kim and 
Kim, 2011). In nearly all cells, DSBs are repaired by one of two highly conserved processes, non-
homologous end joining (NHEJ) and homologous recombination (HR) (Figure 1.12 B). For the NHEJ 
pathway, the broken genome site/chromosome is often rejoined imprecisely which commonly 
results in small insertions or deletions at the break site that can be exploited to interrupt gene 
function.  Alternatively, HR occurs in the presence of DNA repair template, the DNA surrounding 
the cleavage site can be used for introducing foreign DNA. The sequence of the repair template 
can be designed or manipulated to replace with specific mutations or to insert additional 
sequences. Due to the flexibility of donor choice, a defined locus with desirable features 
(including restriction enzyme digestion sites, ectopic fusion tags, or selection markers) can be 
modified by incorporating these features with a piece of foreign homologous sequence. Either 
plasmid construct or synthesised DNA fragment can be employed as the donor template (Ran et 
al., 2013). In general, the plasmid donor can be used when long insertions need to be 
incorporated (Beumer et al., 2013; Beumer and Carroll, 2014). In comparison, for small insertions 
or deletions, single-stranded DNA (ssDNA) is preferred (Beumer and Carroll, 2014).  
 
1.15.Application of CRISPR 
Comparing to the ZFN and TALEN based methods, the CRISPR/Cas9 system is much easier to 
conduct as it can be directly portable to human cells by co-delivery of plasmids expressing the 
Cas9 endonuclease and the necessary crRNA components (Perez et al., 2008; Chen et al., 2011; 
Valetdinova et al., 2015). CRISPR/Cas9 system is more efficient, as it is suitable for high-
performance and multiplex genome editing by generation of CRISPR/Cas9 libraries (Nemudryi et 
al., 2014) which allows one to perform functional screening of genomes. High-throughput 
create desired mutations through homologous recombination, which provides the basis for performing precise
gene modification, such as gene knock-in, deletion, correction, or mutagenesis. Abbreviations: crRNA, CRISPR
RNA; nt, nucleotide; PAM, protospacer adjacent motif; sgRNA, single-guide RNA; tracrRNA, trans-activating
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screens of CRISPR/Cas9 libraries may yield important information about the physiology and 
biochemistry in a variety of cell lines and in living organisms and could help uncover the molecular 
mechanisms of disease development and identify potential targets for drug and gene therapy 
(Lino et al., 2018). CRISPR/Cas system is also more fixable as it the can be redefined to cleave 
virtually any DNA sequence by only replacing the 20-nt guide sequence of sgRNA. In fact, the 
programmable RNA-guided DNA endonucleases have demonstrated multiplexed gene disruption 
capabilities (Cho et al., 2013) and targeted integration in induced pluripotent stem (iPS) cells 
(Cong et al., 2013). In addition, CRISPR–Cas9 RNA-guided DNA targeting can also be uncoupled 
from cleavage activity by mutating the catalytic residues in the HNH and RuvC nuclease domains 
which converting DSB into nickases (Cho et al., 2013), enabling an additional level of control over 
the mechanism of DNA repair. Making CRISPR/Cas9 system a more versatile platform for many 
other applications beyond genome editing.  
CRISPR/Cas9 technology has been applied in numerous experimental settings to help:  
development of isogenic human stem cells (Horii et al., 2013); methods to correct a mutant cell 
phenotype (Schwank et al., 2013), studies of gene expression regulation (Bikard et al., 2013; 
Farzadfard et al., 2013; Gilbert et al., 2013; Heintze et al., 2013; Perez-Pinera et al., 2013); 
functional relationships between large groups of genes (Shalem et al., 2014; Wang et al., 2014); 
and imaging regions of the active genome regions in living cells (Chen et al., 2013). In addition to 
human cells, CRISPR/Cas-mediated genome editing has been successfully demonstrated in 
zebrafish (Hwang et al., 2013) and bacterial cells (Jiang et al., 2013). 
Of particular note, the CRISPR/Cas9 system has opened new avenues for cancer research (Zhan 
et al., 2018) as it has been employed as an effective technique for functional oncogene scanning 
in both in vitro and in vivo cancer models (Zhang et al., 2017b). In particular, the use of genome-
editing systems enables potential correction of cancer-causing point mutations in the cells 
obtained from patients by using both complex genetic constructs and single strand DNA 
oligonucleotides as donor molecules (Yang et al., 2013b). Significantly, the very first clinical trial 
of applying CRISPR is now approved for therapeutic anti-cancer (Zhan et al., 2018). 
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  Aims  
 
The current commonly adopted method for studying AR mutant function is by transiently 
transfection of AR-encoding plasmids into AR null cells and therefore lacks physiological 
relevance. By incorporating the next-generation genomic editing strategies, we therefore aim to 
generate CRISPR-edited LNCaP and CWR22Rv1 cell lines expressing enzalutamide-activated 
ARF876L mutant. In addition, this project will attempt to assess the function of enzalutamide-
activated ARF876L in cell line models and interrogate if BRD4 and CBP/p300 plays a part in 
controlling its activity. Overall, two main aims of this project are: 
 
i.       Generation and validation of an ARF876L CRISPR model system, enabling a more 
physiological model of aberrant AR activity. 
ii.  Generation of an ARF876L replacement model, using the LNCaP cell, enabling an enhanced 
understanding of the molecular mechanisms of enzalutamide resistance. 
iii. Conduct global gene analysis, using an LNCaP_ARF876L model, to define the ARF876L global 
transcriptome and cistrome. 
iv. Interrogate the involvement of BRD4 and CBP/p300 for ARF876L transcriptional 
competence to offer new insights into discriminate functionality and opportunities for 
selective drug targeting of enzalutamide resistance-associated AR mutants. 
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 Methods and Materials  
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3.1 General expression plasmids and primers,  
The following plasmids were used for mammalian cell transfection: wild-type pVP16-AR-TD, wild-
type pM-Gal4DBD-AR-DBD/LBD, pCMV-FLAG-AR (full length), pCMV-FLAG-ARF23A/F27A (full 
length), pGAL4AR- Luciferase reporter, (TATA) Luciferase-ARE reporter plasmid and pCMV-β-gal 
and have been reported previously (Gaughan et al., 2005). All primers and siRNA were pushed 
form Sigma-Aldrich unless stated otherwise.  
 
3.2 Bacterial transformations and plasmid preparation  
For each transformation, 1 μg of sample plasmid was added to 25 μl of E.coli Top 10 competent 
cells (Invitrogen) incubated on ice for 30 minutes, then heat-shocked at 42oC for 30 seconds and 
immediately placed on ice for 2 minutes. 500 μl of Luria bertani (LB) medium was then added 
and incubated at 37oC with rotary shaking at 220 rpm for 1 hour. After incubation, 100 μl of the 
cell sample and competent cells only (as transformation control) was plated onto LB-agar plates 
containing ampicillin (50 μg/ml) and incubated at 37oC overnight. Resultant clones were 
transferred into 10 ml LB containing ampicillin (50 μg/ml) and incubated for approximately 8 
hours or overnight with rotary shaking. A 2 ml aliquot cell suspension was then transferred to 
200 ml LB ampicillin medium and incubated at 37oC overnight with rotary shaking. Cells were 
then harvested the following day by centrifugation at 4500 rpm at 4oC for 15 minutes and pellets 
were subject to prep or stored at -20oC.  
 
Plasmid Maxi Prep kits (QIAGEN and Life Sciences) were used for plasmid prep, according to the 
manufacturer’s protocol. Prepped plasmids were eluted with molecular grade H2O and 
concentration/purity measured using a Nanodrop ND-1000 spectrophotometer (Thermo 
Scientific) prior to storage at -20oC.  
 
3.3 Site- directed mutagenesis 
All site-directed mutagenesis was conducted using the QuikChange II Site-Directed Mutagenesis 
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Kit (Stratagene), according to the manufacturer’s protocol. Mutagenesis primers were designed 
manually (sequences listed in Table 3.2) and mutations verified by Sanger sequencing (Beckman 
Coulter Genomics, UK). Mutated AR coding sequences were cloned into the pLVx vector 
(Clontech). PCR reaction for Site-Directed Mutagenesis was set up as below:  
Denaturation step: 95°C, 30 seconds;  
Annealing step: 55°C, 1 minute;  
Extension/elongation step: 68°C 1minute/kb for 18 cycles.  
 
Mutant plasmids were then transformed into XL1-Blue supercompetent cells (Stratagene) 
according to the manufacturer’s protocol. 
3.4 Primers   
Table 3.1 The list of all the general primers used in this thesis.  
AR mutation Forward Primer Reverse Primer 
 
FLAG 
AR_F876L 
5’ -
AGAGAGCTGCATCAGTTCGCTTTTG
ACCTGCTAATC 
5’ -
GATTAGCAGGTCAAAAGCGAACTGATGC
AGCTCTCT 
 
 
3.5 Mammalian cell culture and passage  
All tissue culture media and supplements used were supplied by Sigma-Aldrich and plasticware 
and plates were purchased from Corning (Corning Ltd, UK).  
 
Full medium or 10%FCS medium — Gibco® RPMI 1640 (R5886) medium (containing 25mM HEPES 
buffer and 1% 20mM L-Glutamine) supplemented with 10% heat-inactivated fatal calf serum 
(FCS).  
DCC media — Gibco® RPMI-1640 +1% L-glutamine + 10% dextran-coated charcoal treated FCS 
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that contains reduced levels of androgens and is used for AR inactivation/reactivation studies.  
 
Basal media — Gibco® RPMI 1640 (R5886) supplemented with 25mM HEPES buffer and 1% L-
Glutamine (20mM).  
 
Cells were grown at 37oC in the presence of 5% CO2 and passaged every 3-4 days (upon reaching 
80% cell confluence). For each cell passage, 5 ml phosphate-buffered saline (PBS) was used to 
wash adherent cells twice prior to addition of 1x Trypsin-EDTA solution (10% volume of cell 
medium) and incubation at 37oC for 5 minutes. Cells were then mixed with full medium to 
neutralise trypsin and collected by centrifugation at 2000 rpm for 5 minutes. A 10 ml volume of 
fresh full medium was used to resuspend the cell pellet and 1ml of resultant cell suspension was 
transferred to a fresh flask continuing culture with an appropriate volume of full media.  
 
3.6 Transient plasmid DNA transfection  
In general, an appropriate number of cells were plated in DCC medium, unless otherwise stated, 
and transfection performed on the following day. For transfection reaction preparation, DNA was 
diluted in basal medium and TransIT-LT1 (Mirus) transfection reagent was added, according to 
the manufacturer’s guidelines, and mixed completely by gently pipetting up and down. After 
incubation at room temperature for 30 minutes, transfection mixes were added drop-wise to 
different areas of the wells and gently rocked back-and-forth and side-to-side to evenly distribute 
the DNA-LT-1 complexes. Cells were incubated for an additional 48 hours at 37oC in the presence 
of 5% CO2 before harvesting and analysis as required.  
 
 
3.7 Construction of lentiviral expression vectors 
A lentiviral-based transduction strategy was chosen to generate an LNCaP cell line derivative 
that stably expresses ARF876L. This requires initially generating a recombinant mammalian 
lentiviral construct containing ARF876L cDNA which will be used to transduce LNCaP cells. To this 
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end, the F876L point mutation was induced into the pCMV-Flag-AR plasmid, containing FLAG-
tagged ARwt (O’Neill et al., 2015), by mutagenesis (QuikChange II Site-Directed Mutagenesis 
Kit, Thermo Scientific) according to manufacturer’s recommendations. Once verified, ARF876L 
cDNA was amplified by PCR using the primers list in Table 3.1 and then ligated into pENTR-
V/TOPO vector (Life Sciences). Recombinant vectors were selected and incorporated into an LR 
recombination reaction (Life Sciences) with pLenti6.3 plasmid to generate the pLenti-6.3-Flag-
ARF876L construct. Successful recombinant constructs were subject to maxiprep (PureLink™ 
HiPure Plasmid Filter Purification Kits, life Technologies) and stored at -20oC as stock.  
3.8 Virus production and titre determination 
pLenti6.3-Flag-ARF876L or Cas9/sgRNA196- containing virus was produced using ViraPower™ 
Lentiviral Expression System (Life Technologies) according to the manufacturer’s 
recommendation. HEK293FT cells (life Technologies, UK) were cultured with complete medium 
containing 500 μg/ml Geneticin for 3 passages pre-virus transductions. The lentiviral expression 
plasmids were produced as described in (O'Neill et al., 2015).  
 
3.9 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting 
Protein expression in mammalian cell culture was assessed using Western blotting. Prior to 
analysis, cells were seeded in 6 well-plates containing 2 ml 10% DCC medium. After 48 hours of 
500 ng vector per well transfection, cells lysates were collected from culture wells by directly 
adding 100 μl SDS sample buffer (100 mM dithiothreitol, 125 mMTris-HCl (pH 6.8), 2% SDS, 20% 
glycerol and 0.005% bromophenol blue) post PBS wash to lyse cells.  
 
Lysates was denatured at 100oC for 10 minutes before loading onto a 10% polyacrylamide gel 
according to manufacturer’s recommendations (Mini-PROTEAN III system, Bio-Rad, UK). 
Fermentas Spectra™ Multicolor Broad Range Protein Ladder (ThermoScientific Pierce, UK) was 
used to determine protein size.  
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             Table 3.2 The list of all the general antibodies used in this thesis. 
 
Antibody 
 
Species 
 
Supplier 
 
Applications 
 
WB Exposure 
time 
 
AR (N-20) (sc-816) 
 
Rabbit 
 
Santa Cruz 
 
WB, IP, ChIP 
 
< 1 min 
 
AR (C-19) (sc-815) 
 
Rabbit 
 
Santa Cruz 
 
WB, IP, ChIP 
 
< 1 min 
 
AR-V7 (ab198394) 
 
Rabbit 
 
Abcam 
 
WB, IP 
 
< 20 min 
 
PSA (2E9) 
 
Mouse 
 
Kind gift from Kim 
Pettersson 
 
WB 
 
<10 min 
 
α-tubulin (T9026) 
 
Mouse 
 
Sigma Aldrich 
 
WB 
 
< 10 secs 
 
FLAG-tag 
 
Mouse 
 
Sigma Aldrich 
 
WB, IP, ChIP 
 
< 1 min 
 
P300 
 
Mouse 
 
abcam 
 
WB, IP, ChIP 
 
< 1 min 
 
GR (G-5) 
 
Mouse 
 
Santa Cruz 
 
WB 
 
< 10 min 
 
Rabbit IgG 
 
Rabbit 
 
Diagenode 
 
IP, ChIP 
 
N/A 
 
 
3.10 Cytoplasmic and nuclear extract preparation 
Cells were seeded in DCC medium at a density of 1.5x105 per well in 6-well plates for 24 hours. 
500 ng of pLenti6.3-AR constructs per well were transfected for 48 hours and subsequently 
treated with 10 nM DHT or 1 μM enzalutamide. Cells were then trypsinised, washed in PBS and 
pelleted. Cytoplasmic and nuclear fractionation was carried out on cell pellets using the NE-PER 
Nuclear and Cytoplasmic Extraction Reagents Kit (Catalog #40010 & 40410, Thermo Scientific) 
according to manufacturer’s protocol. 
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Briefly, cells were pelleted by centrifugation, resuspended in 500 μl Hypotonic Buffer, and 
incubated for 15 minutes on ice. 25 μl of CER II buffer was added and the sample was vortexed 
for 10 seconds at the highest setting. The cell lysate was subject to centrifugation for 30 seconds 
at 14,000×g at 4°C and the supernatant (cytoplasmic fraction) was transferred into a 
microcentrifuge tube and stored at -80°C until needed. The nuclear pellet was resuspended in 50 
μl NER buffer and subjected to vortexing for 10 s, incubated for 30 minutes on ice, and 
centrifuged for 10 minutes at 14,000×g at 4°C. The supernatant (nuclear fraction) was transferred 
into a microcentrifuge tube and stored at −80°C. Subcellular fractions were analysed by western 
blotting. 
 
3.11 Immunofluorescence 
An appropriate number of HEK293T cells were seeded on glass coverslips in 6-well tissue culture 
vessels and allowed to adhere for 48 hours. Following drug treatments, cells were fixed with 2 ml 
paraformaldehyde (2% v/v) per well overnight at 4oC. Cells were then washed twice in PBS and 
permeablised with 0.1% Triton-X-100 in PBS for 15 minutes. Cells were blocked in 2 ml, 0.1% 
Triton-X-100/ 4% BSA per well for 1 hour at room temperature before being incubated with an 
anti-AR antibody (N20; 1:50 dilution) in 1 ml blocking solution overnight at 4oC. Cells were then 
washed 3x with PBS before being incubated with secondary Alexa Fluor 594 antibodies (1:200 
dilution) (Life Technologies) for 1 hour at RT. Excess antibody was removed by washing twice with 
PBS and coverslips were mounted to glass slides with DAPI (vectorshield) and visualised using a 
Leica DMR fluorescent microscope. 
3.12 Co-immunoprecipitation sample preparation 
Pre-prepared cultured cells were trypsinised and collected following 3 ice-cold PBS washes. Cell 
samples were spun down at 13,000g for 5 minutes. Pellets were subject to IP sample 
preparation (or snap freezing at -80 oC).  Each cell sample was lysed with 1ml of fresh made IP 
lysis buffer: 50 nM Tris, 150 mM NaCl, 0.2mM of Na3VO4, 0.5% NP-40, 1mM of PMSF, 1mM 
DTT and a protease inhibitor tablet (Roche Applied Science) adding dH2O to a final volume of 
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10ml.  Samples were then incubated on ice for 1 hour (or overnight until lysis was complete).  
50µl aliquot of each sample was transfer into a fresh tube to act as inputs and stored at -20°C. 
To prepare Protein G-sepharose (PGS) beads, 700 µl of PGS (GE Healthcare) was spun at 1,400g 
for 3 minutes and supernatant discarded. Then, 500µl IP lysis buffer was added and thoroughly 
mixed using a vortex-mixer. Beads were then spun at 1,400g for 3 minutes. The wash step was 
repeated a further 2-3 times. After final supernatant removal, fresh IP lysis buffer was added 
to reach an overall volume of 700µl. The pre-prepared beads were then stored on ice.  
Each completely lysed IP samples were centrifuged at 4°C 1,400g for 3 minutes. Supernatants 
were transferred into a fresh tube and added with 20 µl of fresh prepared PGS and rotated at 
4°C for 1 hour to remove any proteins that interacted non-specifically with PGS.  After spinning 
down at 13,000g for 3 minutes, per-cleared supernatants were split into two fresh tube and 
incubated with antibody and appropriate isotype IgG control at 4°C overnight. Additional 20 µl 
of PGS was added into each tube the following day, and incubated at 4°C for 1 hour. PGS-
protein complexes were collected by centrifugation at 13,000g for 3 minutes and then washed 
in 1 ml  buffer A (PBS, 350 mM NaCl, 0.1% NP-40) and 1 ml buffer B (PBS, 350 mM NaCl). The 
final PGS (including corresponding inputs) were diluted with an appropriate volume of SDS 
sample buffer and subjected to western blotting as described above to analyse the protein-
protein interaction of interest.  
3.13 Cell proliferation assays 
To investigate the effect of each anti-androgen on cell proliferation, an appropriate density of 
cells (~3000 cells / well) were seeded into each well of a 96-well plate at a volume of 90 μl growth 
medium using an Eppendorf Repeater Stream pipette. Cells were allowed to adhere for 24 hours 
before being treated with 10 μl of a pre-diluted 10 nM DHT or anti-androgens stock, bringing the 
final volume to 100 μl/well with desired drug concentration. Cells were incubated with 
compound for 7 days. Each well surface coverage is measured in real-time (every 6 hours) using 
the Inucyte Zoom (Essen Bioscience) and later analysed using the Basic Analyzer Software (Essen 
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Bioscience). Analysis parameters were implemented to eliminate the detection of dead cells 
when quantifying the confluence. 
 
3.14 RNA extraction, reverse transcription and real-time quantitative PCR 
 RNA extraction 
TRIzol (Life Technologies) was used for extracting RNA from prepared cells according to the 
manufacturers’ instruction. In short, culture medium were removed from each well (typically 6-
well plates), before washed twice with 2 ml PBS/per well. To harvest cell samples, 1 ml TRIzol 
was directly added on top of each well and shaken gently for 10 minutes at room temperature. 
The homogenised samples were transferred into 1.5 ml Eppendorf tubes and 200 μl of 
chloroform (Sigma Aldrich) was added into each tube before shaking vigorously. Samples were 
incubated at RT for 3 minutes allowing phase separation, before centrifugation at 12,000g for 15 
minutes at 4oC. The aqueous phase (clear upper layer) were transferred to a fresh tube and mixed 
with 500 μl of isopropanol (Fisher Chemicals) and incubated at RT for 10 minutes before 
centrifugate at 12,000g for another 10 minutes at 4oC. The supernatant was removed and the 
visible RNA pellet was washed with 75% ethanol in nuclease-free water (Life Sciences, Invitrogen) 
and centrifugate at 7,500 g for 5 minutes at 4°C. The ethanol wash was then discarded and the 
RNA pellet was air-dried for approximately 10 minutes.  RNA was resuspended in 30 µl of DEPC-
treated H2O before incubation at 55°C for 10 minutes. Quantification of RNA samples was 
determined using a Nanodrop spectrophotometer (Thermo Scientific). RNA samples was subject 
to  reverse transcription (see below) or kept at -80°C for long-term storage.  
 
 RNA reverse transcription 
To reverse transcribe mRNA to cDNA, moloney murine leukaemia virus reverse transcriptase (M- 
MLV RT) (Promega) was used according to the manufacturer’s protocol. Briefly, 1 μg RNA of each 
sample was diluted with DEPC H2O to a final volume of 12.7 μl. For each sample, a RT cocktail 
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mastermix was prepared as list in Table 3.1. Diluted RNA was briefly incubated at 65oC for 5 
minutes to reduce RNA secondary structure. The RNA sample and pre-pared cocktails were mixed 
and incubated at 37oC for 2 minutes before combining into one tube.   
 
Table 3.3 A table outlining the reagent mix for 1μgRNA reverse transcription reaction 
Component Volume 
5x M-MLV reaction buffer  
Free dNTPs  
Oligo-dT  
M-MLV enzyme 
Total volume 
4μl 
2μl 
1μl 
0.3μl 
7.3μl 
 
 
Combined sample were incubated at 37oC for 1 hour after which the samples were transferred 
to 95oc for 2 minutes to inactivate the M-MLV enzyme. Addition of 80 μl DEPC treated H2O was 
added into each complete cDNA samples. cDNA samples were further analysed by RT-PCR or 
stored at -20oC until used. 
 PCR Quantitative real-time polymerase chain reaction (qPCR) 
The gene expression was quantified by subjecting cDNA samples to qPCR using SYBR Green I Dye 
(Life Technologies) in 7900HT Fast Quantitative real-time PCR (qPCR) system (Applied 
Biosystems). PCR reaction was carried out using the 384-well plate ABI 7900HT thermocycler 
(Applied Biosystems). For each well, 8 μl of reaction cocktail (Table 3.4) with appropriate primers 
were added first, and 2 μl of pre-prepared cDNA sample were added manually into each well. In 
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addition, a standard curve was employed using a serial dilution of a sample known to express the 
gene of interest and included 5 dilution data points: 10%, 5%, 2%, 1%, 0.5% and  H2O only was 
included as negative control. A list of PCR primers used can be found in section Table 2.5 Table 
2.6 Table 6.1 and Table 6.2. 
 
Table 3.4 A table outlining the reagent mix per RT-PCR reaction 
Component Volume/well 
SYBR Green I Dye  
dH2O  
Forward primer  
Reverse primer  
Total volume 
5μl 
2.2μl 
0.4μl 
 0.4μl 
 8μl 
 
The following PCR conditions was used for sample analysis: 95oC for 10mins, 95oC 15 seconds, 
60oC 1 min for 40 repeats or stored at -20oC. The data was analysed using Sequence Detection 
System software (SDS) version 2.3 (Applied Biosystems). 
Table 3.5 primers used for gene expression validation in q-PCR. 
 
Gene 
 
Forward primer sequence (5’-3’) 
 
Reverse primer sequence (5’-3’) 
 
PSA 
 
GCAGCATTGAACCAGAGGAG 
 
AGAACTGGGGAGGCTTGAG 
 
TMPRSS2 
 
CTGCTGGATTTCCGGGTG 
 
TTCTGAGGTCTTCCCTTTCTCCT 
 
KLK2 
 
AGCATCGAACCAGAGGAGTTCT 
 
TGGAGGCTCACACACCTGAAGA 
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AR-FL 
 
AAGAGAAGTACCTGTGCGCC 
 
TTCAGATTACCAAGTTTCTTCAG 
 
HPRT1 
 
TTGCTTTCCTTGGTCAGGCA 
 
AGCTTGCGACCTTGACCATCT 
 
 
Data acquired was analysed using Sequence Detection System (SDS) software version 2.3 
(Applied Biosystems). Relative quantities for each gene of interest was calculated from the 
standard curve generated, these values were subsequently normalised using the relative quantity 
HPRT1 gene expression values for each sample. 
 Chromatin Immunoprecipitation 
The protocol for chromatin immunoprecipitation (ChIP) assays was optimised from (Schmidt et 
al., 2009) and typically consists of six steps: cell fixation via formaldehyde cross-linking, chromatin 
preparation and sonication, dynabeads preparation and immunoprecipitation, elution/cross-link 
reversal and protein digestion, DNA purification and DNA quantification. To prepare each ChIP 
assays, 3x106 cells were seeded using 150 mm tissue culture dishes with the appropriate media 
and the treatment were conducted as indicated.  
 Cross-linking fixation 
The cross-linking buffer was prepared as below: 50mM HEPES-KOH (pH7.5), 100 mM NaCl, 1 mM 
EDTA, 0.5 mM EGTA and 11% formaldehyde.  Prepared cells were fixed by directly adding 10% 
volume of cross-linking buffer on top of culture media and incubated at room temperature for 
10 minutes. 10% volume of 1.25 M glycine was added to quench additional cross-linking reaction 
by incubated at RT for 7 minutes before discarding all medium.  To harvest cells, ice-cold PBS was 
used to wash cells twice prior to cell collection by scraping into 2 ml ice-cold PBS containing 
protease inhibitor cocktail (Roche) and transferred into a pre-chilled 15 ml falcon tube. The cell 
suspension was centrifuged at 2000g for 5 minutes at 4°C. The supernatant was discarded and 
the cell pellets was collected for chromatin preparation or were snap frozen with liquid nitrogen 
and placed at -80 °C for long-term storage.  
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 Chromatin preparation and sonication 
Fresh cell pellets (or snap frozen pellets thawed on ice first) were suspended using 10 ml pre-
prepared LB1 buffer: 50 mM HEPES-KOH (pH 7.5), 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% 
NP-40, 0.25% Triton-X-100. Cell suspensions were rocked gently on ice for 5 minutes before 
centrifugation at 4°C for 5 minutes at 2,000 x g. The supernatant was discarded before adding 10 
ml of LB2 buffer: 10 mM Tris-HCl (pH 8.0), 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA. Cell samples 
were gently rocked on ice for second 5 minutes then centrifuged at 2,000g for 5 minutes at 4°C 
to pellet cell nuclei. These were then resuspended in 400 μl of LB3 buffer: 10 mM Tris-HCl (pH 
8.0), 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, 0.5% N-lauroylsarcosine. 
Each sample was split equally into 2 Eppendorf tubes prior to sonication. 
A Bioruptor with regulated cooling system (Diagenode) was used to sonicate nuclear fractions on 
the ‘high’ setting for 30 minutes using cycles of 30 seconds on, 30 seconds off at 4oC. The 
sonicated samples were centrifuged at 11,000g for 10 minutes at 4oC in order to remove nuclear 
debris. The supernatant was transferred to new tubes before using a Nanodrop (Thermo 
Scientific) to quantify DNA concentration. 
 Dynabead preparation and Immunoprecipitation 
40 μl magnetic dynabeads (Life Technologies) was used for each immunoprecipitation sample. 
To prepare dynabeads, 700 μl of syringe filtered 0.5% BSA in PBS was used to wash 3 times. For 
each sample, 2 μg of appropriate primary antibody was added into beads preparation buffer and 
were incubated for at least 6 hours on a rotating wheel at 4oC. 
For each sample, 100 μg aliquot of chromatin was diluted in LB3 buffer containing 1% Triton X-
100 a final volume of 700 µl. Samples were mixed and a 10% volume of  LB3 buffer-containing 
chromatin sample was isolated as ‘inputs’ samples and stored at -20oC. The primary antibody 
incubated dynabeads were collected by discarding bead preparation buffer and the remaining 630 
μl of chromatin/LB3 samples were added and incubated for 16 hours at 4°C with rotation. 
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 Cross-link reversal  
Following immunoprecipitation, the beads were collected magnetically and chromatin/LB3 
solution was removed. RIPA buffer (50 mM HEPES-KOH, pH7.5, 500 mM LiCl, 1 mM EDTA, 1% 
NP40, 0.7% Na-deoxycholate) was used to wash beads 5 times and 1xTBS was used for the last 
wash. Dynabead/DNA complexes were incubated with 200 μl elution buffer (50 mM Tris-HCl, pH 
8.0; 10 mM EDTA; 1% SDS) to elute DNA. The inputs samples were also processed in elution buffer 
in parallel. All samples were incubated at 65oC with gentle mixing every 5 minutes for the first 15 
minutes. Following this, the samples were left to incubate for 8 hours.  
 
 Protein digestion and DNA purification  
Following the cross-link reversal, 200 µl TE buffer (pH8) and 4 µl of proteinase K (Qiagen) was 
added into all samples and incubated at 55 °C for 1 hour to degrade proteins. Finally, the 
GenElute™ Mammalian Genomic DNA Miniprep Kit (Sigma Aldrich) was employed to elute DNA 
according to the manufacturer instruction.  
 
  Quantification of protein enrichment by QPCR. 
Resultant DNA was measured by quantitative PCR (see section 3.14.3) using appropriate primers 
in Table 3.5 and Table 6.1. The data was analysed using the percentage input method, as this 
includes normalisation for background recruitment and the amount of chromatin added.Data 
was calculated as % Input using Ct (cycle threshold) values attained from the qPCR in the 
following equation: % Input=100x2
((Input Ct-3.2)-IP Ct)
. Data was subsequently presented as 
fold change of % Input between different experimental arms. 
Table 3.6 Primer sequences of specific androgen response elements of target genes 
 
DNA element 
 
Forward primer sequence (5’-3’) 
 
Reverse primer sequence (5’-3’) 
 
PSA ARE I promoter 
 
CCTAGATGAAGTCTCCATGAGCTACA 
 
GGGAGGGAGAGCTAGCACTTG 
68 
 
 
PSA ARE III enhancer 
 
TGGGACAACTTGCAAACCTG 
 
CCAGAGTAGGTCTGTTTTCAATCCA 
 
TMPRSS2 ARE enhancer 
 
TGGTCCTGGATGATAAAAAAAGTT 
 
GACATACGCCCCACAACAGA 
 
Control AR exon I 
 
GTGCTGTACAGGAGCCGAAG 
 
AACTTCACCGAAGAGGAAAGG 
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  Generation of CRISPR-edited PC model. 
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4.1 Introduction 
 
In the past 5 years, a novel ‘gene-editing’ technique, the prokaryotic type II CRISPR/Cas9 
(clustered regularly interspaced short palindromic repeats/CRISPR-associated) system of viral 
defense in bacteria, has emerged that enables scientists to manipulate and interrogate genes of 
interest in a wide range of model systems. The general CRISPR system contains two modules: a 
CRISPR RNA (crRNA) module that specifies the target DNA sequence, and a CRISPR associated 
(Cas) endonuclease module that cleaves double-stranded DNA. The S. pyrogenes type II CRISPR 
system is the most studied and wildly used genetic editing tool of all CRISPR types.  Functional 
analysis revealed the constitute CRISPR type II activity requires three components: the Cas9 
endonuclease, a target specific crRNA, and a structural trans-activating CRISPR RNA (tracrRNA) 
(Jinek et al., 2012). This system was further simplified by fusing the crRNA and tracrRNA to form 
a single guide RNA (sgRNA). 
 
The CRISPR/Cas9 system has  recently  been  adapted  for  genome  engineering  in  many  
organisms  including  zebrafish (Hwang et al., 2013; Xiao et al., 2013),  mouse (Wang et al., 2013; 
Yang et al., 2013a) and Drosophila (Bassett et al., 2013; Gratz et al., 2013; Kondo and Ueda, 2013; 
Ren et al., 2013; Yu et al., 2013; Sebo et al., 2014). This core methodology of CRISPR/Cas9 relies 
upon an engineered sgRNA to direct and enable Cas9-mediated endonuclease double-strand 
DNA cleavage at a specific genomic locus.  The resultant DNA break is recognized by the host 
cell’s surveillance machinery and triggers the process of DNA repair via two cellular mechanisms: 
non-homologous end-joining (NHEJ) and homologous recombination/homology-directed repair 
(HDR); both of which can be exploited for genome editing.  NHEJ is an imprecise/ error-prone 
process that, through the activity of  Ku70/ 80 heterodimer and DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs) (Tomkinson et al., 2013), results in small insertions and deletions 
(Indels) of DNA at the site of cleavage. In the context of genome editing, CRISPR utilizes this 
mechanism of DNA repair to irreversibly compromise the integrity of the targeted locus and 
effectively introduce gene knockouts in mammalian cells. By designing sgRNA targets at open 
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reading frames, CRISPR/Cas9 is recruited to the desired gene region where cleavage occurs and 
subsequent repair by NHEJ results in indels that often cause frame-shifts in the target gene.  This 
leads to either the production of a non-functional, truncated protein or the degradation of 
mutant mRNA through non-sense mediated mRNA decay. Whereas RNA interference (RNAi) 
rarely achieves complete silencing, CRISPR/Cas9 can generate genuine gene knock-out models. 
 
Additionally, CRISPR/Cas9 is utilized for precision genome engineering through enrollment of the 
HDR pathway to facilitate mutations, precise deletions and insertions. By supplying the cell with 
a donor DNA sequence homologous to the Cas9-targeted locus, but containing a desired 
mutation or Indel, CRISPR/Cas9-mediated DNA breaks repaired by HDR will enable accurate 
generation of knock-in mutations/indels at precise regions of the target gene. Furthermore, it 
can also be used for tagging protein-coding genes or the generation of duplicate genes. In the 
context of cancer biology, this approach is particularly useful for the generation of cell line and 
animal models with complex genetic alterations that mimic the mutational landscape of human 
tumors.  
 
CRISPR-Cas9 provides a robust technology for studying genomic rearrangements and the 
development and progression of cancers and other diseases. In fact, the flexibility and 
programmable capability of the CRISPR-Cas9 system has already led to the development of 
numerous genome engineering applications, most of which have been conducted successfully in 
the field of cancer genetics, such as lung cancer (Choi and Meyerson, 2014), acute myeloid 
leukemia (Chen et al., 2014a), and Ewing’s sarcoma (Torres et al., 2014). Moreover, , Heckl et al. 
(2014) and Xue et al. (2014)   have recently reported the application of an improved CRISPR-Cas9 
method for liver cancer and myeloid malignancy mouse model generation. Furthermore, by 
designing and using an efficient CRISPR system, Shtraizent et al. (2015) successfully corrected the 
oncogenic driver, Y163C hotspot mutation of TP53 in breast cancer cell lines. Significantly, in 
2016, the first clinical trial of applying CRISPR for cancer therapy has enrolled the first patient at 
Sichuan University’s West China Hospital in Chengdu (Cyranoski, 2016). Another human trial has 
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been approved in the US (Jubair and McMillan, 2017) for application of CRISPR-Cas9 to enable T 
cells to recognize and target several types of cancers.  
 
Although new treatments for castrate-resistant prostate cancer (CRPC), such as enzalutamide 
and abiraterone, have shown promise, moderate response rates and development of resistance 
to these agents has limited their clinical effectiveness. It is therefore vital we improve our 
understanding of the androgen receptor (AR) re-activation in advanced disease, focusing 
particularly on regulatory processes governing activity of AR mutants and splice variants (AR-Vs), 
to enable the development of patient orientated treatments in CRPC. By incorporating CRISPR-
based technology, we wanted to enable more physiological modelling of disease- particularly 
ADT-resistant tumours in which the AR was mutated.  Hence, the expected outcomes for this 
chapter was to comprehensively profile aberrant AR signalling that is vital for therapeutic 
exploitation by incorporating the next-generation genomic editing strategies to ultimately 
benefit advanced PC patients. Given the existence of the F876L mutation in enz-resistant 
patients, it is important to improve our understanding of the mutant receptor for the 
development of new treatments.  To this end, we designed a CRISPR workflow with the intention 
of generating CRPC cells lines containing this endogenous mutation.   
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4.2 Specific material and methods 
 Expression plasmids and constructs 
Lentiviral-CRISPR vectors (pLV-U6g-EPCG) sgRNA/CRISPR_186 (sgRNA: 
CATGTGTGACTTGATTAGC AGG) and sgRNA/CRISPR_196 (sgRNA: 
AAGTCACACATGGTGAGCGTGG) that express CAS9 and the specific guide RNA, were purchased 
from Sigma-Aldrich, order number 8019135988. Maxiprep kit (Sigma-Aldrich) was used to 
prepare the sgRNA/CRISPR_186 and sgRNA/CRISPR_196 plasmids.  
 Primers and repair DNA template  
Table 4.1 Primers for AR exon 8 amplification and Sanger sequencing 
Primers Sequences ( 5' to 3') Ref 
ARex_8 s’ GAGGCCACCTCCTTGTCAACC Used for AR exon 8 PCR 
amplification ARex_8as’ CAGGCAGAAGACATCTGAAAG 
CRISPR_LNCaP_e8 F CAGTGGATGGGCTGAAAAAT 
For Sanger sequencing 
CRISPR_LNCaP_e8 Re AATTCCCCAAGGCACTCAG 
 
 Repair oligo sequences (5' to 3'): 
The designed single stranded donor oligonucleotides (ssODN) was chosen as a repair donor to 
‘knock-in’ F876L via homology direct repair (HDR) post Cas9 induced-double strand break (DSB). ‘Cat’ 
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and ‘Act’ in each ssODN was used to substitute endogenous mutation H874Y and T877A in CWR22Rv1 
and LNCaP cell lines, respectively. Ctc was used to knock in F876L mutation. tCg was used to silence PAM 
code as well as introduce a Sal I restriction site for downstream RFLP analysis. 
All the primers used to detect single-stranded oligodeoxynucleotides (ssODN) incorporation are 
list below:  
Table 4.2 primers for detecting ssONDF876L in LNCaP and 22Rv1 cells. 
Primers Sequences ( 5' to 3') Ref 
LNCaP_T877A F CAGTTCGCTTTTGACCTGCT Used to verify ssONDF876L 
incorporation in LNCaP 
cells  
LNCaP_F876L F CATCAGCTCACTTTTGACCT 
LNCaP Re GGGGTGGGGAAATAGGGTTT 
22Rv1_H874Y F CTGTATCAGTTCACTTTTGACCT Used to verify ssONDF876L 
incorporation in 
CWR22Rv1 cells 
22Rv1_F876L F CATCAGCTCACTTTTGACCT 
22Rv1 Re GGGGTGGGGAAATAGGGTTT 
 
 Nucleofection 
Nucleofection transfection protocol for PC cells was optimized using Amaxa® Nucleofector® Kit 
(Lonza Cologne AG, USA /Canada). For each transfection reaction, 5 μg sgRNA/CRISPRs plasmids 
and 40 μl of 50 mM ssDNA (1 µl of a 10 µM ssODN template stock) were add into 100 μl room 
temperature Nucleofector® Solution R (including 18 μl supplement). 2*106 cells were 
trypsinised and cell pellet was collected by centrifugation at 100g for 10 minutes. The cell pellet 
and prepared DNA/ Nucleofector Solution and all components were transferred into a certified 
cuvette and subject to the Nucleofector® Program T-009 (T-09 for Nucleofector® I Device) for 
transfection. ~400 μl of the pre-equilibrated culture medium was immediately added to the 
cuvette once the program completed before transferring into the prepared polyLysine-coated 
6-well plate (final volume 1.5 ml per well) and incubated at 37oC for 8-20 hours before 
examining GFP expression. Images were acquired using a Leica DMR fluorescent microscope 
with appropriate filters.  
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 Fluorescence-activated cell sorting (FACS).  
The efficiency of CRISPR/CAS9 genomic editing in nucleofected LNCaP and CWR22Rv1 cells was 
assessed by the Surveyor (CEL-1) assay. This required cells to be initially sorted based on 
expression of GFP as a marker of uptake of the pLV-U6g-EPCG vector. Two days after transient 
transfection, cells were sorted using FACS (Aria III, BD Biosciences) and GFP-positive cells were 
identified and sorted by comparing to a non-transfected population of cells. GFP-positive cells 
were collected and plated accordingly. For the Surveyor assay, 1 × 104 cells were plated on 6-
well plates and maintained until confluent; whereas for isolation of individual clones, cells were 
plated on 10-cm dish at 500-2,500 cells per dish with puromycin containing medium (10μg/ml) 
until individual colonies were visible. 
 
 Surveyor assay 
The Surveyor assay (optimized from Surveyor Mutation Detection Kit protocol, Integrated DNA 
Technologies) was used to assess sgRNAs/CRISPR targeting efficiency. HEK293, CW22Rv1 and 
LNCaP cells were nucleofected for 48 hours before being subject to fluorescence-activated cell 
sorting (FACS) to sort GFP-positive, pLV-U6g-EPCG-containing cells. FACS enriched cells were 
seeded back into 6- well plates and cultured with puromycin-containing media for 7 days. 1 
week post transfection, genomic DNA was extracted (GeneElute Genomic DNA extraction kit, 
Sigma) from each control and CRISPR transfected cell pool and subject to PCR (Platinum™ Taq 
Green Hot Start DNA Polymerase, Invitrogen) to amplify the regions spanning CRISPR/Cas9 cut 
sites using specific primers pairs (Table 4.1). Plasmids C and G fragments (Transgenomics, Inc.) 
were also amplified and run in parallel as a positive control. 
 The optimized PCR reaction as bellow:  
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Composition Volume 
10* reaction buffer  
50 µM MgCl2 
10 mM dNTP mix  
10 nM AR exon8 primer forward  
10 nM AR exon8 primer reverse  
Genomic DNA sample 
DNA polymerase 
Nuclease‐free H2O 
5 µl  
1 µl  
1.5µl  
1μl 
1 μl 
≤ 100 ng 
0.2 µl  
Up to 50 µl 
 
Thermocycler reaction was set up as bellow:  
Initial denaturation  94°C 2 minutes 
Denature 94°C 30 seconds 
Anneal ~55°C 30 seconds 
Elongation 72°C 2 minute 
PCR cycles 30 
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To facilitate the formation of mismatched fragments, 400 ng control or hybridised DNA was 
denatured at 95oC for 10 minutes and re-annealed by gradually ramping from 95 °C to 85 °C at 2 
°C/s, 85 °C for 1 minute, ramping from 85 °C to 75 °C at 0.3 °C/s, 75 °C for 1 minute, ramping from 
75 °C to 65 °C at 0.3 °C/s, 65 °C for 1 minute, ramping from 65 °C to 55 °C at 0.3 °C/s, 55 °C for 1 
minute, ramping from 55 °C to 45 °C at 0.3 °C/s, 45 °C for 1 minute, ramping from 45 °C to 35 °C 
at 0.3 °C/s, 35 °C for 1 minute, ramping from 35 °C to 25 °C at 0.3 °C/s, and 25 °C for 1 minute to 
25oC before digesting with 1 unit of Surveyor endonuclease enzyme for mismatching detection.  
Each digestion reaction component including:  
Composition Volume 
Control/ hybridized DNA  
 
0.15 M MgCl2 Solution 
Surveyor Enhancer S 
Surveyor Nuclease S 
400 ng 
( within ≤ 10 μl 1*PCR reaction buffer) 
1 μl 
1 μl 
1 μl 
 
After incubation at 42oC for 60 minutes, 1.3 μl stop solution was added.  The digestion products 
were resolved on a 2% Agarose TBE gel and the fragments were visualized using Bio-Rad Chemi 
XRS Gel Documentation system and Bio-Rad Quantity One® software (Bio-Rad Laboratories, Inc.). 
The fragments quantified using Image J.  
Indels were calculated using the following formula, 
𝑖𝑛𝑑𝑒𝑙(%) = 100 × (1 − √
𝑏 + 𝑐
𝑎 + 𝑏 + 𝑐
) 
78 
 
where a is the intensity of the undigested fragment, and b and c are the intensities of the cleavage 
products. 
  DNA polyacrylamide gel electrophoresis (DNA-PAGE) 
PCR products that consisted of amplicons shorter than 300 bp were run using a PAGE gel in order 
to provide appropriate separation of the bands. The electrophoresis was performed on 8% PAGE 
in 1 x TBE buffer as denoted below.  
Table 4.3 8% PAGE composition 
Composition Volume Final concentration 
1 x TBE 
30% acrylamide/bis-acrylamide 
10% ammonium persulfate 
TEMED 
8 ml 
2.5 ml 
120 µl 
10 µl 
~1 x 
8% 
0.1% 
0.1% 
 
 
The gel was run on vertical electrophoresis apparatus using 1 x TBE buffer as running buffer. Each 
sample was mixed with 6 x loading dye and subject to PAGE at 50 V for approximately 1 hour. 
Afterwards, the gel was stained with GelRed (Biotum) and visualised using a Geldoc camera and 
software (BioRad). 
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4.3 Results 
 Design and testing of Cas9/sgRNA complexes targeting exon 8 of the AR gene to 
facilitate generation of the enzalutamide-activated ARF876L mutant. 
Firstly, LNCaP and CWR22Rv1 were chosen for CRISPR model generation. Both PC cell lines are 
commonly used in in vitro cell culture assays as well as in xenograft mouse experiments. LNCaP 
is an androgen-sensitive and full-length AR (AR-FL)-expressing cell line that was derived from a 
lymph node metastasis (Zhau et al., 1996); whilst CWR22Rv1, a cell line derived from a xenograft 
tumour grown in castrate conditions, co-express AR-FL and AR-Vs species (Dehm and Tindall, 
2011). Of particular note, as shown in Figure 4.1, LNCaP and CWR22Rv1 cell  lines endogenously 
express one LBD-mutation, T877A (ACT-GCT) and H874Y (TTC-CTC), respectively. 
Figure 4.1 Schematic representation of desired CRISPR-induced editing in LNCaP and CWR22Rv1 cells. 
The AR exon8 and exon7 coding region are indicated by grey color. F876 mutation site is highlighted in 
blue and endogenous mutations H874Y and T877A within CWR22Rv1 and LNCaP shown in red and green, 
respectively.  
 
Two all-in-one lentiviral CRISPR vectors (pLV-U6g-EPCG, purchased from Sigma), that express 
both S. Pyogenese-derived Cas9 and bespoke gRNAs, were used to target AR exon 8. Each plasmid 
(Figure 4.2 A) encodes one Cas9 enzyme and one gRNA, and were named sgRNA186 and 
sgRNA196. Both gRNAs targeted AR exon 8 at distinct sites based on the position of the 
protospacer adjacent motif (PAM, highlighted in pink in Figure 4.2.B). In addition to the custom 
designed CRISPR reagents, a single-strand oligodeoxynucleotide (ssODN) complementary to exon 
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8 was designed as a repair donor template to facilitate ‘knock-in’ of the ARF876L mutation via HDR 
post Cas9-induced DNA break.  
 
Figure 4.2 Design of the Cas9/sgRNA targeting AR exon 8.  (A) Vector map of the all-in-one CRISPR vector 
pLV-U6g-EPCG.  Cas9 open reading frame (ORF) flanked by puromycin and GFP elements allows for 
selection, and enrichment of desired positive cells. (B) Schematic of custom designed sgRNA186 and 
sgRNA196 target site in AR exon 8 coding sequence. Each target sequence (protospacer) and ‘PAM code’ 
for sgRNA186 and sgRNA196 are given in bold. Red arrows and vertical dotted line indicate the expected 
cleavage site of each sgRNA.  Black arrows represent PCR primers using to amplify targeted regions. 
 
To validate ‘on-target activity’ of the two CRISPRs, HEK293T cells were firstly transfected with 
Cas9/sgRNA expression plasmids using LT-1 (Mirus Bio) for 72 hours. GFP expression derived from 
the plasmids was subsequently analysed using a fluorescent microscope as an indication of 
transfection efficiency. As shown in Figure 4.3 A, in HEK293T cells, both plasmids demonstrate 
high GFP expression post Cas9/sgRNA186 and Cas9/sgRNA196 transfection. 
 
Next, CRISPR target efficiency was assessed. Genomic DNA was extracted from transfected and 
non-transfected cell pools and subject to AR gene exon 8 amplification by PCR using pre-designed 
primers (list in Table 4.1) before incorporation in to the Surveyor assay (Figure 4.3 B). This 
experiment relies upon a mismatch-specific DNA endonuclease, Surveyor Nuclease, which cuts 
both strands of a DNA heteroduplex on the 3’-side of the mismatch site with high specificity. This 
initial optimisation experiment relies upon NHEJ-based DNA repair to ligate the CRISPR-induced 
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cleavage event. Due to the error-prone nature of this mechanism, CRISPR efficiency can be 
assessed using the Surveyor Nuclease to quantify the rate of indels within the targeted DNA 
region as a measure of CRISPR efficiency. 
Figure 4.3 Assessing designed- Cas9/sgRNA targeting efficiency using Surveyor mutation detection 
assay. (A) Equal amounts of two designed Cas9/sgRNA plasmids were transfected into HEK293T cells. The 
florescence image is taken 24 hours post-transfection.  (B) The flow chart of Surveyor assay. Genomic DNA 
is harvested from the transfected pool of cells and amplified at the locus of interest. The PCR product is 
denatured and re-annealed creating heteroduplexes between wild-type and modified amplicons. The 
Surveyor mismatch endonuclease assay results in cleavage of heteroduplex molecules. The Surveyor 
enzyme digests are resolved by PAGE. The observed ratio of cleavage product to parental band indicates 
the fraction cut, and hence, efficiency of DSB. (C) Surveyor Nuclease digestion products of amplicons 
derived post transfection and the control/ wildtype sequence in HEK293T cells. Lane heading indicates 
non-transfected wildtype cells (wt) and sgRNAs index names. “-” denotes PCR amplicon products of control 
or Cas9/sgRNA transfected cells prior to Surveyor treatment. “+” indicates Surveyor enzyme digestion 
products. Red arrows highlight Surveyor enzyme detected heteroduplexes in the plasmid-
transfected/wild-type samples. Cleavage frequency was analyzed using Image J.   
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As illustrated in Figure 4.3 B, equal quantities of PCR amplicons containing potential Cas9-induced 
Indels are denatured and reannealed with the wild-type amplicon and then digested with 
Surveyor nuclease to discriminately cleave on the 3’-side of the heteroduplexes formed between 
mismatched Indel- and wild-type-containing duplexes. The resultant DNA is resolved using 2% 
agarose gel electrophoresis and successful Cas9-mediated cleavage was identified by shifts in 
fragment size with respect to the wild-type fragment.  
As shown in Figure 4.3 C, the total size of AR exon 8 is 269 bp based on pre-design primers. Upon 
CAS9-induced cleavage and NHEJ-mediated DNA repair at the desired site, a 116 bp, and 153 bp 
size was observed as a consequence of digestion by the Surveyor enzyme. The indels were 
identified at a frequency of ~6.9% in cells transfected with sgRNA196, which contrasted with cells 
expressing sgRNA186 which demonstrated negligible heteroduplex formation, suggesting that 
the sgRNA196 plasmid performs more efficiently to cleave exon 8 of the AR gene.  
 
 Cas9/sgRNA196 is ‘on-target’ in CWR22Rv1 and LNCaP cells. 
Having confirmed that the Cas9/sgRNA196 had more efficient ‘on-target’ capability in vitro, we 
next moved to assess its editing ability in both LNCaP and CWR22Rv1 cells. As both cell lines are 
challenging to transfect, particularly with large plasmids such as pLV-U6g-EPCG, several delivery 
approaches were performed to elevate transfection efficiency sufficiently to facilitate generation 
of edited cells lines downstream.  
Table 4.4 Optimising Cas9/sgRNA delivery methods for different cell lines.  To achieve sufficient 
transfection efficiency, several exogenous nucleotide delivery approaches were used in HEK393T, LNCaP 
and 22Rv1 cell line.   
As listed in Table 4.4, lipophilic reagents, such as LT-1, are sufficient to transfect HEK293T cell, 
but not for LNCaP cells. Surprisingly, post LT-1 transfection, GFP was expressed in CWR22Rv1 
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cells to modest levels, but resultant Indels were not detected within AR exon 8 (data not shown) 
( Appendix 4B A), suggesting a more improved means of plasmid delivery is required for both 
prostate cancer cells lines.  
 
Given that CWR22Rv1 cells demonstrated modest lipophilic-based transfection, it was next 
sought to address if electroporation-based methods may elevate uptake of the Cas9/sgRNA196-
expressing plasmid. To this end, we applied Nucleofection to introduce the CRISPR plasmid into 
CWR22Rv1 cells, and after 48 hours GFP-positive cells were sorted and cells harvested for 
Surveyor assay. As results show in Figure 4.4 A, post 48 hours Nucleofection, GFP expression was 
detected in approximately 75% of CWR22Rv1 cells indicating that transfection efficiency is 
markedly improved using this technique. Importantly, the Surveyor assay confirmed 
Cas9/sgRNA196’s ‘on-target activity’ as evidence by approximately 16% heteroduplex formation 
in transfected cells compared to untransfected cells (Figure 4.4 B). Importantly, cleavage 
products were dependent on the presence of the Surveyor enzyme and are not artefacts of the 
PCR reaction.  As shown Figure 4.4 B, comparing lane 1, additional two small size of DNA 
fragments can be seen in lane 2 in the presence of Surveyor enzyme, suggests that the 
Cas9/sgRNA196 plasmid presenting ‘on-target’ activity in 22Rv1 cells. The lanes 3 and 4 were 
severed as negative control for wild-type amplicon and Surveyor enzyme, respectively. Given 
successful Indel detection, the Surveyor assay was applied to all subsequent CWR22Rv1 cell 
experiments. 
Figure 4.4 Nucleofection of CWR22Rv1 results in a successful Cas9/sgRNA196 mediated-cleavage at AR 
exon 8.  (A) 48 hours post-Nucleofection, GFP positive cells in CWR22Rv1 cells were sorted using a FACS 
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Aria III flow cytometer (Becton Dickenson). (B) Surveyor assay was carried on GFP-positive cells to assess 
Cas9/sgRNA196-induced cleavage of target region.   
 
Although Nucleofection increased GFP expression in LNCaP cells in comparison to LT-1 reagent, 
the subsequent Surveyor assay failed to detect any heteroduplexes (Appendix 6A) indicating 
transfection efficiency remains too low to effectively edit the LNCaP genome. Therefore, we 
decided to package Cas9/sgRNA196 plasmids into lentivirus to transduce LNCaP cells, which in 
theory will increase efficiency significantly.  
 
Lentiviral particles containing the Cas9/sgRNA196 plasmid was generated using HEK293T cells as 
described in section 3.8. 7 days post viral infection, GFP expression was assessed using 
fluorescent microscopy. As shown in Figure 4.5 A, compared to the bright field image, most 
LNCaP cells transduced with the Cas9 plasmid express GFP, albeit heterogeneously. Importantly, 
the Cas9/sgRNA196 plasmid presenting ‘on-target’ activity in LNCaP cells as evidenced by 
detection of approximately 15% cleavage events within the target locus using the Surveyor assay 
(Figure 4.5 B). 
Figure 4.5 Targeting AR gene exon 8 in LNCaP cells. (A) Representative images of LNCaP cells infected with 
the Cas9/sgRNA196-containing lentivirus. Fluorescence images were taken 7 days post-transduction of 
LNCaP cells with virus particles containing pLV-U6g-EPCG_ Cas9/sgRNA196.  Transduced group, (B) bright 
field, (F) fluorescent field. (B) Surveyor assay confirmed genomic editing in transduced LNCaP cells within 
the target locus. 
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 Confirming Cas9/sgRNA196-mediated genome editing of AR exon 8 using a Sanger 
sequencing-based approach. 
As a consequence of imperfect DNA repair after Cas9-mediated cleavage, DNA in the transfected 
cell pool consists of a mixture of wild-type and Indel-containing sequences as demonstrated 
above using the Surveyor assay. To confirm the effect of Cas9/sgRNA196 editing of exon 8 of the 
AR gene, the PCR amplicons from both control (untransfected) and Cas9/sgRNA-transfected cells 
were subject to Sanger sequencing. The resultant sequencing chromatogram was subject to 
analysis using an online tool, named TIDE (Tracing Indel by DEcomposetion), to validate and 
quantify Indel type in each sample (Brinkman et al., 2014). TIDE software quantifies sequence 
trace data from two standard capillary (Sanger) sequencing reactions. By decomposing target 
sequence traces, and based on identification of the predominant types of insertions and 
deletions (indels) in the DNA of a targeted cell pool, TIDE can ultimately quantify editing efficacy 
of specific CRISPRs.  
 
As shown in Figure 4.6 A, compared to non-transfected CWR22Rv1 cells, cells transfected with 
the Cas9/sgRNA196 clearly revealed a heterogeneous sequencing pattern 3 bp upstream of the 
PAM sequence, which is consistent with NEHJ-mediated repair (Wu et al., 2014)). The sequence 
trace after cleavages site (vertical dotted line in Figure 4.6 B) consists of a mixture of signals 
derived from both intact DNA and cleaved DNA. A different number of nucleotides therefore are 
shifted due to insertions and deletion following Cas9-induced DNA cleavage. The overall 
Cas9/sgRNA196-induced Indel frequency in CWR22Rv1 cells was approximately 34% that is 
consistent with previous reported Surveyor assay results. However, quantification of CRISPR 
efficiency using TIDE demonstrates a 2-fold increase compared to that calculated using the 
Surveyor assay (Figure 4.4) which may be due to the less accurate Image J-based method being 
not fully quantitative. 
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Figure 4.6 DNA sequencing chromatograms of Cas9-targeted region in AR exon 8 and TIDE analysis. (A) 
Chromatograms of AR exon 8 amplicon sequencing from a control and Nucleofected cell pool. The 
positioning of the gRNA196 and PAM site were indicated in relation to the sequencing plot. The predicated 
cutting site was indicated with red-arrow. (B) Assessment of genome editing efficiency by TIDE to quantify 
the overall Indel frequency and major Indel type in the sample. Visualization of aberrant sequence signal 
in wild-type (black) and sgRNA196 sample (green), the expected break site (vertical dotted line) and the 
region used for decomposition (grey bar). See main text and http://tide.nki.nl for explanation (C). 
Decomposition yielding the spectrum of indels and their frequencies; the TIDE software decomposes the 
composite sequence trace into its individual components by means of multivariate non-negative linear 
modeling, with the control sequence trace serving as a template to model the individual indel components. 
This decomposition results in an estimate of the relative abundance of every possible indel within a chosen 
size range. 
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 Enrichment of positive cell populations for increased gene editing events in LNCaP cells. 
We next sought to determine whether enrichment of successfully-transduced LNCaP cells would 
enhance Cas9/sgRNA196 efficiency in order to increase knock-in efficiency when the repair 
template was incorporated in future experiments. Therefore, 7 days after lentivirus infection, 
LNCaP cells were cultured with/without puromycin-containing medium for an additional week to 
enrich Cas9/sgRNA196-transfected cells before conducting PCR and CRISPR efficiency analysis.  
 
As can be seen from the sequencing chromatogram in Figure 4.7 B, puromycin-selected cells 
show higher ‘on-target’ effects when compared to control and cells not under puromycin 
selection pressure. The total efficiency of Cas9/sgRNA196 is approximately 30% in LNCaP cells 
without selection and is increased to 46.6% post-puromycin selection. These results are 
consistent with the Surveyor assay data (shown in Figure 4.7 C) that demonstrates Indel 
frequency of AR exon 8 is increased from 15% to over 21% post-antibiotic selection, indicating 
that selection increases editing events in LNCaP cells by enriching transfected cells from a mixed-
cell pool.  
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Figure 4.7 Enrichment of cell populations for increased gene editing events in LNCaP. (A) DNA sequencing 
chromatograms of AR exon 8 amplicons from control and Cas9/sgRNA196-transfected cells with and 
without puromycin selection post viral infection. (B) The enhanced Indel frequency in the LNCaP post 
puromycin selection culture as calculated by TIDE analysis. (C) Surveyor assay was conducted using same 
gDNA from (A). Surveyor-generated small fragment were indicated with red dots.  Compared to 
puromycin-lacking samples, the puromycin-selected cell samples contains higher level of DNA indels within 
AR exon 8. 
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 Design of donor template and knock-in of the F876L mutation. 
Given that the Cas9/sgRNA196-expressing plasmid was shown to effectively induce Indels within 
AR exon 8, it was important to next design and utilize a 200 bp single-strand oligodeoxynucleotide 
(ssODN) (Figure 4.8 A) containing the ARF876L mutation that would enable the creation of knock-
in clones via HDR that express the enzalutamide-activated ARF876L mutant in LNCaP and 
CWR22Rv1 cells. The ssODN contains a 200 bp sequence homologous to exon 8 of the AR gene, 
encompassing the F876 codon, as well as two homology arms on both sides (see 4.2.3, full 
sequence see Appendix 4C). In addition, we also designed an ssODN with wild-type sequence in 
order to reverse endogenous mutations T877A and H874Y back to wild-type in LNCaP and 
CWR22Rv1 cells, respectively.  In addition to removing the PAM (TGG-TCG) site to avoid Cas9-
mediated cutting once the knock in mutation was achieved, we purposefully introduce a novel 
restriction digest site (Sal l, G^TCGAC) into each ssODN. Thus, post HDR, the successful knock-in 
mutation within the genome of LNCaP and CWR22Rv1 cells can be identified using a restriction 
fragment length polymorphism (RFLP) assay.  
 
 
Interestingly, co-delivery of the Cas9/sgRNA196 plasmid and ssODN by nucleofection into 
CWR22Rv1 resulted in cells forming colonies; with GFP expression lasting up to 7 days. As 
heterogeneous GFP expression was detected in the (Figure 4.8 C), 10 colonies were selected for 
potential successful insertion/ or gene replacement detection. 
90 
 
Figure 4.8 Co-transfection of CWR22Rv1 cells with Cas9/sgRNA196 plasmid and ssODN.  (A and B) A 
schematic of designed ssODN donor template.  F876L coding sequencing is introduced via two homology 
arms (gray regions). The additional inserted restriction enzyme sequence is indicated in blue. (C) 
CWR22Rv1 cells formed colonies post nucleofection with Cas9/sgRNA196 and the ssODN.  Fluorescence 
image taken 7 days post co-transduction.   
 
The CRISPR-targeted sequence of AR exon 8 was amplified from selected colonies by PCR and the 
resultant product was purified and digested with the Sal l restricted enzyme which represented 
our bespoke RFLP assay to detect knock-in mutations. All colonies screens harbored Cas9-
induced Indels at the targeted locus, but unfortunately, none of them showing successful ssODN 
insertion following RFLP analysis ( Appendix 4A). The same results were observed in LNCaP cells 
( Appendix 4B). It may be due to HDR events being generally less frequent than the repair of DNA 
by non-homologous end-joining. Additionally, the sensitivity of RFLP may not be sufficient to 
detect low level of ssODN ‘incorporation’ that occurred in a small cell population.  
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 Screening successful gene editing events in heterogeneous samples. 
In order to validate whether desired knock-in events were present in the heterogeneous LNCaP 
cell pool, we designed two pairs of specific primers in an attempt to enhance our sensitivity of 
knock-in mutation detection by quantitative PCR. Both primer sets (Figure 4.9 A) share the same 
reverse primer that anneals downstream of the target region. The first forward primer amplifies 
outside of the target region to be used as a reference, whilst the second forward primer, termed 
the detection primer, is complementary to the knock-in mutant sequence.  
 
Figure 4.9 Screening successful gene editing events in heterogenetic sample.  (A) Two pairs of primers 
were designed to detect ssODN ‘knock-in’ level from whole CRISPR-edited heterogenetic cell pool. Both 
primer set share the same reverse primer while the first forward primer amplifies outside of target region 
and is used as a reference; whilst the second forward primer (indicated as grey dotted line) flanks the 
desired mutation sequence. Samples were analysed using both quantitative PCR (B) and conventional PCR 
(C).  
 
Using quantitative PCR analysis incorporating genomic DNA derived from LNCaP cells 7 days post 
transfection with either control, Cas9/sgRNA196 or Cas9/sgRNA196 + ssODN, it is shown in Figure 
4.9 B that by using the F876L primer, which should only detect the F876L mutants, the F876L 
mutation was specifically detected in the Cas9/sgRNA196 + ssODN co-transfected sample but not 
in parental or cells that were only transfected with the Cas9/sgRNA196 plasmid. Similar results 
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were obtained using conventional PCR (Figure 4.9 C). Co-transfected LNCaP (n1, n2 are two 
individual repeats) shows higher F876L amplify products than that in parental or cells post single 
Cas9/sgRNA transfection.  Of particular note is that although repeated readouts were consistent 
between experimental repeats, there is only one nucleotide difference between the wild-type 
and mutant detection forward primers, hence it would be more robust to verify the efficiency of 
each primer pair by performing a QPCR on plasmids encoding wild-type vs F876L. 
 
Pure clonal isolation from a single progenitor cell is a critical step in the genetic and functional 
characterisation of mutations achieved by the CRISPR/Cas9 system. Hence, having confirmed a 
low level of desired editing events in mixed cell populations, we next sought to generate ‘knock-
in’ clones that were derived from single cells. LNCaP and CWR22Rv1 cells were transfected with 
Cas9/sgRNA196 and ssODN according to their optimized conditions (indicated in black and red, 
respectively, Figure 4.10 A). To enrich for GFP-positive cell populations, FACS sorting was carried 
out in each cell pool before plating in 48-well plates to obtain transfection-positive cells. Although 
it is desirable to establish clonogenic cultures from single cells, it was difficult to propagate cells 
post-selection when seeded individually in culture vessels which may due to the impact of FACS 
sorting or compromised growth as a consequence of diminished cell to cell contact. 
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Figure 4.10 Overview of the approach to isolate rare ‘knock-in’ mutants from mixed populations. (A) The 
optimised CRISPR approach applied in LNCaP and CWR22Rv1 cells. The two PC cell line are 
transduced/Nucleofected with both Cas9/sgRNA and ssODN accordingly.  (B) Sequential PCR screening of 
‘knock-in’ colonies.  Through first (top), second (middle) and third (bottom) round screening, the F876L 
coding sequence frequency in each well will be measured as described in Figure 4.9. Red dots indicate 
wells that contain mutated cells; blue arrow highlights the best well. 
 
Therefore, further consideration was made by increasing cell number in each well after FACS 
sorting and additional selection condition was included to enrich the desired ‘knock-in’ cells. 
Firstly, given that repair of Cas9-induced DSBs can be mediated by either NHEJ or HR pathways, 
it was sought to facilitate detection of knock-in mutants by utilizing the QPCR-based mutation 
reporter assay as described above. In addition, the enzalutamide containing medium was used 
for selective growth in the heterogeneous cell populations of LNCaP cells. Of note, it wasn’t used 
for CWR22Rv1 due to the presence of AR variants expression. As illustrated in Figure 4.10 B, in 
order to sequentially select and enrich ARF876L ‘knock-in’ colonies, half of the cells from each 48-
well plates post-FACS sorting were analyzed for ‘knock-in’ frequency. More specifically, the 
primers used in Figure 4.9 was used to identify the wells containing F876L coding sequence. Cells 
from the corresponding replica plate well was subdivided into another 48-well plate. In addition, 
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as the intended ‘knock-in’ F876L mutation enables enzalutamide resistance, theoretically, upon 
Cas9-mediated ‘knock-in’, the F876L mutation may further support selection of genome edited 
cells by long-term growth in enzalutamide. To that end, puromycin- and enzalutamide-containing 
medium was used as additional selection pressure to facilitate outgrowth of successfully edited 
LNCaP and CWR22Rv1 cells. Therefore, after sequential PCR screening, we should enrich the 
progeny of mutant cells with each round of selection. Ultimately it should allow us to isolate 
ARF876L knock-in clones.  
Figure 4.11 Summary of the sequencing screening of mixed LNCaP and CWR22Rv1 cell population. (A). 
Characterisation of indels induced by CRISPR-Cas9 as determined by Sanger sequencing of selected 
colonies. Deletion/inversion frequency and characterisation of outcomes when using AR exon 8 primers. 
(B). Mutation patterns in single-cell colonies were determined by Sanger sequencing. (C & D). Sanger 
sequencing chromatogram reveals large fragment insertion and deletion upon Cas9/sgRNA196 cleavage.  
 
Both LNCaP and CW22RvI cells were transfected/transduced with both Cas9/sgRNA196 and 
ssODN components as described in Figure 4.10 . PCR amplicons containing AR exon 8 from 
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enriched cell colonies were subsequently processed by Sanger sequencing analysis. Compared to 
the unenriched heterogeneous population (Figure 4.11 A) that, as expected, displays 
considerable sequence variation within the targeted locus, near clonal populations of cells 
demonstrated a significantly reduced signal noise (Figure 4.11 C &D). Genomic features of AR 
exon 8, including deletion, insertion, scar, and complex alleles or no editing frequency, for all 91 
clones were calculated across both LNCaP and CWR22Rv1 examined in detail and summarized  in 
Figure 4.8 B. A large number of colonies were found to undergo Cas9/sgRNA-mediated NHEJ: 37 
colonies (40.6%) displayed small or larger DNA fragments deletion and 27 (29.6%) had small 
nucleotides insertion (one example of each are presented in Figure 4.11 C &D). 18 sub-clones 
(19.8%) were ‘uncut’ or wild-type while the remaining 9 clones reveals genomic scar-based 
sequencing failure (9.7%).  
 
Disappointingly, no intended ARF876L mutation was detected in all selected colonies; this was 
confirmed in 2 randomly selected cell populations by cloning the genomic DNA PCR product and 
sequencing. One potential reason for this observation is that not all cells were edited as intended 
due to NHEJ predominating as the DNA repair pathway in these growth conditions. Additionally, 
given that the cell populations were not truly clonal, outgrowth of wild-type or NHEJ-repaired 
cells may have occurred at the expense of precise knock-in mutations. Clonogenic isolation and 
assessment of genomic editing type is time-consuming and labour-intensive. To design the most 
effective screening strategy, a crucial step is to realistically estimate the chance of obtaining the 
desired mutant cells in the pool undergoing CRISPR-mediated genome engineering. Although a 
number of successful ‘knock-in’ events have been reported (Richardson et al., 2016; Wang et al., 
2016; Yoshimi et al., 2016), a considerable number of unstudied factors may have also impacted 
the ultimate efficiency of Cas9-mediated knock-in via HDR. This will be discussed in more detail 
in the next section. 
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4.4 Discussion 
 Design and generation of sgRNA/Cas9-editied enzalutamide-resistant PC cell model by 
knock-in of the ARF867L mutation. 
CRISPR/Cas9 contains two key components, a small guide RNA and a Cas9 protein. Upon delivery 
into cells, the Cas9 protein is readily targeted to DNA sequences of interest based on designed 
sgRNAs. For the Streptococcus pyogenes Cas9 particularly, the enzymatic activity is driven by a 
20 nucleotide DNA sequence that is complementary to the crRNA and upstream of a 'NGG’ 
protospacer adjacent motif (5ʹ-PAM-3ʹ). Binding between Cas9 and PAM is vital for the initiation 
of target activity. Cas9 unwinds the DNA duplex upstream of the PAM to allow cleavage of both 
the target and nontarget strands of substrate DNA (Fuguo and Jennifer, 2017). Upon cleavage, 
Cas9-mediated DSB site undergo DNA repair which most frequently leads to genetic aberration 
as a consequence of error-prone NHEJ repair and the generation of indels. This approach is now 
often used for gene knockout studies (Li et al., 2014). Alternatively, in the presence of a repair 
template, the Cas9-targeted double-strands break site undergoes HDR, which can be used to 
insert a gene (Yoshimi et al., 2016) or in our case, used for precise gene editing of desired knock-
in mutations. 
 
In our CRISPR system, we initially designed two small guide RNA that targets AR exon 8 that are 
adjacent to the F876 codon (Figure 4.1). By co-delivery of our Cas9/sgRNA with a repair DNA 
template containing the F876L mutation into LNCaP cells, our primary objective was to introduce 
the F876L mutation within  AR exon 8 gene of the PC cell line. An additional aim using a wild-type 
DNA template, was to reverse the endogenous T877A mutation in LNCaP cells back to wild-type 
(wt-AR). From this wt-AR LNCaP cell line, CRISPR would then subsequently enable the generation 
of an LNCaP_ARF876L mutant cell line by incorporating a distinct donor template containing the 
F876L mutation. 
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In addition, in this Chapter, we have also employed the CW22Rv1 cell line that expression both 
AR-FL and several splice variant isoforms of the receptor (AR-Vs) that lack the ligand-binding 
domain. This truncated version of the receptor has been recently discovered and has been found 
to play an important role in disease progress (Dehm and Tindall, 2011). Importantly, AR-Vs has 
been found overexpressed in over 60% of CRPC patients (Zhang et al., 2011). Therefore, 
CWR22Rv1 cells provide an additional cell line to establish the CRISPR pipeline and represent a 
further clinically-relevant background to study the impact of AR mutations; critically since they 
express an endogenous ARH874Y mutant (Figure 4.1) that is abnormally activated by the antagonist 
Cyproterone Acetate (CPA). Importantly, a clinical correlation between estrogenic stimulation 
and H874Y mutation has recently been reported (Vasudevamurthy et al., 2017). One PC patient 
was found to harbor the H874Y mutation following ADT therapy and who later had a poor 
response to enzalutamide. Therefore, by reversing the endogenous mutation back to wild-type 
or performing knock-in of the F876L, we will provide an extensive repertoire of models to study 
enzalutamide resistance in the presence of AR-Vs and pre-existing AR mutants. Critically 
however, these exciting aims were never realized due to the challenge of generating specific 
knock-in mutations within both cell lines as discussed below.  
 Targeting of AR gene exon 8 in LNCaP and CWR22Rv1 cells.   
Two individual sgRNA with different PAM sites encompassing the F876 codon in exon 8 (Figure 
4.2) were designed and cloned into a single vector system encoding Cas9 and a GFP transfection 
marker (Figure 4.2). We next assessed the most efficient of the CRISPRs by delivering the two 
Cas9/sgRNA plasmids into HEK293T cells. The delivery approaches of CRISPR are flexible: for in 
vivo experiments, CRISPRs are often introduced into whole organisms, such as mouse, zebrafish 
(Hwang et al., 2013; Xiao et al., 2013) and Drosophila (Ren et al., 2013; Yu et al., 2013; Sebo et 
al., 2014) by microinjection; whilst for in vitro assays, typical transfection/transduction 
approaches are utilised. By using lipid-based transfect reagents, we firstly observed, via analysis 
of GFP expression, that both CRISPR plasmids can be easily delivered into HEK293T cells (Figure 
4.3), which may not be surprising as HEK293T cells are a well-accepted vehicle line for the 
expression of ectopic proteins (Thomas and Smart, 2005). In fact, the HEK293T/HEK293FT cell 
lines are commonly used for validating the efficiency of the TALEN and CRISPR/ Cas systems in a 
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human in vitro model, because they can be transfected easily by plasmids and are relatively 
simple to maintain (Sanjana et al., 2012; Cho et al., 2013; Cong et al., 2013; Hu et al., 2013; Mali 
et al., 2013a).  
 
Validation of transfection efficiency of Cas9/sgRNA is a vital step for generating genetically-edited 
models. For our CRISPR system, detecting GFP expression is the most efficient and convenient 
approach, as it can be simply visualized by florescence microscopy (Figure 4.3). Moreover, by 
FACS sorting florescence in cells, GFP expression can also be quantified as an indicator for 
transfection efficiency (Figure 4.4). The successful transfection of Cas9/sgRNA plasmids were 
confirmed via detecting of GFP expression in tested cell line.  
 
Once transfection has been validated, it is important to subsequently assess CRISPR efficiency. 
To date, several methodologies are commonly undertaken to screen NHEJ-induced Indels (Local 
Point Mutation, Insertion, and Deletion) produced by the CRISPR/Cas9 system, including the 
Surveyor nuclease and T7 Endonuclease I (T7E1) assays; High Resolution Melting Analysis (HRMA) 
and PAGE electrophoresis (Miller et al., 2007; Gravina et al., 2010; Guschin et al., 2010; Niu et al., 
2014; Sung et al., 2014; Zhu et al., 2014). Additionally, several modified methods have also been 
developed for detecting CRISPR/Cas9-induced mutants that utilise microfluidic capillary 
electrophoresis or fluorescent PCR (Ramlee et al., 2015; Chenouard et al., 2016; Kc et al., 2016) 
however, these methods are expensive, as pre-designed probes and expensive equipment are 
required.  
 
Surveyor nuclease and T7 endonuclease I (T7EI) assays are wildly used among all validation 
approaches as both are relatively easy to perform and can be carried out using standard 
equipment. Importantly, these endonuclease-based assays are suitable for any target sequence 
and can recognise and digest mismatched heteroduplexed DNA. By conducting Surveyor assays 
in HEK293T cells transfected with our two CAS9/sgRNA-expressing plasmids, Cas9/sgRNA196-
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mediated indels were observed at exon 8 of the AR gene (Figure 4.1 C), but not in cells containing 
Cas9/sgRNA186. Hence, Cas9/sgRNA196 was considerably more efficient at targeting the desired 
locus than the sgRNA186-containing CRISPR vector and hence was subsequently selected for the 
ARF876L knock-in pipeline. 
 
Although using cationic lipid-based reagents is the conventional and most popular methods for 
plasmid DNA (and siRNA) transfection, it can be toxic and restricted to certain cell types and both 
LT-1 or lipofectamine 2000 was not sufficiently efficient for delivery of Cas9/sgRNA196 into 
LNCaP and CW22Rv1 cell lines (Table 4.4). Recently, Nucleofection (Lonza Cologne AG, USA 
/Canada) has been reported as an attractive electroporation approach for delivering CRISPR into 
transfection-resistant cell types. Indeed, we observed positive transfection of Cas9/sgRNA196 in 
CW22Rv1 48 hours post nucleofection (Figure 4.4) using the Surveyor assay.  
 
However, this method does not appear to be compatible with LNCaP cells. Although GFP 
expression was visualized (data now shown), there was no detectable cleavage within the target 
region in LNCaP cells. (Holkers et al., 2013) and (Owens et al., 2012) previously investigated 
transfection capability of CRISPR’s counterparts TALEN and ZFN into primary cells or cells 
refractory to plasmid transfection. They found that viral vectors were among the most effective 
gene transfer vehicles. (Li et al., 2011) showed that using viral vectors can enhance the efficiency 
of TALEN-mediated HDR and drive ZFN-mediated gene editing in vivo. Moreover, (Gwiazda et al., 
2016) have successful achieved CRISPR-mediated gene-editing in multiple mammalian cells using 
adenovirus vectors. Hence, as an alternative to non-viral gene delivery systems, we packaged the 
Cas9/sgRNA196 plasmid into lentivirus in an attempt to increase efficiency of plasmid delivery 
into LNCaP cells. After infection, comparing to control cells, we were able to detect the custom 
designed Cas9/sgRNA196-mediated endogenous AR gene disruption in LNCaP cells (Figure 4.5). 
Ultimately, Cas9/sgRNA-delivered CWR22Rv1 and LNCaP cell pools were sorted based on GFP 
expression and 75% and 31% transfection-positive cells were detected, respectively (Figure 4.4). 
In all, our results suggest a specific cell-type dependency for effectively delivering CRISPR 
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plasmids into CWR22Rv1 and LNCaP cells (Table 4.4). Importantly, the desired Cas9/sgRNA196-
mediated ‘on-target’ effects were achieved among all studied cell lines.  
Although Cas9/sgRNA196-medicated indels were detected in both LNCaP and CWR22Rv1 cell 
lines using the Surveyor assay (Figure 4.3, Figure 4.4 and Figure 4.5), the endonuclease-
associated methodologies have limitations involving DNA extraction, PCR, amplicon purification 
and gel electrophoresis which are time-consuming and labour-intensive. Moreover, the Surveyor 
assay lacks a robust means of quantifying CRISPR efficiency as it utilizes densitometry to compare 
intensity of wild-type and mutant heteroduplexes post electrophoresis. To enable a more 
quantitative means of assessing CRISPR-mediated indels within AR exon 8, we sequenced PCR 
amplicons encompassing the targeted region and analysed the sequencing data using TIDE 
(Tracking of Indels by Decomposition, https://tide.deskgen.com/) which is a web tool designed 
to facilitate analysis of CRISPR-Cas9 efficiency. By uploading control and sample chromatogram 
alongside the sequence of the gRNA, TIDE will predict the cutting site of the CRISPR and 
subsequently analyses differences between control and CRISPR-modified sequences both up- 
and downstream of the cleavage site (typically 3 bp from the PAM site). As shown in Figure 4.6 A 
and Figure 4.7, the Cas9/sgRNA196 combination induced random insertions and deletions at 
proximately 3 bp upstream of the PAM code in both CW22Rv1 and LNCaP cell lines. Furthermore, 
by decomposing the chromatogram sequences around the target site, details of deletion and 
insertion was also quantified in both cell line (Figure 4.6 and Figure 4.7). We therefore utilized 
this method for confirming CRISPR efficiency in all of the subsequent experiments. 
 
 ssODN design and knock-in F867L mutation via Cas9-mediated HDR 
Having confirmed the successful delivery and selective enhanced ‘on target’ efficiency of 
Cas9/sgRNA196 in both CWR22Rv1 and LNCaP cells (Figure 4.7), we next sought to co-deliver the 
pre-designed repair template in order to achieve the desired ‘knock-in’ ARF876L mutation. Firstly, 
to enhance indel frequency and increase the chance of cells uptaking the repair template, LNCaP 
cells were transduced with CRISPR expression virus. By selectively culturing cells with puromycin 
containing medium, higher efficiency on-target effects and indels was observed in selected cells.   
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Cas9 contains two nuclease domains, HNH and RuvC. Upon binding of chromatin, Cas9 makes a 
double-strand break in the target locus in the presence of Magnesium ions; with the HNH 
nuclease domain of the enzyme cutting the DNA strand complementary to crRNA, and the RuvC 
domain cutting the non-complementary strand (Chen et al., 2014b). By labelling substrate DNA 
on each side of the nuclease cut site with a distinct fluorophore and monitoring the dissociation 
of cut fragments. (Richardson et al., 2016) demonstrated that before complete dissociation, Cas9 
preferentially releases HNH nuclease domain from the 3’ end of the cleaved DNA strand while 
RuvC domain remains bound with complementary to the sgRNA (nontarget strand). This 
observation suggests that donor DNA complementary to the nontarget strand may be more 
effective than donor complementary to the target strand. In support of this theory, by using 
symmetric single stranded donor oligonucleotides (ssODNs) that are complementary to the 
nontarget strand, (Lin et al., 2014) and (Yang et al., 2013b) successfully introduced mutation in 
to EMX1 and AAVS1/PPP1R12C loci in human cell lines, respectively. Hence, the single-stranded 
DNA (ssDNA) donors of the optimal length complementary to the strand that is released first was 
considered for incorporation into the AR CRISPR/sgRNA196 knock-in pipeline. 
 
Using repair templates for insertion of specific mutations by CRISPR, homology arms 
complementary to the ends of the planned DNA break is required for the flanking regions of the 
donor template. The length of the homology arm is also proposed to play an essential role in 
increasing HDR rate. Several gene-editing studies focusing on homology arm length have recently 
been conducted and overall, they suggested that increasing the homology arm size may increase 
modification frequency. Although (Yoshimi et al., 2016) observed robust HDR with homology 
arms of 30–60 bases when creating small insertions, by increasing homolog arm length from 50 
bp to 200 bp in the same Cas9+ssODN system, (Li et al., 2014) increased the frequency of inserting 
a 720 bp fragment by  8-fold at the Oct4 locus.  
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Considering the large size of an ssODN may result in low transfection efficiency and may be 
difficult for synthesis, a 200bp sequence complementary to the target sequence in exon 8 was 
chosen as the ssODN (Figure 4.8 A) that contains the F876L mutant codon with 75bp homology 
arms flanking both sides. Within the donor template, the PAM ‘TGG’ site was substituted with 
‘TCG’ to prevent re-cutting of the site by Cas9 which may subsequently remove the knock-in 
mutation by NHEJ-mediated repair. Additionally, for further assessing the successful insertion of 
the donor template within the genome, Sal 1 restrict digest site (G^TCGAC) was also artificially 
insert into the ssODN. Hence, upon CRISPR-mediated knock-in of the donor template, RFLP assays 
will specifically identify successful genome editing events using Sal I digestion as an initial 
diagnostic tool.  
 
Upon co-transfection of the CWR22Rv1 cell line with the repair donor and the Cas9/sgRNA196 
plasmid, it was observed that the phenotype of the cells appeared distinct from the group that 
were transfected with the plasmid only (Figure 4.8). Typically, cells co-transfected with two 
components demonstrated altered growth characteristics to the extent that grew as colonies as 
opposed to a more evenly distributed layer as seen in the control arm.  GFP expression was 
observed 7 days post nucleofection. Hence, 10 colonies was picked for potential successful 
ssODN insertion/knock-in mutation detection. Unfortunately, no successful desired knock-in 
mutation was detected by the polymerase chain reaction (PCR)/restriction enzyme (RE) assay ( 
Appendix 4B). This was disappointing, but not a surprising result as this is a decidedly difficult 
process due to the process of HDR, which is required for the insertion of the donor template into 
the genome, occurring at a low frequency in the cell population; most repair in interphase is 
conducted by NHEJ. (Cong et al., 2013) demonstrated that in the absence of a repair template, 
the Cas9-mediated Indel frequency was 7-27% in human cells which is consistent with the 
efficiencies observed in both CWR22Rv1 and LNCaP cells in this study. In contrast, however, the 
same study indicated that co-transfection of cells with a ssODN template and measurement of 
HR activity was merely 0.46% indicating that considerably more colonies will need to be assessed 
103 
 
before potentially detecting a precise knock-in clone. Similar results were also reported in other 
studies (Lin et al., 2014; Schumann et al., 2015).  
 
Although CRISPR/Cas9 has a broad range of applications in science and human therapeutics, the 
results presented in this chapter indicate that several factors affect efficiency and specificity of 
utilizing CRISPR for precise genome editing, including delivery approaches, short guide RNA 
design, target gene loci selection, off-target effects and the incidence of homology-directed 
repair. In the rest of the discussion, I will summarize the potential factors that affect the 
application of CRISPR/Cas9 for precise gene editing, as well as possible strategies for resolving 
these problems. 
 
As noted previously, Cas9 nuclease mediated DSBs at desired target sites can stimulate two 
distinct endogenous DNA repair mechanisms, NHEJ and HDR. Evidently, the choice of DNA-repair 
pathways is largely beyond experimental control. In general, NHEJ is error-prone but highly 
efficient, hence, even in the presence of donor templates, NHEJ is the more frequently repair 
pathway when using CRISPR/Cas9 systems. NHEJ is initiated by the recruitment of Ku70/ 80 
heterodimer and DNA-PKcs (Tomkinson et al., 2013). This complex stabilizes the two DNA ends 
and a series of proteins was subsequently recruited, including DNA ligase IV, to ligate the DNA 
breaks (Robert et al., 2015). Whilst for HDR, the DNA strands break are cleaved to generate 3’-
ssDNA overhangs that can recruit a set of repair proteins and invade with a homologous donor 
template (Robert et al., 2015).  Critically, impairing NHEJ components in cell lines increases the 
level of HDR suggesting that two repair processes are in direct competition (Srivastava et al., 
2012; Tomkinson et al., 2013; Chu et al., 2015; Vartak and Raghavan, 2015; Yu et al., 2015). 
Knockdown of KU70/80 or DNA ligase IV by short hairpin RNA sequences, (Chu et al., 2015) were 
able to promote HDR efficiency in both human and mouse cells. In addition, (Robert et al., 2015) 
also confirmed that by using two small molecule inhibitors of DNA-PKcs (NU7441 and KU-
0060648) NHEJ was reduced and conversely, the frequency of HDR was enhanced. Hence, by 
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silencing key component that are required for NHEJ in our cell line model, this may increase the 
incidence of F876L knock-in via Cas9-mediated HDR pathway. 
 
The cell-cycle phase upon which HR occurs in repair mechanism may be another considering 
factor to improve the efficiency of knock-in rate. NHEJ is generally the predominant repair 
mechanism in the growth 1 (G1) and the mitotic (M) phases of cell cycle whilst HR takes place in 
the synthesis (S) and the premitotic (G2) phases when there are sister chromatids available  (Mao 
et al., 2008). Therefore, by incorporating small molecule cell-cycle inhibitors of the S and G2 
phases to elevate the cell populations in these HR-proficient phases may also enhance desired 
knock-in incidence.  
 
Another possible issue surrounding the protocol employed here is achieving the appropriate level 
of Cas9/sgRNA196-mediated DNA damage to occur simultaneously with a repair template 
proximal to the site of damage. Successful transfection and subsequent transcription/translation 
of the Cas9 enzyme and interaction with the sgRNA196 activity requires upwards of 8 hours; 
while once bound to DNA, the dissociation of the Cas9/sgRNA from the target locus is as slow as 
6 hours (Richardson et al., 2016) suggesting that it may be challenging to maintain optimal 
chromatin environments for Cas9-ssODN interactions and precise HDR-mediated editing. 
Moreover, transfected plasmids and the ssODN remain episomal and hence are lost over 
successive cell cycles which further reduces the window for successful genome engineering. 
Hence, one of the potential solutions to these issues is to ectopically express the ssODN 
sequence, containing the ARF876L mutation, from the Cas9/sgRNA196 plasmid to achieve optimal 
expression of the three components required for generating knock-in mutations. In addition, 
using phosphorothioate bonds at both 5’- and 3’- ends of ssDNA donor oligonucleotides, 
(Prykhozhij et al., 2017) demonstrated more efficient HDR comparing to control donor template. 
Thus, stabilizing donor template by phosphorothioation of the ssODN may also be another 
partially strategy to improve knock-in events.  
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The distance between the predicted cutting site and the desired editing site (e.g. mutation) has 
recently also been suggested to be a major consideration for improving uptake and incorporation 
of the ssODN into the process of HDR (Paquet et al., 2016). The less nucleotides between the 
desired editing site and the site of Cas9 cleavage has been found to robustly enhance knock-in 
mutation frequencies by HDR. Although we have chosen the more robust ‘on-target’ and efficient 
Cas9/sgRNA196 for the purpose of knock-in generation, the F876 target codon sits over 30 nt 
distal to the Cas9/sgRNA196-mediated cutting site which, according to previous studies, will have 
a detrimental effect to precise editing efficiency.   
 
For future studies, a more robust approach may be to switch to another type of CRISPR class type 
that relies on different PAM codes for directed DNA cleavage. For instance, SmCms1 and AsCpf1 
(both from CRISPR Type V) utilizes respective ‘TTN’ and ‘TTTN’ as the PAM code for their activity. 
Similar to Cas9, both CRISPR Type Vs result in a DSB site adjacent to PAM code (Begemann et al., 
2017).  Hence, by employing other CRISPR types that utilize distinct PAM sites, it may be possible 
to mediate DSB cleavage adjacent to the F876 codon and hence improve knock-in efficiency.   
In this chapter, we have firstly verified our designed sgRNA/Cas9 ‘on-target activity’ at AR exon 8 
in the two PC cell lines.  Moreover, we optimized a systemic high throughput screening approach 
to enable detection of knock-in mutants that did provide some evidence of precise editing in 
pooled cell populations, but these were never clonally expanded due to technical difficulties. 
However, with low level of transfection/transduction efficiency and HDR frequency in both cell 
lines, it is likely that a larger number of colonies will need to be screened in order to create a 
clonal ARF876L–expressing cell line derivative. Considering the time-scale of the work conducted 
in this chapter and the lack of a genuine CRISPR edited cell line for study, a contingency plan was 
carried out in parallel which was based on a recently published AR rescue system developed by 
the Gaughan lab (O'Neill et al., 2015). Instead of persisting with the CRISPR model system for the 
full duration of study, LNCaP cells were transduced with lentiviral mammalian expression vector 
encoding a FLAG-tagged-ARF876L construct to generate a stable ARF876L-expressing LNCaP 
derivative to enable analysis of this mutant in a physiological background upon depletion of the 
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endogenous ART877A. Moreover, this new cell model can also be an excellent platform for testing 
of next generation targeted therapies. Our previous research utilizing an AR-replacement model 
in LNCaP cells demonstrated that the bicalutamide-activated ARW741L mutant selectively regulates 
a gene-set distinct from endogenous ART877A. My current results shown in the next two chapters 
suggests that the ARF876L mutant retains activity in the presence of enzalutamide in LNCaP cells 
and offers insights into discriminate functionality of the mutant receptor and opportunities for 
selective drug targeting of AR mutants. The details of cell line model will be focus on discuss in 
next two chapters. 
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 Generation and characterise of stable LNCaP-ARF876L cell line 
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5.1 Introduction 
With increasing understanding of the physiology and molecular mechanism of AR function 
in advanced disease in the past two decades, the development of direct or indirect AR 
targeting agents has seen marked improvements to PC treatments in the UK and beyond. 
Many AR-targeting drugs have been developed and are most frequently used in the clinic for 
intermediate- and high-risk patients, principally in combination with ADT, such as LHRH 
agonists.  
Although initially sensitive to anti-androgen and ADT therapies, unfortunately, most PC 
patients will relapse, with disease progressing to refractory, untreatable CRPC. At this stage, 
tumours either become endocrine-therapy resistant during the course of treatment or 
possesses a small population of pre-existing hormone-refractory cells that remain viable in 
spite of castration levels of androgen (Heck et al., 2012). By selective outgrowth of resistant 
cells with acquired genetic alterations that could contribute to disease progression, tumors 
aggressively progress, are refractory to current therapies and eventually claim the life of 
patients.  
Clinically, approximately 50% of patients after hormone therapy present with anti-androgen 
withdrawal syndrome (AAWS). This condition is characterized by cancers that grow in the 
presence of anti-androgens and whose growth is attenuated by stopping anti-androgen 
treatment (Gottlieb et al., 2012). Acquiring somatic mutations in the AR gene is likely 
responsible for the 15–30% of patients that exhibit a withdrawal syndrome after cessation 
of first-generation therapies (Paul and Breul, 2000).  
DNA sequencing of tissue biopsied from CRPC patients identified 159 AR gene coding 
mutations (last update 2012). Importantly, almost 50% of them were found to reside within 
the LBD cofactor binding regions (Schweizer and Antonarakis, 2012). This evidence strongly 
suggested that mutation selection under pressure of anti-androgen treatment contributes, 
in part, to drug resistance. Long-term treatment with the AR antagonists could selectively 
enable outgrowth of tumor cells that are driven by AR mutants causing drug resistance by 
turning anti-androgens from antagonists to agonists. These included L701H, H874Y and 
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T877A, noticeably, all of which were identified from patients that had been treated with anti-
androgens (Steketee et al., 2002). Further studies (van de Wijngaart et al., 2012)  found that 
most mutations resulted in reduced ligand specificity and hence permitted inappropriate 
receptor activation by binding to adrenal androgens or other steroid metabolites. ARL701H is 
activated by other steroids, including estrogen, cortisone; while ARH874Y is activated by 
progesterone. Certain LBD mutations identified are also sufficient to convert AR antagonists 
to AR agonists in vitro. T877A and H874Y mutations were found in LNCaP and CWR22Rv1 cell 
lines, respectively, and were shown to be abnormally activated by the antagonists Flutamide 
and Cyproterone Acetate (CPA). Another mutation, W741L was later found both in LNCaP 
and ADT-treated metastatic patient sample-derived xenograft tumors which exhibit increase 
tumor growth and PSA secretion in response to bicalutamide (Yoshida et al., 2005b). This 
was confirmed in an LNCaP derivative cell line stably expressing the ARW741L mutant (O'Neill 
et al., 2015) which demonstrated endogenous AR-target gene expression upon 
bicalutamide-activation of the ectopic mutant. 
A next-generation anti-androgen enzalutamide (XtandiTM) has recently been FDA-approved 
for use in advanced prostate cancer and has had a positive clinical impact in prolonging 
longevity and quality of life of advanced prostate cancer patients (Silberstein et al., 2013). 
Consistent with other AR-targeted agents however, the efficacy of enzalutamide therapy is 
reasonably short-lived, extending median survival by only 2-8 months and upwards of 50% 
of patients are refractory to treatment. Most forms of CRPC are still dependent on the AR-
axis for survival (Dhingra et al., 2013). Recently, a specific AR mutation, F876L has been 
reported that is sufficient to confer partial resistance to enzalutamide and the related AR 
antagonist apalutamide (Joseph et al., 2013). The mutation was discovered by the Sawyers’s 
Group, using a reporter based mutation screen approach, and was found to confer resistance 
to enzalutamide (Balbas et al., 2013).  This observation was then supported by in vivo and in 
vitro experiments that demonstrated specific ARF876L mutations can confer partial agonist 
activity to enzalutamide in models of CRPC (Rodriguez-Vida et al., 2015). Importantly, the 
mutant was later detected in CRPC patients after treatment with apalutamide (Nelson and 
Yegnasubramanian, 2013).  
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In view of this antagonist to agonist switch phenomenon in response to chronic 
enzalutamide treatment, it is hypothesised that patients harbouring the F876L-mutated AR 
might clinically benefit from withdrawal of enzalutamide. Importantly, the same mutation 
has been detected in circulating tumor DNA from apalutamide-treated CRPC patients (Dellis 
and Papatsoris, 2018). Taken together, the evidence highlights the selective outgrowth of 
ARF876L-expressing cells is a clinically relevant mechanism of second-generation anti-
androgen resistance. 
The current commonly adopted method for studying AR mutant function is by transient 
transfection of AR-encoding plasmids into AR null cells and assessment of receptor function 
principally by luciferase-based read-outs. Although useful, this approach lacks physiological 
relevance. To understand the molecular mechanisms of ARF876L function, and to model more 
physiologically the mutant in order to assess sensitivity to other clinically-relevant targeted 
agents, we sought to generate an AR rescue/replacement system to permit a more effective 
platform to determine the endogenous activity of ARF876L. This is consistent with the model 
developed by the Gaughan group (O'Neill et al., 2015) to study the bicalutamide-activated 
ARW741L mutant.  
This chapter will commence by firstly using an androgen-responsive luciferase reporter as a 
surrogate for assessing the agonistic activity of enzalutamide towards ARF876L and to confirm 
previous reports (Balbas et al., 2013). It will be then be followed by generation and thorough 
validation of an ARF876L rescue model system in the androgen-responsive LNCaP cell line 
which will enable more robust modelling of the AR mutant and assessment of response to 
next-generation AR antagonists and other therapeutics, including bromodomain inhibitors.  
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5.2 Specific method and materials  
 siRNA oligo design (and transfection)   
LNCaP or LNCaP-ARF876L (~3 x 106) were seeded in 20 ml 10% FCS medium in a 150 mm dish for 
48 hours until cell confluence reached over 80% per dish before replacing medium with steroid-
depleted media. siRNAs (25 nM final concentration) were transfected with 2 ml basal medium 
(free of phenol-red) per dish for 48 hours. A second round of siRNA transfection was repeated 
following 48 hours of culture.  96 hours post-transfection, the indicated treatments (DHT-10 
nM; bicalutamide-10 μM, enzalutamide-10 μM) were applied to cells for the last four hours of 
the experiment. Post-2x ice cold PBS washes, the cells were trypsinised and spun down, 
collecting pellets to be used for the subsequent mRNA extraction (as descripted in 3.14) or 
Western blotting. Alternatively, cells were scraped prior to ChIP assay as described in 3.14.4.  
 
 Luciferase-activity assay  
AR-negative PC3 and HEK293T cells were seeded at a density of 2x104/well in 24-well plates 
(Corning) in steroid-depleted media for 24 hours. 50 ng pCMV-FLAG-AR wild-type or pCMV-
FLAG-ARF876L and the AR-dependent ARE Luciferase reporter (containing a three repeats of a 
consensus ARE)(O’Neill et al., 2015) or PSA Luciferase reporter (containing ~600 bp of the PSA 
promoter region) were transiently transfected into the cell lines using LT-1 transfect reagent. 
100 ng/well of transfection control vector pCMV-β-galactosidase was also co-transfected. 24 
hours after transfection, indicated treatments were applied for an additional 24 hours. Cell 
lysates were harvested using Luciferase reporter lysis buffer (Promega, UK). Luciferase activity 
was determined using a FLUOstar plate reader, Omega, and normalized to β-galactosidase 
activity (see below). Luciferase activity was presented as relative hormone-induced luciferase 
activity (Figure 5.1). Each bar represents the mean of three independent experiments 
performed in triplicate. Transcriptional activation of wild-type AR by DHT was set to 100%. All 
statistical analysis was performed using GraphPad Prism software (GraphPad, San Diego, CA, 
USA) by one-way analysis of variance (ANOVA). 
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 β-galactosidase normalization assay 
β-gal assays, which utilises the β-galactosidase (β-gal) substrate o-nitrophenyl- β-D-
galactopyranoside (ONPG), was used to measure β-gal activity in each transfection. 10 μl of cell 
lysate were added to in a clear bottomed 96-well plate and mixed with 10 μl β-gal assay 
substrate prior to incubation at 37oC for approximately 5-10 minutes until samples yielded a 
yellow colour. Reactions were then neutralized by addition of 50 μl 1M Na2CO3 and absorbance 
measured at 415 nm using a 96-well model 680 plate reader (BioRad). β-galactosidase readings 
were used to normalise corresponding luciferase assay data as described above and presented 
using GraphPad Prism software (GraphPad, San Diego, CA, USA) by one-way analysis of variance 
(ANOV activity in each transfection). 
 Cell proliferation assays using the Incucyte Zoom platform 
To investigate the effect of each anti-androgen on cell proliferation, an appropriate density of 
cells (~3000 cells / well) were seeded into each well of a 96-well plate in a volume of 90 μl 
steroid-depleted growth medium using an Eppendorf Repeater Stream pipette. Cells were 
allowed to adhere for 24 hours before being treated with 10 nM DHT or 10 µM 
bicalutamide/enzalutamide to bring the final volume to 100 μl/well. Cells were subsequently 
incubated for 7 days. Cell confluency, as a measure of well surface coverage, is measured in 
real-time (every 6 hours) using the Inucyte Zoom (Essen Bioscience) and later analysed using 
the Basic Analyzer Software (Essen Bioscience).  
 
 Proliferation assays using Sulforhodamine B assay 
Sulforhodamine B (SRB) assays were performed according to Skehan et al., (1990). Briefly, cells 
were seeded out as described above (3,000 cells per well in 90 µl steroid-depleted medium in 
96-well plates). Cells were incubated with compounds (DHT, bicalutamide and enzalutamide) 
at appropriate concentrations for 5 days before being fixed with 25 μl ice cold 50% 
trichloroacetic acid for 1 hour at 4oC. 
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Fixative was removed by washing with tap water and cells were stained with 0.4% (wt/vol) SRB 
dissolved in 1% acetic acid. Excess was removed by washing five times with 1% acetic acid. 
Plates were then air-dried at RT, after which bound SRB was dissolved with 10 mM Tris-HCl, pH 
10.8. Absorbance was measured at 570 nm using a 96-well plate reader (BioRad). 
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5.3 Results  
 
 Enzalutamide Increases transcriptional activity of ARF876L in luciferase assays. 
Investigating the regulatory mechanisms of the ARF876L mutant may potentially provide new 
therapeutic targets to enable inactivation of ARF876L-driven enzalutamide resistance in CRPC. 
To interrogate the roles of AR mutant function, model optimization was required prior to 
assessing the transcriptional potential of ARF876. A luciferase reporter method therefore was 
first selected to determine whether the next-generation anti-androgen enzalutamide is 
indeed an agonist for the ARF876L mutant.  
 
For the luciferase-based reporter assay, AR mutant expression plasmids and an AR-dependent 
luciferase reporter were transiently transfected into the AR negative PC cell line. A pGAL4-β-
galactosidase plasmid was co-transfected to act as a transfection efficiency control. As illustrated 
in Figure 5.1 A, the luciferase reporter expression is driven by a promoter region which contains 
three repeats of a consensus 15-mer ARE sequence. In the presence of an activating ligand, the 
ectopically expressed AR can actively bind to the ARE region and promote activation of luciferase, 
therefore providing a direct readout of AR transcriptional activity.         
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Figure 5.1 Enzalutamide increases ectopic ARF876L activity in AR negative PC3 cells. (A) A. Diagrammatic 
representation of the luciferase reporter assay to assess AR activity; showing activated AR binding to an 
androgen response element (ARE) and driving expression of the downstream luciferase gene. (B) Bar 
graphs showing normalized luciferase activity following transfection of HEK293T cells with wild-type AR 
(WT) or ARF876L (F876L) expression constructs and a PSA reporter in steroid-depleted medium. The 
indicated treatment of vehicle (DMSO), 10 nM DHT, 10 μM enzalutamide (enz) or 10 μM bicalutamide 
(bic) were conducted for 24hours. All data are normalized to DMSO control. Each AR derivative and data 
represents the mean of triplicate experiments performed in quadruplicate (+/- SEM;). All statistical 
analysis was performed using GraphPad Prism software (GraphPad, San Diego, CA, USA) by one-way 
analysis of variance (ANOVA). Values are presented as mean±SEM, ***p-value ˂0.001**** ˂0.0001 as 
calculated using a student’s T-test. 
 
As shown in Figure 5.1 B, in the presence of 10 nM DHT, wild-type AR (ARwt) transcriptional 
activity as expected increased over 6-fold, whilst no increased activity was observed following 
enzalutamide and bicalutamide treatment. It suggests that both anti-androgens do not present 
agonistic activity on wild-type receptor. Consistent with ARwt, 24 hours DHT treatment increased 
ARF876L activity by over eight-fold indicating the mutant remains responsive to natural agonists. 
In contrast, however, enzalutamide treatment alone significantly induced ARF876L activity over 7-
fold compared to control whilst no increase to activity was observed following bicalutamide 
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treatment. This result is consistent with previously published data  (Korpal et al., 2013a) that 
reported enzalutamide functions as an agonist for the ARF876L mutant. Furthermore, our data also 
suggested that ARF876L does not presents agnostic activity to bicalutamide. The luciferase data 
overall suggests that in the presence of enzalutamide, the F876L mutant possesses a similar 
active response as wild-type AR response to DHT. In addition, my results also indicate that no 
agonistic activity of bicalutamide was observed on ARF876L. 
 
 Generation of pLenti6.3 ARF876L constructs. 
Although the data from the luciferase reporter-based assay supported our theory of the F876L 
mutant exhibiting agonistic response to enzalutamide, most current models are based on 
transient overexpression of mutant receptors in AR negative cells, which is suitable for assessing 
transcriptional activity on candidate reporters but provides very little information regarding their 
role in global transcriptomics. In order to have a more physiologically-relevant background study 
model, we next adapted a lentiviral-based strategy to establish a stable prostate cancer cell 
model which can facilitate more global analyses of the ARF876L mechanism of action.  
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Figure 5.2 The workflow for generating the pLenti6.3-ARF876L construct.  (A) The illustrated workflow of 
generating the pLenti6.3 ARF876L construct. (B) Sanger sequencing chromatogram and protein expression 
of pLenti6.3-FLAG-ARF876L. Sanger sequencing chromatogram outlining relevant elements of the vector 
backbone shows successful ligation of pLenti6.3 FLAG-ARF876L. (C) Western blotting verifying transient 
expression of pLenti6.3ARwt and pLenti6.3ARF876L in HEK293T cells. 
 
A lentiviral-based expression construct was generated using a previously established system 
(O’Neill et al., 2015) in order to create an LNCaP cell derivative that expressed ARF876L. The desired 
pLenti6.3-ARF876L construct was generated as illustrated in Figure 5.2 using a two-step approach 
(Gateway; Life Sciences). Firstly, FLAG-tagged ARF876L cDNA was PCR amplified from the original 
pCMV-ARF876L plasmid using pre-designed primers (Table 3.1); the forward primer incorporating 
a 5’-‘CTCC sequence to facilitate subsequent recombination. The overhang can facilitate PCR 
product cloning into the pENTR/ D-TOPO vector (Life Sciences) to further enhance ligation into 
an entry clone. Lastly, the destination vector pLenti-ARF876L was generated by conducting an LR 
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recombination reaction between the recombinant entry clone and the pLenti-6.3 plasmid 
backbone.  
 
To determine the orientation of insert, the pLenti6.3-ARF876L construct was subject to Sanger 
sequencing (Beckman, UK) using a CMV forward primer. The sequencing chromatogram (Figure 
5.2 B) confirmed the successful recombination of FLAG-ARF876L cDNA into the pLenti6.3 V5/DEST 
vector, including annotated elements of the backbone, the 5’ CACC sequence to ensure 
directional cloning carried forward from pENTR/ D-TOPO cloning and the 5’ sequence of the FLAG 
tag upstream of the AR coding sequence. The M13 reverse primer was used to confirm that the 
ARF876L sequence was maintained throughout pLenti6.3 V5/DEST vector cloning. 
 
Next, to establish a stable ARF876L-expressing LNCaP cell line, viral particles containing 
pLenti6.3 ARF876L were produced using the ViraPower™ Lentiviral Expression System (Life 
Sciences) according to manufacturer’s recommendations. HEK293FT cell line (life 
Technologies, UK) were cultured with complete culture medium containing Geneticin for 3 
passages before co-transfecting with pLenti-ARF876L and ViraPower™ Packaging Mix. 48 hours 
after co-transfection, viral particles were harvested form culture medium by 
ultracentrifugation.  
 
Before transducing into LNCaP cells, ARF876L-expressing lentivirus stock was transiently 
transduced into HEK293T and LNCaP for 48 hours and 7 days, respectively, to assess 
expression of ectopic protein. Whole cell lysates were collected and subsequently subject to 
western blotting (Figure 5.3) using the AR N-20 polyclonal antibody (Santa Cruz 
Biotechnology). As LNCaP endogenously express AR, anti-FLAG (Sigma-Aldrich, USA) 
monoclonal antibody was used to exclusively detect ectopic FLAG–tagged ARF876L expression 
in LNCaP cells.  
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Figure 5.3 Successful transduction of pLenti6.3-ARF876L in HEK237T and LNCaP cells.  Increasing 
amounts of virus stock was transiently transduced into both HEK293T (A) and LNCaP (B) for 48 hours 
and 7 days, respectively. Antibodies used for each blots are indicated above. α-tubulin was probed 
as loading control. N/T represents as non-transduction negative control.  
 
As shown in Figure 5.3, by using specific antibodies, ectopically expressed AR (as arrow 
indicated in red) can be detected in both HEK293T and LNCaP cells, but not in non-
transduced control samples. Moreover, the expression level of AR gradually elevated with 
increasing amounts of transduced virus.  After successfully confirming expression of ARF876L, 
LNCaP cells were transduced for 24 hours and subsequently cultured in blasticidin-containing 
medium to clonally select pLenti-6.3-FLAG-ARF876L stable integrants for further study. 
 
To generate a stable homogenous population of cells culture, the transduced LNCaP cell 
population were seeded into 96 well-pates at 1 cell/well and cultured with selection medium. 
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Antibiotic-resistant colonies were picked 2 weeks post selection and FLAG expression and 
endogenous AR targets expression in the clonal populations was firstly assessed. A total of 
10 individual clones were picked and 7 of them were able expanding growth for ectopic 
FLAG-tag expression. The subsequent AR-regulated gene expression were carried out for 
each clones (Appendix 5A). By comparing to LNCaP cells, clones c3 were subsequently 
selected and named as LNCaP-ARF876L for the subsequent studies.  
 
Expression of the endogenous AR-target genes PSA and KLK2 in the newly developed LNCaP-
ARF876L cells in response to DHT and enzalutamide was compared to parental LNCaP cells by 
Q-PCR (Figure 5.4). As expected in LNCaP parental cells, PSA and KLK2 expression was 
increased in the presence of DHT, but not enzalutamide. This indicates that the endogenous 
ART877A mutant expressed in LNCaP cells is not activated by enzalutamide. Consistent with 
parental LNCaP cells, DHT induced PSA and KLK2 expression in the LNCaP-ARF876L cell line.  
Importantly, in contrast to LNCaP cells, expression of the two AR-target genes PSA and KLK2 
was markedly up-regulated by enzalutamide in the LNCaP-ARF876L derivative, suggesting that 
enzalutamide induces expression of endogenous AR-target genes via the ectopic ARF876L 
mutant.  
 
Figure 5.4 Enzalutamide actively induces AR target gene expression in the LNCaP-ARF876L derivative.  
Expression of the endogenous PSA and KLK2 genes in the LNCaP cell line derivative that stably 
expresses ARF876L cells was assessed using QRT-PCR and compared to LNCaP parental cells. 10 nM DHT 
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and 10 µM enzalutamide were applied to both cell lines grown in steroid-depleted media for 24 hours. 
All statistical analysis was performed using GraphPad Prism software (GraphPad, San Diego, CA, USA) 
by one-way analysis of variance (ANOVA). Values are presented as mean±SEM, ***p-value 
˂0.001**** ˂0.0001 as calculated using a student’s T-test. 
 
 
 Up-regulated AR target gene in LNCaP-ARF876L is driven through ectopically expressed 
ARF876L in response to enzalutamide. 
Given the fact that LNCaP parental cells endogenously express AR, to further discriminate 
ARF876L function from endogenous receptor, two siRNA oligos were manually designed 
according to Tuschl’s rules of siRNA design (Elbashir et al., 2001)  to deplete either 
endogenous ART877A, via a 3’-UTR sequence not present in the ectopic ARF876L cDNA  (referred 
to as siART877A), or ectopic ARF876L via a sequence within the linker region encompassing the 
FLAG sequence upstream from the ARF876L cDNA (referred to as siARF876L )(Figure 5.5 A).  
 
To validate the effects of the endogenous- and ectopic-AR-targeting siRNAs, knockdown of 
AR levels was firstly assessed using western blot analysis in LNCaP parental cells and the 
LNCaP-ARF876 derivative (Figure 5.5 B). An N-terminal AR antibody was used to detect 
endogenous ART877A and ectopically-expressed ARF876L (total AR level), whilst the FLAG 
antibody was used to specifically determine ectopic AR expression in LNCaP- ARF876L cells.            
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Figure 5.5 Up-regulated AR target gene expression in LNCaP-ARF876L is driven through ectopically 
expressed ARF876L in response to enzalutamide. (A) The illustration of target site for custom designed 
oligonucleotides siART877A and siARF876L. (B) AR western analysis to assess efficacy of endogenous and 
ectopic AR-targeting oligonucleotides in LNCaP and LNCaP-ARF876L cells. LNCaP and LNCaP-ARF876L cells 
were grown in full media and transfected with 25nM of scrambled (siSCR), siART877A or siARF876L siRNA for 
48 hours prior to western analysis using AR and FLAG antibodies. (C and D) Validation AR target gene 
expression in LNCaP ARF876L cells upon enzalutamide treatment. Data represents N=3 ± SEM. Cells were 
seeded in steroid-depleted media for 48 hours and transfected as above prior to 24-hour enzalutamide 
treatment and Q-PCR and western blot analysis.  
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As shown in Figure 5.5 B, transfection of pre-designed oligonucleotides confirmed the ability 
of siART877A to specifically target endogenous ART877A; whereas siARF876L had no effect on 
endogenous receptor expression levels in LNCaP parental cells. The level of total AR was 
expectedly elevated in LNCaP-ARF876L cells compared to the parental cells due to ectopic 
expression of ARF876L in addition to endogenous receptor isoforms. Transfection of LNCaP 
cells with the ART877A-targeting siRNAs demonstrated effective reduction in AR expression 
not in the presence of siARF876L. Conversely in LNCaP-ARF876L cells, transfecting siARF876L, 
which specifically targets ectopic ARF876L, had no effect on endogenous ART877A whilst it 
effectively knocked down expression of FLAG ARF876L. This result suggests that our designed 
siRNA can specifically target the 3’UTR of endogenous AR mRNA whilst permitting the 
ectopic expression of an AR mutant in the stable derivative cell clone. 
 
Having developed and validated a system enabling the modulation of endogenous and 
ectopic AR protein levels, we next sought to assess the function and activity of ARF876L by 
starting with investigating AR-regulated gene expression. In contrast to parental LNCaP cells, 
enzalutamide elevated expression of both endogenous PSA and KLK2 genes (Figure 5.5 C) in 
the presence of both scrambled and ART877A-targeting oligonucleotides. In contrast, 
enzalutamide-activated KLK2 and PSA gene expression was largely abrogated/ reduced when 
ARF876L expression was down-regulated using siARF876L, which suggests that ectopically 
expressed ARF876L promotes endogenous PSA and KLK2 expression in the presence of 
enzalutamide. The downregulation effects of siARF876L on AR targets was further confirmed 
using western blots. As Figure 5.5 D shows, in the presence of enzalutamide, the increasing 
PSA protein level is driven through ARF876L not endogenous receptor. 
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 Enzalutamide increases co-enrichment of ARF876L and RNA polymerase ll at cis-regulatory 
elements of target genes. 
 
Having confirmed up-regulated endogenous PSA and KLK2 mRNA expression in response to 
enzalutamide in the LNCaP-ARF876L derivative, we next sought to examine in greater detail 
transcriptional activation of endogenous genes by the ARF876L mutant in response to 
enzalutamide.  
 
In order for AR to exert its transcriptional effect upon target genes, it is first recruited to 
androgen response elements (AREs) of cis-regulatory regions whereby recruitment of 
transcriptional machinery and additional transcription factors are required for target gene 
expression. Chromatin immunoprecipitation (ChIP) assays therefore were performed to 
investigate FLAG-ARF876L recruitment to AR target genes in response to agonistic ligands in 
LNCaP ARF876L cells. AR (N-20) has been previously used in ChIP to assess the recruitment of 
endogenous AR to the distal enhancer regions of the PSA promoter in parental LNCaP cells 
(O'Neill et al., 2015). By having demonstrated AR recruitment to canonical AREs in the 
presence of DHT in parental cells, FLAG and phospho-Serine 5 RNA polymerase II antibodies 
were used in ChIP to investigate the effect of DHT and enzalutamide on AR chromatin binding. 
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Figure 5.6 Increasing co-recruitment of ARF876L and RNA polymerase ll at cis-regulatory elements of 
target genes in response to DHT and enzalutamide.  LNCaP-ARF876L cells grown in steroid-depleted 
media were transfected twice with 25 nM of indicated siRNA before being treated with DHT (10 nM) 
or enzalutamide (10 μM) for 4 hours. Cells were subject to ChIP analysis using (A) anti-FLAG and (B) 
anti-phosphorylated serine 5 RNA polymerase (pSer5 RNA pol II) antibodies. Recruitment was 
determined by qPCR using primers specific to the enhancer regions of the PSA and TMPRSS2 genes. 
Data represents N=3 ± SEM. 
 
As shown in Figure 5.6 A, in the presence of DHT, ARF876L was found to be recruited to both 
cis-regulatory elements of PSA and TMPRSS2, with respective 12-fold and 17-fold increase in 
enrichment compared to vehicle control. Importantly, FLAG-ARF876L recruitment was robustly 
elevated upon enzalutamide treatment to levels equivalent to DHT. ARF876L-targeting siRNAs 
were subsequently used to confirm AR enrichment in response to enzalutamide was ectopic 
ARF876L; in the presence of DHT and enzalutamide ARF876L recruitment to both PSA and 
TMPRSS2 enhancer regions was markedly diminished following transfection of the FLAG-
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targeting oligo, which demonstrates competency for chromatin binding of the ARF876L mutant 
in this model.  
 
To determine whether the recruitment of FLAG- ARF876L to cis-regulatory elements could 
promote the assembly of an active transcription complex, the recruitment of phosphorylated 
RNA polymerase II at serine 5 was next examined as a marker of transcriptional initiation. 
pSer5 RNA polymerase II antibody was used in ChIP assays to indicate transcriptional 
competency of AR-target genes in response to both DHT and enzalutamide in cells depleted 
of either endogenous or ectopic AR isoforms. At the PSA enhancer, DHT and enzalutamide 
increased pSer5 RNA pol II recruitment by approximately 2- and 4-fold, respectively (Figure 
5.6 B). Similarly, at the promoter regions of TMPRSS2, DHT and enzalutamide treatment 
increased pSer5 RNA pol II co-recruitment by approximately 2- and 4-fold, respectively. 
Consistent with Figure 5.6 A, knockdown of ARF876L before treatment with DHT and 
enzalutamide results in robust reduction in enrichment of pSer5 RNA polymerase II at the 
enhancer of both genes.  
 
In all, the ChIP data indicates that in the presence of enzalutamide, ARF876L mutant is 
recruited to cis-regulatory regions of AR target genes, PSA and TMPRSS2, facilitates 
recruitment of an active transcriptional complex and subsequently drives transcription of 
these genes.   
 
 Enzalutamide promotes ARF876L cells growth in androgen-depleted conditions. 
Having confirmed AR target gene activation in response to enzalutamide in the LNCaP-ARF876L 
cell line derivative, we next sought to determine whether this agonistic effect of the anti-
androgen is sufficient to impact cell phenotype. 
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To this end, proliferation assays were conducted to investigate if enzalutamide was pro-
proliferative in the presence of ectopic ARF876L. This was assessed using SRB assays which 
relies on sulforhodamine B stoichiometric binding to proteins under mild acidic conditions; 
with the amount of bound dye used as a proxy for cell mass and hence as a surrogate for cell 
number/proliferation. LNCaP parental and LNCaP-ARF876L cells were seeded in androgen-
depleted media supplemented with or without enzalutamide for 5 days before assessing cell 
number by SRB analysis. As shown in Figure 5.7 A, LNCaP parental cells cultured in the 
presence of enzalutamide for 5 days demonstrated reduced cell growth, while in contrast, 
enzalutamide did not down-regulate growth of the LNCaP-ARF876L cell derivative, and instead 
caused a modest increase in proliferation compared to untreated cells. 
 
Figure 5.7 Enz-induced ARF876L signalling promotes the growth of LNCaP-ARF876L cells.  (A) 
Sulforhodamine B (SRB) growth assays performed in LNCaP parental cells and LNCaP-ARF876L 
derivatives after being grown in steroid-depleted media +/- enzalutamide for 5 days. (B) Cell cycle 
analysis of LNCaP and LNCaP-ARF876L(C) using propidium iodide staining. 
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We next assessed overall cellular phenotype of the LNCaP-ARF876L cell line derivative, using 
light microscopy, upon depletion of ART877A or ARF876L and grown for 48 hours in steroid-
depleted media supplemented with either DHT or enzalutamide. Given these indications, 
propidium iodide (PI)-based flow cytometry was utilised to analyse the impact of ARF876L 
expression on LNCaP cell cycle status in greater detail. The percentage of cellular DNA 
content in each cell cycle stage was quantified using PI staining which allows the percentage 
of cells in each of the distinct phases of the cell cycle to be calculated. LNCaP parental and 
LNCaP-ARF876L derivative cells grown in full media were treated with DHT or enzalutamide for 
48 hours. In response to DHT (Figure 5.7 B), an increase in the percentage of LNCaP parental 
cells undergoing DNA replication (S-phase) and transition to mitosis (G2/M) were observed; 
whilst enzalutamide significantly enhanced the proportion of cells in the apoptotic sub-G1 
phase of the cell cycle. In contrast, treatment of DHT and enzalutamide significantly 
promoted the proportion of LNCaP-ARF876L cells (Figure 5.7 C) in S- and G2/M-phases of the 
cell cycle without any cytotoxic effects which is consistent with data in Figure 5.7 A indicating 
that the ARF876L mutant can drive proliferation of LNCaP cells in the presence of enzalutamide. 
Overall, our data has successfully demonstrated that the F876L mutant can drive AR target 
gene expression and importantly maintain a tumor phenotype in the presence of 
enzalutamide. 
 
5.4 Discussion 
It is well-accepted that acquiring gain of function mutations within the ligand-binding domain of 
the AR contributes to resistance to AR-targeted therapies, including enzalutamide. By conducting 
a reporter-based mutagenesis screen, Balbas and colleagues (Korpal et al., 2013a) recently 
identified the F876L mutation as the only amino acid substitution within the ligand-binding 
pocket of the AR that is capable of inducing an antagonist to agonist switch for enzalutamide. 
Molecular structure simulations of the F876L amino acid residue revealed a repositioning of the 
LBD which results in a favorable conformation of helix 12 to enable transcriptional activation 
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when bound to enzalutamide (Joseph et al., 2013). Consistent with these early indications, our 
initial luciferase-based transactivation experiments indicated that the F876L mutation enables 
an agonistic response to enzalutamide (Figure 5.1).  
 
Despite the development of improved PC therapies over the past decade, including enzalutamide 
and abiraterone, resistance to these treatments invariably occurs, but cells remain largely 
dependent on the AR signalling cascade suggesting new AR targeted agents could be efficacious 
in this setting. Given that acquisition of AR mutations has been identified as a driver of therapy 
resistance, it is important that the activation profile of these aberrant AR species is analyzed in 
response to a cohort of antagonists to assess clinically-relevant sensitivities. Importantly, how 
one particularly AR mutant identified in disease that is resistant to second-generation anti-
androgens, e.g. enzalutamide, responds to hormonal therapies utilized at an earlier stage of the 
treatment pipeline, such as bicalutamide, may suggest alternate application of agents to improve 
patient outcome. This notion is supported by our luciferases results investigating sensitivity of 
the ARF876L mutant to anti-androgens (Figure 5.1). In response to 24 hour bicalutamide treatment, 
we found that no increasing luciferase reads were observed suggesting that unlike the previously 
characterised ARW741L, transactivation of ARF876L retains sensitivity to bicalutamide. However, we 
did not determine if bicalutamide would out-compete enzalutamide to inactivate the F876L 
mutant, which would be a useful experiment to perform. It is interesting to speculate that 
because of enzalutamide-mediated activation of receptor signaling, combination therapy with 
structurally distinct anti-androgens either in combination or in series together with ADT may 
provide an appealing therapeutic strategy for combating AR-mediated enzalutamide resistance 
mechanisms. 
 
In vitro and in vivo experimental models of PC are vital tools for discovery of mechanisms of drug 
resistance, and for the evaluation of new and alternate therapies. However, the most commonly 
adopted methods for studying AR mutant function are conducted by transient expression of AR 
isoforms into receptor negative cells and assessment of activity using reporter-based methods 
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(as shown in Figure 5.1) which lacks physiological relevance. Hence, having confirmed the 
agonistic activity enzalutamide towards the ARF876L mutant, an LNCaP cell line that stably 
expresses ARF876L mutant was generated to enable more robust modelling of the mutant and 
provide a better understanding of the driver mechanisms behind resistance.  
 
Our lab has previously created a rescue cell line model and applied it successfully to study the 
molecular function of the bicalutamide-activated ARW741L mutant (O'Neill et al., 2015). This 
system relies upon the ability to deplete endogenous AR via 3’UTR siRNA oligonucleotides which 
enables analysis of the ectopic mutant in the physiologically-relevant LNCaP cell line. Here, the 
same strategy was employed to generate an LNCaP cell line derivative that stably expressed 
FLAG-tagged ARF876L, named LNCaP-ARF876L (Figure 5.3). In support of the luciferase 
transactivation data, by analysis of mRNA expression of AR target genes PSA and KLK2 in LNCaP-
ARF876L cells, we observed similar agonism by DHT and enzalutamide on stably expressed ARF876L 
(Figure 5.4). Importantly, compared to previous luciferase transactivation data, this model offers 
the capability to assess mutant AR activity in a CRPC cell line upon endogenous target genes and 
to enable assessment of sensitivity of the mutant to other agents and provide potential 
biomarkers of ARF876L expression. These findings indicate that not only can the ectopically-
expressed ARF876L respond to ligands and activate endogenous target genes PSA and KLK2 
consistent with its endogenous ART877A counterpart, it confirms the antagonist-agonistic switch 
of enzalutamide in a more physiologically-relevant model that can be further explored to improve 
our understanding of how the ARF876L mutation functions in CRPC.    
 
LNCaP cells endogenously express ART877A that is activated by DHT and the first-generation 
antagonist flutamide which may interfere with bespoke analysis of the ectopic ARF876L mutant in 
the LNCaP-ARF876L cell line. To enable discriminate analysis of either ART877A or ARF876L isoforms, a 
custom siRNA oligonucleotide, named siART877A, was designed to specifically target the 3’UTR of 
endogenous AR mRNA as the target sequence is not present on the ectopic ARF876L transcript 
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(Figure 5.5 A). Using this approach, endogenous ART877A can be depleted; leaving ectopic ARF876L 
to be studied without hindrance from the potentially competing isoform (Figure 5.5 B).  We firstly 
confirmed that siART877A is able to effectively knockdown endogenous AR protein levels for up to 
96 hours (Figure 5.5 C) which was deemed to be sufficient for subsequent experiments that 
focussed on gene expression and cell phenotype analyses. Importantly, the siART877A oligo was 
not able to target transiently expressed FLAG-wtAR in PC-3 cells (data not shown) or FLAG tagged 
ARF876L in LNCaP-ARF876L cells due to the absence of the 3’UTR siRNA target sequence (Figure 5.5 
D).  
 
By confirming the efficiency of specific endogenous AR knockdown in LNCaP and LNCaP-ARF876L 
cells, another oligonucleotide was designed to target the FLAG tag/ linker sequence upstream of 
the ARF876L start codon, termed siARF876L. By optimising transfection conditions, it was shown that 
siARF876L had no effect on endogenous AR expression while it is able to specifically target the 
FLAG-ARF876L mutant resulting in substantial knockdown (Figure 5.5 B). The siARF876L and siART877A 
siRNAs therefore served to increase the flexibility of the model by being able to regulate both 
endogenous (siART877A) and ectopic (siARF876L) AR isoforms in the LNCaP-ARF876L derivative. 
Importantly, both the siART877A and siARF876L oligo consistently achieved substantial levels of 
specific AR isoform knockdown.  
 
Of note, comparing to parental LNCaP cells, western blot analysis in the LNCaP derived ARF876L 
subclone cells displayed a substantial higher level of total AR. The same enhanced level of total 
AR was previously reported in LNCaP-developed subclones which stably express wtAR (Chen et 
al., 2004), as well as in the LNCaP-ARW741L derivative (O’Neill et al., 2015). It is important for us to 
modulate enhanced AR expression levels by using siRNA oligonucleotides as the similar elevated 
AR is rather commonly observed in PC patients with advance disease (Waltering et al., 2009). Of 
note, in the control experimental arm from work described in O’Neill et al., 2015, using an AR 
wild-type expressing LNCaP derivative, we did not detect any major changes to AR target gene 
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expression- hence even though total AR abundance was higher in the W741L cell line, it was the 
activation of the mutant that caused most of the distinct changes to the AR transcriptome. Also, 
given that in this report, we are using enzalutamide to activate the ectopic AR, the endogenous 
AR will be inactive and hence active forms of the AR will be equivalent to normal LNCaP cells.  
 
Loading of the AR at androgen response elements (AREs) adjacent to target genes in response to 
activating ligands is an essential step in the receptor signalling cascade that is required to 
facilitate downstream transcription. In the typical pathway, ligand-activated AR translocates to 
the nucleus and binds to AR-targeted cis-regulatory elements in chromatin and recruits co-
regulators to form a pre-initiation complex and together with the basal transcriptional machinery 
initiates transcription of specific AR target genes. By using ChIP experiments in LNCaP cells, the 
DHT-bound AR was found to be recruited to both enhancer and promoter regions containing 
AREs of genes, such as PSA, but not to sequences in-between that lacked these specific target 
sequences. Several studies, e.g. (Louie et al., 2003) have latterly reported that compared to 
promoter regions, more robust hormone-induced recruitment of the AR was observed at 
enhancer regions of AR targets, such as PSA. By using FLAG-specific antibody in ChIP assays, we 
observed higher recruitment of FLAG-AR at enhancer regions (Figure 5.6) than to the promoter 
of PSA in the LNCaP-ARF876L cell line derivative which is consistent with endogenous ART877A in 
parental LNCaP cells (Appendix 5B). Moreover, enrichment of ARF876L occupancy was also 
detected at PSA, and KLK2 in response to enzalutamide supporting the concept that ARF876L 
utilises enzalutamide as an agonist to promote AR-target gene expression. Of note, comparing 
DHT versus enzalutamide ChIP data, there was still ARF876L present on chromatin when siARF876L 
was utilised, which may be due to enhanced stability of a population of ectopic receptor when 
bound to chromatin and hence is resistant to knockdown.  
 
For AR to exert transcriptomic regulation, RNA polymerase and other co-regulators are required 
to be recruited to regions proximal to the target gene (Louie et al., 2003; Wiench et al., 2011). 
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Hence, we used ChIP assays as surrogate for analysis of the activation status of the AR-bound 
gene. We next sought to assess if the ectopic AR can not only bind target sequences, it can also 
recruit RNA pol II to commence transcription. By employing phosphorylated serine 5 RNA 
polymerase II antibody which is a marker of transcriptional initiation, we have successfully 
detected occupancy of RNA polymerase II within same regulatory elements of analysed AR target 
genes. Importantly, enzalutamide-induced transcriptional regulation of ARF876L was further 
confirmed by silencing of FLAG-ARF876L which resulted in reduced enrichment of RNA polymerase 
II at PSA and KLK2 genes (Figure 5.6).  
 
Having shown that the ARF876L mutant drives gene expression in the presence of enzalutamide, 
including PSA and KLK2, and hence mimics the effects of DHT-activating endogenous ART877A 
(Wang, 2006), it was important to address if ARF876L activation by enzalutamide could impact cell 
phenotype. To this end, cell cycle analysis was carried out using propidium iodide (PI)-based flow 
cytometry to analyse the percentage of cells in a particular cell cycle phase based on DNA 
content. Cells were grown in full medium and supplemented with either DHT or enzalutamide. 
The cell cycle analysis indicated that enzalutamide promotes ARF876L-driven cell cycle progression 
that was, as expected, not observed in parental LNCaP cells (Figure 5.7). Enzalutamide treatment 
caused LNCaP parental cells to undergo apoptosis, as indicated by elevated numbers of cells in 
sub-G1, while in contrast, the anti-androgen increases the proportion of ARF876L cells in S-phase 
at the expense of G1- and G2/M-phases of the cell cycle.  Importantly, these observations of 
enzalutamide acting as a driver of cell proliferation in the LNCaP-ARF876L derivative were 
confirmed by SRB assay, as increasing cell numbers was detected under prolonged treatment 
with enzalutamide.  
 
By showing that the ARF876L mutation in our stable model induces an antagonist to agonist switch 
for enzalutamide that can promote AR signalling and growth of cells, we next asked whether 
ARF876L-bearing cells become dependent on this switch for cellular growth under androgen-
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deprivation conditions, a dependence that has been observed in the clinic for other anti-
androgens such as flutamide (Korpal et al., 2013a). By growing cells in the presence of DHT and 
enzalutamide post knockdown ART877A and FLAG-ARF876L, we firstly found that consistent with the 
resistance phenotype observed before, the absence of endogenous AR has no effects on 
enzalutamide-induced proliferation of LNCaP-ARF876L cells whilst knockdown of ARF876L restores 
cell sensitivity to enzalutamide (Figure 5.7 B). This result is consistent with previous reports that 
ectopic expression of ARF876L rescued the growth inhibition of enzalutamide treatment (Balbas et 
al., 2013). 
 
To further explore the molecular mechanisms that drive resistance, we next conducted global 
transcriptomics analysis of LNCaP-ARF876L cells in the presence and absence of endogenous AR 
and ARF876L following treatment with enzalutamide for 24 hours. The next chapter will therefore 
focus on global transcriptomic regulation by ARF876L upon treatment with enzalutamide. 
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 Global analysis of ARF876L-driven gene expression that depict 
transcriptomic mechanisms of enzalutamide resistance. 
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6.1 Introduction 
Despite the recent successes in application of newly-approved therapies in prostate cancer 
treatment, including abiraterone and the second-generation anti-androgen enzalutamide, 
durable responses are limited, presumably owing to acquired resistance via deregulated AR 
signalling. Over the past decade, our understanding of the role of androgen signalling as a 
molecular driver of CRPC has significantly improved, but there are also mechanisms that 
possibly govern resistance to ADT that do not directly involve androgen signalling. In the 
previous chapter, by using Luciferase reporter as a surrogate, we have initially demonstrated 
elevated ARF876L activity in response to enzalutamide compared to ARwt. Furthermore, we 
have established a stable ARF876L expressing LNCaP cell line that enables analysis of the 
clinically-relevant antagonist to agonist switch of enzalutamide in a physiologically-relevant 
setting. Although the previous chapter indicated that the enzalutamide-activated AR mutant 
facilitated expression of the endogenous PSA and KLK2 genes, it is critical that a study of 
global transcriptomics in response to activation of the ARF876L mutant is undertaken as it has 
the potential to highlight biomarkers for enzalutamide resistance and other therapeutically-
exploitable pathways for improved patient care. Therefore, in this chapter, global gene 
expression will be assessed in the LNCaP-ARF876L cell line in response to enzalutamide. From 
this data, other pathways that drive enzalutamide-resistance, including activation of the 
glucocorticoid receptor (GR) pathway, will be assessed. Finally, as a means of utilising this 
rescue model to assess efficacy of novel AR signalling targeting agents, this chapter will also 
interrogate the therapeutic potential of impairing activity of the bromodomain and 
extraterminal (BET)-family of bromodomain-containing proteins, including BRD4, in the 
background of ARF876L-driven enzalutamide resistance to establish clinically-relevant 
sensitivities. 
 
By analysing the global transcriptome of the enzalutamide-activated ARF876L mutant in the 
LNCaP-ARF876L derivative, we aim to understand if this receptor isoform displays altered gene 
regulation distinct from the endogenous AR which may provide clues to how ARF876L drives 
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disease progression. Importantly, we observed that enzalutamide-activated ARF876L drives a 
gene profile that strongly overlaps with a reported GR-regulated gene signature. Hence, we 
here focus on further exploring the interplay mechanism between ARF876L-driven agnostic 
signalling programme and GR-regulated transcriptomic profiling in CRPC.  
 
The primary sequence of the DNA-binding domain of AR and GR share 80% homology and 
share an extensive overlap of chromatin-binding and transcriptional activities. One recently 
proposed mechanism of enzalutamide-resistance in PC is by selective activation of the GR 
signalling pathway that acts to mimic AR function to facilitate disease progression (Kach et 
al., 2017). A significant increase in the number of GR positive cells was detected in patients 
who were tolerant of enzalutamide compared to both baseline and enzalutamide-responsive 
patients (Wadosky and Koochekpour, 2016). By administering dexamethasone (an 
alternative glucocorticoid) in LNCaP cells that stably express GR, and applying ChIP-seq, 
Arora et al. (2013) found that over half of the occupation of AR DNA binding sites was bound 
by the GR. Additionally, by conducting ChIP-Seq in the VCaP cell line that expresses 
endogenous GR and AR, it was revealed that a 58% overlap existed between AR and GR 
cistromes, which indicates the contribution of GR transcriptional regulation to disease 
progression (Isikbay et al., 2014); Moreover, using an enzalutamide-resistant LNCaP-derived 
xenograft model, Arora et al. (2013) detected increased mRNA and protein levels of GR 
compared to enzalutamide-sensitive LNCaP cells and observed enhanced GR activity in this 
enzalutamide insensitive population which suggests a selective outgrowth of cells with 
elevated GR function to override the effects of the anti-androgen. Altogether, the evidence 
presented above indicates that increased GR expression and function is a potential 
mechanism governing continued survival of CRPC during second-line ADT with enzalutamide.  
 
Currently, over 50% of CRPC patients who have failed conventional hormonal treatments 
have at least one aberration of the AR pathway (Asangani and Chinnaiyan, 2014). Hence, 
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targeting ‘downstream’ of AR has been considered as alternative therapeutic strategies for 
treating CRPC. A number of current studies have recently reported the promising progression 
of targeting BET-family protein in CRPC treatment (Raina et al., 2016). Unlike enzalutamide, 
which directly targets the LBD of the AR, BET domain inhibitors function downstream of the 
receptor. By competitively binding to the acetyl lysine recognition pocket within  the 
bromodomain of the BET family of proteins, BET inhibitors, such as JQ-1 and I-BET762, 
diminish AR recruitment to cis-regulatory elements of target genes and subsequent AR-
mediated gene transcription (Filippakopoulos et al., 2010). However, these experiments 
were performed in non-ARF876L–expressing backgrounds hence it is important to address the 
efficacy of these compounds in mutant backgrounds. To that end, this chapter will focus on 
two bromodomain inhibitors that selectively target the bromodomains contained within the 
BET family of transcriptional regulators and p300. The purpose of these experiments is to 
address the potential of bromodomain suppression on reducing activity of the clinically-
relevant ARF876L that could provide important pre-clinical indications that BET/p300/CBP 
inhibitors may be efficacious in models of enzalutamide resistance. 
 
BRD4 is a conserved member of the BET family of proteins. Similar to other family members, 
BRD4 has a critical role in transcription regulation by facilitating the recruitment of RNA 
polymerase II (RNA Pol II) and positive transcription elongation factor P-TEFb (Yang et al., 
2005). BRD4 has been recently found to play a role in several malignancies, including breast 
cancer (Crawford et al., 2008), non-small cell lung cancer (Shimamura et al., 2013) and 
melanoma (Segura et al., 2013). It is a co-regulator for the AR; facilitating transcription of 
AR-target genes by associating with acetylated chromatin and enabling recruitment of the 
basal transcription machinery (Coutinho et al., 2016). Moreover, several BET inhibitors (BETi) 
that interrupt BRD4 chromatin recruitment are being assessed in clinical trials for CRPC 
(https://clinicaltrials.gov). 
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p300 is a histone acetyltransferase (HAT) enzyme which has been long known to be an AR 
co-activator which is largely dependent upon the HAT activity of the enzyme to facilitate 
receptor function via both histone and AR acetylation (Fu et al., 2000); Gaughan et al., 2002). 
In PC cells, p300 is found play a role for androgen-dependent and independent 
transactivation of the AR (Debes et al., 2002). In clinical samples, expression of p300 
positively correlates with AR protein levels in human PC specimens (Zhong et al., 2014). Here 
this chapter we will take BRD4 and P300 as example for investigating sensitivity to 
bromodomain inhibition in the background of our ARF876L-signalling-competent human CRPC 
model. 
 
6.2 Specific methods and materials 
  Sample preparation for HT-12v4.0 Illumina Bead chip gene expression. 
To prepare RNA for micro-array analysis, LNCaP-ARF876L cells were reverse transfected with siAR 
T877A and siARF876L siRNAs (25μM) in 6-well plates (Corning) and cultured in 2 ml 10% steroid-
depleted medium for 48 hours before performing a second siRNA transfection. 96 hours post-
transfection, 10 nM DHT and 10μM enzalutamide were added for 24 hours prior to harvesting 
and RNA extracted using TRIzol (Life Technologies) according to the manufacturer’s manual.  
The RNA samples were quality checked and normalised by HTG. All RNA samples were 
processed using the Illumina TotalPrep-96 RNA Amplification Kit followed by the Illumina 
Whole-Genome Gene Expression Direct Hybridisation Assay. The labelled RNA was then 
hybridised to Human HT- 12_V4_BeadChip for gene expression. All samples achieved the 
minimum number of ≥8000 detected genes (whereby P=0.01). The number of detected genes 
ranges from 9526 to 10724. We thank the High-Throughput Genomics Group at the Wellcome 
Trust Centre for Human Genetics (funded by Wellcome Trust grant reference 090532/Z/09/Z) 
for the generation of gene expression data. 
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 Sample analysis  
Illumina HT-12v4 BeadChip array analysis was performed using GenomeStudio software 
(Illumina). Basic differential expression analysis was accomplished using Illumina’s in-built 
normalisation and error model to include multiple testing correction using the Benjamini and 
Hochberg false discovery rate (p < 0.05). Genes were filtered further using custom equations to 
exclude genes with an insignificant detection p-value as recommended by Illumina (p< 0.05). 
Compound treated samples were expressed as fold-change by dividing the average sample signal 
by vehicle treated controls. Data is represented as the mean of three independent experiments. 
Genes without a gene symbol/ID and those with locus specific entries were removed from the 
overall analysis. Genes that were analysed in greater detail were validated by qPCR according to 
section 3.14.3.  
 
 Specific primers and compounds 
Table 6.1 primers used for gene expression validation in q-PCR.  
gene Forward Primer Reverse Primer 
ORM1 5’ –AGCATTTCGCTCACTTGCTG -3’ 5’-GACAGCCCCCAGTTCTTCTC-3’ 
ACSL3 5’ -TGACACAAGGGCGCATATCT-3’ 5’- CCAGTCCTTCCCAACAACGA -3’ 
LRIG1 5’-CCTTCTCCTTCTCTGGCTGC -3’ 5’- AACTCAGGTTTAGGCTCCGC - 3’ 
VCL 5’- CGCTGAGGTGGGTATAGGTG-3’ 5’- GTAGCTTCCCGATGCAAGGA - 3’ 
NFIB 5’- CGAACTCCACCTCCACCTTC-3’ 5’- TGGTTTGTGGACTGGATGGG-3’ 
LIFR 5’- CCTAACCCTCTCTCCCAGAAC-3’ 5’- GATGAATGAGTCGCAGAGGC-3’ 
PDIA5 5’- GAAAGTTGACCTGAGCCCGA-3’ 5’- GGGCCCTTTTGGATCCTTCA-3’ 
ATP1A1 5’- GTCACCTCCTTCTCCTTCCTTTTC-3’ 5’- GGAGCGCGCCTTTCCTCA-3’ 
LONRF1 5’-CAGGAGGGAGTCGGGAGATG -3’ 5’-CTTCCCAGAACCGGCCTC -3’ 
FBXO31 5’- GTGTGTGCTCGCCTTTGC-3’ 5’- TCCTCCTCGGGGTCTGTG-3’ 
ELF1 5’-GCTGAAGCACAGACACCACT -3’ 5’- AGCTTCTTGGCCTTCAAGTATT-3’ 
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RAB3B 5’-CACAGGAAGCACCCTCAGTC -3’ 5’-TGATAAGACTGCCCTGCCCT -3’ 
NR3C1 5’-TCTGAACTTCCCTGGTCGAA-3’ 5’-GTGGTCCTGTTGTTGCTGTT-3’ 
KLK3 5’-TCATCCTGTCTCGGATTGTG-3’ 5’-ATATC AGAGCGGGTGTGG-3’ 
MKP1 5’-CCTGACAGCGCGGAATCT-3’ 5’-GATTTCCACCGG GCCAC-3’ 
SGK1 5’-AGGCCCATCCTTCTCTGTTT-3’ 5’-TTCACTGCTCCCCTCAGTCT-3’ 
GAPDH 5’-GAGTCAACGGATTTGGTCGT-3’ 5’-TTGATTTTGGAGGGATCTCG-3’ 
 
Table 6.2 ChIP primers used for gene expression validation in q-PCR.  
gene Forward Primer Reverse Primer 
ORM1_ChIP 5’-GGGTCATTTCCACCACCTCAAACA-3’ 5’-GGAGAAAGGCCTTACAGTAGTCTC-3’ 
SGK1_ChIP 5’-ACCTCCTCACGTGTTCTTGG -3’ 5’- AAC ATTTTGTCCGTTCCGCA -3’ 
NRC31_ChIP 5’-AGTTAACCTTCTCTGGGCTGG -3’ 5’- CGCCTGAGAACAATGTGTG -3’ 
MKP1 ChIP 5’-AAACATTTCTCCACGGCCCA -3’ 5’-TGTGCCAGGTACTGCTAAGG -3’ 
 
Table 6.3 siRNA sequences used to inhibit specific gene expression by RNAi 
siRNA target siRNA sense sequence 
siAR GCCAGCCACACAAACGUUUdTdT 
siGR CCGAGAUGUUAGCUGAAAUdTdT 
 
Compound treatments 
Cells were typically treated with indicated doses of enzalutamide (10 µM), DHT (10 nM), JQ1 (500 
nM) p300 bromodomain inhibitor (Compound G) and the p300/CBP HAT domain inhibitor C646 
(1 uM) for 24 hours unless otherwise stated. 
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6.3 Results 
 Enz-ARF876L driven gene profile shows overlap with a GR-regulated gene signature. 
 
Having confirmed the mutant can drive proliferation in response to enzalutamide in the 
established LNCaP-ARF876L cell line (Figure 5.7; previous chapter), it was important to determine 
if the genes driven by endogenous vs. ectopic AR are different. Hence, to provide a global view 
of gene expression in our LNCaP-ARF876L cell line that is driven by ARF876L, we performed 
microarray analysis to examine expression changes upon ectopic ARF876L knockdown and 
compared to depletion of endogenous ART877A. The experimental setup and sample preparation 
were conducted as described above and resultant data was processed using x GenomeStudio 
software (Illumina). A cut-off of >1.5-fold change for studying differential gene expression was 
applied which is consistent with numerous publications (Nelson et al., 2002; Chen et al., 2004; 
Nyquist et al., 2013; Polkinghorn et al., 2013; O'Neill et al., 2015). Akin to studies described in 
Chapter 5, endogenous AR knockdown was applied to enable a more robust read-out of the 
enzalutamide-activated ARF876L transcriptome prior to micro-array analysis. By comparing 
enzalutamide treatment to vehicle treated controls in the endogenous AR knockdown arm, a 
total of 615 genes were identified as being upregulated > 1.5-fold in the0presence of 
enzalutamide (shown as siART877A in Figure 6.1 A). Additionally, as ligand-induced genes0were the 
primary end-point, hence only genes that0exhibited increased expression0were focussed0on in 
this report. 
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Figure 6.1 Generating an enzalutamide-activated ARF876L transcriptome in LNCaP-ARF876L. A. diagram of 
enzalutamide-ARF876L-driven signature gene lists overlapping with DHT-driven gene list in LNCaP_Laz cells. 
ARF876L signatures were defined as all genes showing ≥1.5 fold change (FDR <. 05) after 24 hours 
enzalutamide treatment in cells depleted of either ART877A or ARF876L knockdown, respectively. (B) 
Enzalutamide-activated ARF876L-driven gene profiling shows high overlap with GR-regulated subset of AR 
targets (Arora et al., 2013). (C) Top 12 most upregulated gene from our list that matches GR-regulated 
genes were chosen for further analysis. 
 
To verify the core list of enzalutamide-upregulated gene in our LNCaP-ARF876L cell line, we next 
compared gene expression profiling in the presence of enzalutamide upon ARF876L knockdown 
relative to both the siARF876L vehicle and siART877A vehicle control arms (shown as siARF876L in 
Figure 6.1 A). Firstly, post ARF876L knockdown, genes that exhibited a >2fold increase in expression 
following enzalutamide treatment were considered as enzalutamide-independent genes and 
were eliminated from the core list of ARF876L-driven enzalutamide-upregulated genes. 
Comparison of the siARF876L transfected arm in the presence of enzalutamide relative to the 
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siARF876L vehicle control identified 154 differentially expressed genes, with only 17 out of 154 
genes not matching to the 615 core data set (Appendix 6A) (Figure 6.1 A), suggesting activation 
independent of the ectopic ARF876L isoform. Of note, most of the up-regulated genes upon ARF876L 
knockdown had expression fold changes on the verge of the cut-off threshold. It is possible that 
incomplete knockdown of ARF876L may account for the persistence in expression of these 
identified genes in response to enzalutamide. Importantly, further annotation analysis of the 17 
genes revealed no significant functional clustering and the majority of the genes had expression 
fold-changes on the verge of the cut-off threshold. Analysis of the siARF876L arm in the presence 
of enzalutamide relative to the siART877A control arm outlined only 4 genes, FKBP5 SLC45A3 and 
TIPARP to have increased expression, with only MIR1974 not matching to the 615 up-regulated 
gene signature. Intriguingly, MIR1974 has been identified as co-regulated by DHT in PC cells (Li 
et al., 2016). The increasing gene expression may be the consequence of basal AR function. 
Hence, MIR1974 was considered as enz-independent gene and was removed from following 
analysis.  
 
A direct compassion was also conducted with a list of androgen-dependent AR-target genes from  
LNCaP-LacZ cells following 10 nM DHT treatment (O'Neill et al., 2015). These cells are a control 
derivative of the LNCaP cell line that has the pLenti6.3-LacZ backbone stably integrated into the 
genome and were used previously to compare ART877A and ARW741L activity in LNCaP cells. We 
observed a 30% (26 of 86 genes, Figure 6.1 A and  Appendix 6B) overlap between the DHT-
activated LNCaP-LacZ and enzalutamide-activated ARF876L expression signatures lists, including 
KLK2, KLK3 TMPRSS2 and EAF2, which are all well characterised AR-target genes. Moreover, 
nearly all of these genes decrease in response to ARF876L knockdown (Appendix 6B). This similarity 
outlines that enzalutamide is able to drive a similar androgenic signature via the ARF876L isoform. 
Some of most up-regulated genes driven by enzalutamide, such as ORM1, TIPARP and NDRG1 
were not up-regulated in the DHT-induced LNCaP-LacZ gene signature. This observation 
potentially suggests the ability of activated ARF876L to preferentially upregulate a distinct subset 
of target genes. In addition, we have shown in Chapter 5: that no activating effects of 
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enzalutamide on selected AR target genes was observed in LNCaP parental cells and is consistent 
with published transcriptomics data (Guerrero et al., 2013), which reported that enzalutamide 
lacked AR agonistic activity LNCaP cells. Critically, it attenuates agonist-induced expression of 
genes involved in processes such as cell adhesion, angiogenesis, and apoptosis.  
The 615 enzalutamide-activated genes from the LNCaP-ARF876L cell line derivative are listed in 
(Appendix 6A); with the top 20 overexpressed genes including several well-known androgen-
regulated genes such as TIPARP, FKBP5, NDRG1 and EAF2. Interestingly, the most highly up-
regulated genes in response to enzalutamide in LNCaP-ARF876L were ACSL3, ERRFI1, ORM1 and 
SGK/SGK1 which are also GR-target genes. Furthermore, as GR activation has recently been 
shown to play an important role in models of enzalutamide-resistant CRPC, the ability for this AR 
mutant to drive genes associated with GR activity is intriguing and may suggest mimicry of the 
GR by this ectopically-expressed receptor isoform.  
To investigate this question in more detail, we compared the core 484 gene list of enzalutamide-
activated ARF876L genes with AR- and GR-ChIP seq data derived from enzalutamide-sensitive and 
-resistant LNCaP xenograft tumors (Arora et al., 2013). Direct comparison of our list with the 
enzalutamide-induced gene sets revealed that 73 (highlighted green in Appendix 6C) of the 122 
enzalutamide-induced genes (Isikbay et al., 2014) , 60% matched directly to GR-bound AR targets 
in the enzalutamide-insensitive tumors. Moreover, 43 genes from our ARF876L-driven signature 
matched to the 67 GR target gene signature derived from the xenograft samples (64%, Appendix 
6D). Additionally, nearly all of these genes are diminished upon depletion of the ARF876L, which 
suggests these genes are controlled by the mutant receptor. This GR-specific signature was 
defined as the gene-set that demonstrated elevated expression in response to the GR agonist 
dexamethasone compared to DHT treated samples.  
 
In contrast, in the DHT up-regulated gene-set derived from the LNCaP-LacZ derivative (O'Neill et 
al., 2015), only 36/122 (29%) and 15/67 (22%) matches were observed with the GR-bound AR 
gene expression and GR-selective gene signatures respectively (see Appendix 6C and Appendix 
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6D). These findings raised the possibility that the ARF876L may drive a GR gene expression 
signature in our model system. Hence, the top 12 most upregulated genes from our list that 
matches GR-target genes were chosen for further analysis (Figure 6.1 C).  
 
Figure 6.2 Assessing AR-/GR-regulated gene expression in CW22Rv1 cells.  A. Protein lysates were 
collected from PC-3, CWR22Rv1, LNCaP and LNCaP-ARF876L cell lines. LNCaP-derived ARF876L cell were 
maintained in androgen-depleted media and then treated with DMSO, 10 nM DHT and 10 µM 
enzalutamide for 48 hours prior to harvesting. Immunoblotting was performed with antibodies specific for 
AR, GR, PSA and -tubulin. B. CWR22Rv1 cells were maintained in androgen-depleted medium for 48 hours 
before applying the indicated treatments for 24 hours and then RNA extraction. Relative mRNA levels of 
selected genes were measured by RT-qPCR. Data represents N=3 ± SEM. 
 
To investigate the possible role for increased GR signalling in enzalutamide resistance, GR 
expression in AR-negative cell lines PC3 and commonly studied AR-positive PC cell lines CW22Rv1 
and LNCaP cell derivatives was firstly assessed. For protein expression analysis, all selected cell 
lines were cultured in steroid-depleted media prior western blot analysis. As shown in Figure 
6.2A, the strong baseline of GR expression was observed in the AR-negative cell lines PC3, while 
the CWR22Rv1 shows similar high expression of both GR and AR. In contrast, no GR protein 
expression was detected in LNCaP parental cells. 
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Although elevated expression of the NR3C1 (GR) gene was not detected in our microarray data, 
we further assessed whether the LNCaP-ARF876L cell line has elevated GR expression in the 
absence of serum and/or in the presence of DHT and enzalutamide. Cells were seeded in the 
presence of 10 % charcoal stripped medium of 48 hours before treatment with 10 nM DHT or 10 
µM enzalutamide for 48 hours and GR protein expression in cells was examined. In androgen-
depleted conditions, GR protein was undetectable in LNCaP ARF876L cells and remained so in the 
presence of DHT and enzalutamide (highlight with red in Figure 6.2A). This data represents an 
important piece of evidence that supports the theory that in the LNCaP-ARF876L cell line, GR 
activation is unlikely to be involved in driving the enzalutamide-activated GR gene signature.  
 
We next sought to examine ARF876L-upregulated genes in CW22Rv1 given that they express the 
GR. Cells were grown in steroid-depleted media in the presence and absence of 10 m DHT, 10 
µM enzalutamide,  100 nM of the GR agonist dexamethasone (Dex) and 100 nM of the GR 
antagonist mifepristone (Mif) for 24 hours before QRT-PCR.  Consistent with CW22Rv1 cells 
demonstrating GR expression (Figure 6.2 A), dexamethasone shows significant induction of GR-
target genes ACSL3, FKBP5 and ORM1 relative to DMSO (Figure 6.2 B). Of note, CW22Rv1 cells 
express both AR variants and full-length AR, which harbours the H874Y mutation within LBD, that 
is able to be activated by other non-androgen hormones, including dexamethasone (Steketee et 
al., 2002). Moreover, AR-Vs are constitutively active which makes the CW22Rv1 cell line a poor 
comparator model for our LNCaP-ARF876L cell line to address parity between ARF876L- and GR-
driven gene signatures.   
 
We therefore employed the LAPC4 cell line, which is an AR/GR-expressing PC cell line, to further 
examine ARF876L-upregulated genes in the background of a GR-expressing cell line in the presence 
and absence of defined ligands. We firstly confirmed that GR was expressed in LAPC4 cells and 
compared NR3C1 (GR) expression in LAPC4 cells to the LNCaP-ARF876L cell line (Figure 6.3 A). 
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Figure 6.3 Analysis of NR3C1 (GR) expression in LAPC4 cells in the presence and absence of defined 
ligands.  Effect of various ligands on changes of GR mRNA expression in LAPC4 and LNCaP-ARF876L cell lines. 
Cells were seeded in steroid-depleted media for 48 hours before treating with indicated ligands. After 24 
hours treatment, cells were harvested, and samples analysed by (A) gene expression profiling and (B) 
immunoblotting. 10 nM DHT, 100 nM Dex, 100nM Mif and 10 μM enzalutamide were used for both 
experiments.  Data represents N=3 ± SEM. 
 
As shown in Figure 6.3 A, markedly higher GR mRNA levels were observed in LAPC4 cells 
compared to the LNCaP-ARF876L derivative. As expected, dexamethasone subtly induced GR 
mRNA expression in LAPC4 cells which was revered by co-treating with the GR antagonist 
mifepristone. Consistent with the AR negatively regulating GR expression (Xie et al., 2015), DHT 
treatment down-regulated GR mRNA levels while enzalutamide had no effect, presumably 
because the cells were already grown in steroid-depleted conditions. These results were 
replicated at the protein level in LAPC4 (Figure 6.3B). These results suggest that ligand-induced 
AR activation down-regulates GR expression at both mRNA and protein levels. To confirm this 
theory, we next sought to compare PSA expression in the same conditions to assess whether GR 
activation was inversely correlated with PSA production, a marker reflecting AR activation. 
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Figure 6.4 Activated-AR mediated feedback repression of GR expression in LAPC4. GR expression levels 
following AR inhibitor therapy was analyzed using LAPC4 and LNCaP-ARF876L cell lines. 24 hours of 10 nM 
DHT, 10 µM enzalutamide, 100 nM dexamethasone and 100nM mifepristone were used as indicated 
before mRNA expression analysis by qRT-PCR. GR and PSA expression level was normalized to GAPDH and 
depicted as fold change relative to vehicle. Data represents N=3 ± SEM. 
 
As expected, in LAPC4 cells (Figure 6.4 A and C), DHT increased PSA mRNA expression while down-
regulating GR expression. Enzalutamide, in contrast, suppressed AR function as indicated by 
diminished PSA expression, and did not stimulate GR mRNA downregulation. In LNCaP-ARF876L 
cells (Figure 6.4 B and D), although increased PSA levels correlated with activated ARF876L by DHT 
and enzalutamide, RT-PCR did not reveal an effect of the various ligands on GR expression in this 
cell line. Of note, mifepristone did not down-regulate enzalutamide-driven PSA expression, while 
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dexamethasone failed to increase PSA mRNA levels, which together supports the theory that 
genes upregulated in the LNCaP-ARF876L cell line is driven through ARF876L rather than GR 
activation. 
 
By conducting global DNA sequencing using ChIP sample, Asangani et al. (2014) found that ligand-
activated AR signalling can negatively regulate GR expression by directly binding to cis-regulatory 
elements of the GR gene. In addition, Xie et al. (2015) also found that GR expression in prostate 
cancer is diminished via AR occupancy at the upstream enhancer and subsequent polycomb-
mediated gene silencing. To that end, the occupancy of AR at promoter regions of the GR gene 
in LNCaP parental cells and LNCaP-ARF876L stable cell line was next assessed to assess if 
endogenous and ectopic AR isoforms bind the GR locus to repress GR expression.  
Figure 6.5 AR negatively regulate GR transcription by stimulating loading of AR on the promoter. (A & 
B)  Cells were maintained in androgen-depleted medium for 48 hr. ChIP assays following by real-time qPCR 
were performed using LNCaP parental and -ARF876L cells treated with DMSO, DHT, and/or enzalutamide 
for 24 hours. Data represents N=2 ± SEM. 
 
We conduced ChIP-qPCR using both LNCaP parental and LNCaP-ARF876L cells to further assess 
potential AR regulation of GR expression in LNCaP cells. Consistent with published results, as 
shown in Figure 6.5 A, LNCaP ARF876L cells demonstrated increased AR occupancy at the promoter 
regions of GR relative to DMSO treatment and control IgG ChIP in response to both DHT and 
enzalutamide. Moreover, enzalutamide triggered a higher recruitment at the GR enhancer 
compared to DHT. In contrast, in LNCaP parental cells, although DHT induced chromatin 
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occupancy of the endogenous AR, recruitment of the receptor was not observed at the GR 
enhancer upon enzalutamide stimulation. This suggests that the ARF876L mutant may maintain 
repression of the GR in the presence of enzalutamide and hence expression of GR-target genes 
in the LNCaP-ARF876L derivative is likely as a result of ARF876L activity.  
Together, the results presented above demonstrate that in the LNCaP-ARF876L cell line, AR is a 
negative regulator for GR transcription and can be maintained by enzalutamide. Furthermore, it 
also provided evidence that GR signalling was not contributing to the effects of enzalutamide 
treatment in the LNCaP-ARF876L cell line.  
To help support this notion, we next examined ARF876L upregulated genes in the presence and 
absence of defined ligands. LNCaP parental and LAPC4 cell lines were used as the comparison.  
Figure 6.6 Profiling AR/GR-regulated gene in LNCaP parental, LAPC4 and LNCaP-ARF876L.  (A and B). mRNA 
was collected from each of the three cell lines grown in steroid-depleted conditions and treatment for 24 
h with 10 nM DHT and 10 µM enzalutamide. Gene expression was assessed by qRT-PCR using specific 
primer as list in 6.2.3 Data represents N=2 ± SEM. 
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By comparing the three cell lines, we found that both DHT and enzalutamide-induced gene 
expression in ARF876L stable cell line is more similar to LAPC4 cells rather than to the LNCaP 
parental cells. As results show in Figure 6.6 A, expression of GR-target genes ACSL3, NFIB, PDIAD5, 
LONPR1 and MKP1 increases modestly in LAPC4 and LNCaP-ARF876L cells. Importantly, in the 
presence of enzalutamide, 8 (highlighted in red) out of 12 tested geneincreased in both LAPC4 
and LNCaP-ARF876L cells, but not in LNCaP parental cells.  
 
As LAPC4 cells express both AR and GR, we suspected that upregulated GR-target gene 
expression in LAPC4 cells may be driven through GR activation in the presence of enzalutamide. 
Therefore, as a prove-of-concept, we next went to interrogate whether enzalutamide activated 
GR or AR function in LAPC4 cells by knockdown of either AR or GR.  
 
Figure 6.7 Profiling AR-/GR-regulated genes in LAPC4. (A) Knockdown efficiency of siAR and siGR in LAPC4 
cells. Cell lysates were harvest post siRNA-mediated AR and GR depletion and nuclear receptor levels and 
PSA expression was assessed by western blots. (B) PSA mRNA expression level in LAPC4 cells upon AR or 
GR knockdown.  (C) GR-target gene MPK1 expression was analyzed in the presence of 10 µM enzalutamide 
using specific primers in LAPC4 cells post AR or GR knockdown. Data represents N=3 ± SEM. 
 
AR and GR knockdown was firstly confirmed via western blots as shown in Figure 6.7 A. 
Comparing to siSCR control, knockdown of AR was effective and reduced PSA levels in in LAPC4 
cells. In contrast, in response to GR knockdown, PSA expression was not affected. Of note, loss 
of GR expression in LAPC4 results in a modest increase in the level of AR and is consistent with 
RT-qPCR results demonstrating an increase in PSA mRNA in response to GR knockdown (Figure 
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6.7 B). Importantly, in the presence of enzalutamide, MKP1 expression was diminished only upon 
GR knockdown (Figure 6.7 C) supporting our previous data suggesting that GR is a driver of GR-
target genes in LAPC4 while it is in LNCaP-ARF876L which drives these genes in the LNCaP-ARF876L 
derivative.  
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Figure 6.8 Mifepristone demonstrates an agonistic effect for AR. Mifepristone exhibits agonist activity in 
both parental and ARF876L –expressing LNCaP cells. qPCR analysis of expression of AR target genes in LNCaP 
and LNCaP-ARF876L cells treated with DMSO or DHT, enzalutamide - /+ Mifepristone for 24 hours. Data are 
presented as percentage of expression in enz-treated sample relative to DMSO. Data represents N=2 ± 
SEM. 
 
During the gene profiling validation, we noticed that Mifepristone demonstrated agonistic 
activity for receptor-target gene expression in both LNCaP parental and LNCaP-ARF876L cell lines. 
We therefore investigated this effect further. As results demonstrate in Figure 6.8, AR target 
genes PSA, ACSL3, NFIB and PDIAS were significantly increased upon mifepristone treatment 
alone. Consistent results were also observed in parental LNCaP cells; a phenomenon previously 
reported demonstrating the compound has a high binding affinity for AR and can function as an 
AR agonist (Song et al., 2004). Kang et al. (2004) also found that Mifepristone exhibited agonist 
activity in LNCaP cells, by stimulating loading of AR and recruitment of Pol II and p300 on the 
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promoter. As mifepristone is currently used in clinical trials in combination with ADTs for CRPC 
patients (https://clinicaltrials.gov/ct2/show/NCT02012296), the potential of mifepristone as an 
AR modulator in clinical prostate cancer has yet to be explored, here, our results for the first time 
provide evidence of transactivation by mifepristone of wild-type and F876L mutant receptors in 
models of CRPC.   
In all, our results presented above demonstrate that the ARF876L mutant drives a GR-target gene 
signature in the LNCaP-ARF876L derivative that lacks GR expression suggesting potential nuclear 
receptor mimicry to promote GR-target gene expression. 
 
 Investigate sensitivities of ARF876L to BET inhibitors 
The identification and therapeutic targeting of co-activators or mediators of AR transcriptional 
signalling is being actively pursued as an alternative strategy to treat CRPC, including newly 
developed BET family bromodomain inhibitors. Hence, in the second part of this chapter, 
experiments in which a panel of BET inhibitors were applied to the LNCaP-ARF876L cell line are 
described to discover new treatment options for ARF876L-driven enzalutamide resistance in CRPC. 
JQ1 is a small-molecule compound that been designed to target bromodomains 1 and 2 of the 
BET family, including BRD4. Given that BET inhibitors are being applied in the clinic as part of 
early phase clinical trials after patients have failed ADT (including enzalutamide), the requirement 
to study their efficacy in distinct AR mutational backgrounds as a result of ADT resistance is 
important.  Pawar et al. (2018) and Ruggero et al. (2018) found that treatment with the BET 
inhibitor, JQ1, can effectively re-sensitise resistant tumours to enzalutamide. JQ-1 works 
downstream of AR and abrogates recruitment of the receptor to cis-regulatory elements 
resulting in removal of RNA polymerase II from AR target genes, to induce apoptosis and down-
regulate AR-regulated gene transcription (Asangani et al., 2014). Hence, JQ-1 was firstly used in 
the newly-derived LNCaP-ARF876L cell line model to investigate the potential of BET-inhibition as 
a tractable treatment for diminishing ARF876L-regulated signalling. 
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Figure 6.9 JQ1 down-regulation of PSA level in LNCaP parental cells and ARF876L.  (A) JQ1 reduced DHT-
resulted PSA level in LNCaP. (B) JQ1 shows inhibitory effects on ARF876. JQ1 reduced enzalutamide-driven 
PSA level in LNCaP-ARF876L cells. AR-441 (abcam) and PSA antibodies were used for detection of total AR 
protein levels in both cell lines.  
LNCaP and LNCaP-ARF876L cells were cultured in steroid-depleted media for 24 hours before 
application of 10 nM DHT, 10 µM enzalutamide and/or 0.5 µM JQ-1 for an additional 24 hours. 
Whole cell lysates were then collected before AR and PSA analysis by western blotting. -tubulin 
was used in each sample as loading control. As results show in Figure 6.9 A, AR protein levels 
were not markedly affected by JQ1 treatment in both cell lines. Importantly, a marked down-
regulation of DHT-induced PSA level was observed in LNCaP parental cells; and a similar inhibitory 
effect of JQ1 was observed on DHT- and enzalutamide-activated ARF876L-driven PSA expression in 
the LNCaP-ARF876L cell line (Figure 6.9 B).  
We next determined the consequences of JQ1 treatment on cellular phenotype by measuring cell 
proliferation and viability using the IncuCyte® ZOOM system. 
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Figure 6.10 JQ-1 treatment attenuates enzalutamide-driven cell growth of LNCaP-ARF876L.  (A & B) 
Parental and ARF876L LNCaP cells were seeded in steroid-containing media in 96-well plates containing 10 
µM enzalutamide or enzalutamide plus 0.5 µM JQ1. Cell confluency of each well was measured in real-
time for 7 days using the IncuCyte® ZOOM as described in section 5.2.4.   
 
In contrast to LNCaP-ARF876L cells, the presence of enzalutamide in LNCaP cells resulted in a 
modest reduction of cell growth. Inhibiting the bromodomain function of the BET family with JQ1 
resulted in markedly decreased cell proliferation (Figure 6.10 A). Importantly, LNCaP-ARF876L also 
demonstrated a significant decrease in cell growth after around 48 hours of BET inhibition, 
suggesting that enzalutamide-driven cell proliferation can be attenuated by JQ-1.  
Given that AR-positive cell growth was preferentially sensitive to JQ1, we next explored 
expression levels of selected AR-target genes in the LNCaP-ARF876L cell line in the presence and 
absence of enzalutamide. LNCaP-ARF876L cells were seeded in the absence of androgen for 48 
hours then treated with DHT (10nM), enzalutamide (10 M) and JQ1 (500 nM) for 24 hours 
before AR gene expression profiling. 
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Figure 6.11 Co-treatment with the BRD4 inhibitor JQ-1 attenuates expression of DHT-/ enzalutamide-
ARF876L-induced PSA KLK2 TMPRSS2, SGK1 expression, but not FKBP5 expression.  (A & B) Quantitative 
RT-PCR analysis of PSA, KLK2, TMPRSS2, FKBP5 and SGK1 gene expression in LNCaP ARF876L cells treated 
with combinations of vehicle (DMSO and ethanol), 0.5 µM JQ1, 10 nM DHT or 10 µM enzalutamide as 
indicated for 24 h. Data represent mean +/− standard error of the mean (s.e.m.) (n =3) 
 
To aid comparison, DHT and enzalutamide-induced gene expression in the absence of JQ-1 were 
normalized to 1 and the effect of JQ-1 on PSA, KLK2 and TMPRSS2 expression was shown as a fold 
change compared to this arbitrary value (Figure 6.11 A). As expected, both DHT and 
enzalutamide-activated PSA expression was effectively downregulated upon JQ1 treatment. This 
result is consistent with our early data showing that JQ1 reduced enzalutamide-elevated PSA 
protein levels (Figure 6.9 B). In addition, another two AR-regulated gene, KLK2 and TMPRSS2 also 
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showed similar negative effects of JQ1. Interestingly, we observed that not all selected genes 
demonstrated diminished expression in response to the BET inhibitor; in the presence of DHT 
and enzalutamide, FKBP5 expression was not affected by JQ-1, while only DHT-activated SGK1 
mRNA expression was diminished by JQ-1 (Figure 6.11B). To sum up, JQ-1 presents selective 
down-regulated effects on the ARF876L mutant in LNCaP-ARF876L cell line. 
 
 Compound G inhibits ARF876L transcriptional function by disrupting with co-recruitment 
of p300 at androgen-responsive elements.  
 
Although we have shown that several canonical AR-target genes are sensitive to JQ1, it is not 
clear why only a subset of genes responds to BRD4-BET inhibitors. Recently, a number of BET-
family proteins were shown to interact with sequence-specific DNA-binding transcription factors 
in a gene-specific manner in CRPC. As the genetic and epigenetic landscape differs between PC 
model types, it is possible that distinct transcriptional regulators that associate with AR might 
influence the action of BET inhibitors. Hence, we next tested inhibitory capacity of targeting 
another bromodomain-containing family protein candidate, p300, by applying a newly-
developed p300 bromodomain inhibitor called Compound G in our cell line model.     
p300 has been shown to regulate AR signalling in CRPC, in part, via direct acetylation of the 
receptor and modulating histone acetylation (Cucchiara et al., 2017). Given that p300 is known 
to engage with sequence-specific DNA-binding proteins and other coregulatory proteins, 
resulting in modulation of transcription through altered protein-protein interactions, thus this 
compound was assessed in our model system is to examine if compound G is effective against 
the ARF876L isoform; and hence represents another tractable target in enzalutamide-resistant 
disease.  
159 
 
 
Figure 6.12 Bromodomain of p300 is not required for AR-p300 interaction.  (A) LNCaP cells were cultured 
in normal growth condition and immunoprecipitation was performed using whole cell lysates using a p300 
antibody before probing immunoprecipitates with an anti-AR antibody. (B) Endogenous p300 expression 
in LNCaP cells was assessed in the presence and absence of 0.5 µM Compound G and DHT. (C) IP assay akin 
to (A) with inclusion of Compound G to assess impact on AR-p300 interaction. 
 
Using immunoprecipitation assays, we were firstly able to detect endogenous AR-p300 
interaction in LNCaP cells which confirms previous reports (Heemers et al., 2008). Next, cells were 
treated with DHT or DHT plus Compound G for 24 hours. As results indicated in Figure 6.12B, 
Compound G treatment did not affect endogenous p300 protein levels in LNCaP cells. 
Importantly, as shown by immunoprecipitating p300 from cells treated with and without 
Compound G, the p300-AR interaction was not affected (Figure 6.12 C) and supports the concept 
that the bromodomain of p300 is not required for AR interaction.   
 
Binding of enzalutamide to ARF876L leads to its translocation from the cytoplasm to the nucleus, 
where it binds to regions of DNA harboring androgen-responsive elements (AREs) and results in 
subsequent recruitment of proteins involved in transcriptional activation or suppression in a 
gene-specific manner (Figure 6.11). p300 modulates gene expression via interaction and 
modification of chromatin, via histone acetylation, as well as DNA-binding transcription factors, 
leading to context-dependent transcriptional regulation of target genes. The p300 bromodomain 
has also been suggested to be important for specific chromatin substrate recognition and for 
chromatin remodeling (Chen et al., 2010). Having earlier observed that the AR–p300 interaction 
is not disrupted by Compound G, we next explored whether inhibition of the p300 bromodomain 
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affects transcriptional activation of AR function by interrupting chromatin occupancy. To that 
end, we performed ChIP-qPCR with antibodies against FLAG-AR and p300 in LNCaP-ARF876L cells 
that were either starved of steroids, treated with either enzalutamide or +/- Compound G.  
 
Figure 6.13 p300 loading at cis-regulatory regions of AR-target genes is lost upon Compound G treatment 
in LNCaP-ARF876L cells.  Indicated treatments were conducted in LNCaP-ARF876L for 24 hours.  Enzalutamide-
mediated recruitment of ARF876L and p300 to enhancer regions of PSA, TMPRSS2 and FKBP5 was assessed 
by ChIP-qPCR. DMSO-dimethylsulphoxide, enz-enzalutamide, G-Compound G. Data represents N=2. 
 
As expected, comparing to DMSO and IgG control arm, FLAG-AR was highly enriched at PSA 
enhancer in enzalutamide-treated cells (Figure 6.13). Robust co-association of p300 recruitment 
was also observed within the same promoters of AR-regulated genes. Although enzalutamide-
driven ARF876L enrichment remains at similar level upon Compound G treatment, interestingly, 
recruitment of p300 to target loci was attenuated. Furthermore, Compound G blocked p300 
recruitment consistently at enhancer regulatory regions of TMPRSS2. In contrast, enrichment of 
both ARF876L and p300 were largely removed from enhancer regions of FKBP5 upon enzalutamide 
and Compound G dual treatment. It suggests that bromodomain inhibition has profound effects 
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on p300 chromatin binding while loss of p300-BET function may also impact on AR chromatin 
occupancy in a gene-specific manner.  
Based our observation of AR and p300 co-association at specific regulatory elements of AR-target 
genes, we next sought to determine the functional consequences of Compound G treatment by 
measuring the expression levels of selected AR-target genes.  
Figure 6.14 Compound G down-regulates DHT- and enzalutamide-activated ARF876L-target gene 
expression in LNCaP-ARF876L.  (A) Western blots were performed with lysates from LNCaP-ARF876L cells 
treated with DHT, enzalutamide or Compound G as indicated. Blots were probed with antibodies specific 
to the FLAG-tag, PSA and -tubulin. (B) Quantitative RT-PCR analysis of AR target gene mRNA levels in 
LNCaP-ARF876L cell lines treated as indicated. For comparison purposes, DHT and enzalutamide-induced 
gene expression level were set to 1. Data represents N=3 ± SEM. 
 
In LNCaP-ARF876L cells, PSA protein levels are elevated in response to DHT and enzalutamide which 
can be reversed with p300 bromodomain inhibition (Figure 6.14 A), Consistent with the PSA 
western data, the selected AR-target genes PSA, KLK2, TMPRSS2 and NDRG1 were up-regulated 
by both DHT and enzalutamide. Importantly, co-treating LNCaP-ARF876L cells with Compound G 
efficiently down-regulated both DHT- and enzalutamide-induced AR target gene regulated gene 
expression (Figure 6.14 B).  
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Next, to evaluate p300 bromodomain inhibitor repression of AR activity in an androgen-
dependent setting, both LNCaP parental cells and LAPC4 were treated with either DHT alone or 
DHT together with escalating concentrations of Compound G for 24 hours. As results show in 
Figure 6.15, both cell lines demonstrate a dose-dependent decrease in DHT-induced PSA protein 
levels upon Compound G treatment. 
Figure 6.15 Inhibition of the p300 bromodomain by Compound G reduces PSA protein levels in LNCaP 
and LAPC4 cell lines.  (A & B) Immunoblot analyses of AR and PSA levels in LNCaP and LPC4 cells treated 
with 10 nM DHT and/or the indicated doses of Compound G for 24 hours. -tubulin served as a loading 
control. Data represents N=3. 
 
Together, these data indicate that Compound G-mediated inhibition of the p300 bromodomain 
results in down-regulated AR transcription function across numerous AR backgrounds by 
potentially interrupting chromatin loading of the enzyme which could perturb histone acetylation 
levels required for AR activity.  
 
The HAT domain of p300 for histone and AR acetylation is a requisite for receptor activity 
(Gaughan et al., 2002). Moreover, the recent evidence that the Bromodomain and HAT domain 
are intrinsically linked indicates that compound G may also be inactivating the HAT activity. 
Hence, in this study, we next sought to assess the effect of an additional, but related reagent that 
163 
 
targets p300 HAT activity, C646, on receptor function in different backgrounds of AR signalling in 
models of CRPC.  
Figure 6.16 p300 HAT inhibitor C646 suppresses DHT- and enzalutamide-induced AR-target gene 
expression in parental and ARF876L LNCaP cell line derivatives, respectively.  (A and C). QRT-PCR analysis 
of selected AR-target genes upon 24 hours of either 10 nM DHT or 10 µM enzalutamide -/+ 10 µM C464 
treatment. Data represents N=2 ± SEM.  B and D. Western blot analysis of protein lysates from LNCaP and 
LNCaP-ARF876L cells treated as in (A) and (C) using antibodies specific for AR, PSA and -tubulin. 
 
Inhibition of the p300 HAT domain was carried out by conducting 24 hours C464 treatment in 
both LNCaP and LNCaP-ARF876L cells. As shown in Figure 6.16 A and C, attenuating p300-HAT 
activity via C646 treatment decreased expression of AR-regulated genes PSA, KLK2, TMPRSS2 and 
FKBP5 in the context of DHT- and enzalutamide-activation in LNCaP and LNCaP-ARF876L, 
respectively. Consistently, down-regulation of AR function was also observed at the protein level 
as demonstrated by reduced PSA levels in response to C464 treatment (Figure 6.16 B and D). 
Together these results demonstrate that diminished p300 HAT activity using c646 reduced DHT-
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/enzalutamide-stimulated AR activity in both LNCaP and LNCaP-ARF876L, respectively.  Of note, 
during these experiments, we noticed that 24 hours C646 treatment resulted in marked elevation 
of cell death in both cell lines which suggests inhibiting p300 activity is cytotoxic and is consistent 
with reports indicating the histone acetyltransferase activity of p300 promotes PC cell survival 
and growth (Gao et al., 2013). To examine this further, we next assessed whether suppression of 
p300 HAT function impacts on the cell cycle of PC cells using flow cytometry. 
 
Figure 6.17 The p300/CBP HAT inhibitor C646 induces apoptosis in LNCaP and LNCaP-ARF876L cells.  (A & 
B) LNCaP and LNCaPARF876L cells were treated with and without 10 µM enzalutamide and 1 µM C646 as 
indicated. Cell cycle distribution was measured after staining the cells with propidium iodide (PI), and 
percentage of positive cells was determined by flow cytometry. Data represents N=2 ± SEM. 
 
To test whether inhibition of p300 HAT activity has anti-proliferative effects in LNCaP and LNCaP-
ARF876L, we measured cell cycle distribution after staining cells with propidium iodide (PI) to 
analyse the percentage of cells in particular cell cycle phases based on DNA content (Figure 6.17). 
Compared to DMSO, DHT and enzalutamide treatment, as expected, increased abundance of 
cells in the S- and G2/M- phases of the cell cycle at the expense of G0/G1 phase in the LNCaP and 
LNCaP-ARF876L cell lines, respectively. Quantification of the sub-G1 peak in both cell lines post 
treatment with C646 revealed that downregulation of p300-HAT by C646 leads to an increase of 
apoptosis in both cell lines. Hence, we concluded that the histone acetyltransferase activity of 
165 
 
p300 is essential for the survival of LNCaP parental and are also important for ARF876L-driven cell 
growth (Figure 6.17 B) in the presence of enzalutamide. 
 
6.4 Discussion 
The selective0outgrowth of AR mutations in advance androgen-insensitive PC has been 
demonstrated as a mechanism whereby the AR mutants are capable of remaining active 
following anti-androgen0treatment (Brooke and Bevan 2009, Steinkamp et al., 2009). 
The0regulatory mechanisms by which AR mutations provide a growth advantage, includes the 
mediation of co-regulator protein recruitment and enhanced ligand promiscuity which0results in 
AR transactivation by non-conventional ligands. In the previous chapter, we established and have 
validated an AR replacement PC model in the LNCaP0cell line to study the enzalutamide-activated 
ARF876L mutant. Following0endogenous ART877A knockdown0via a pre-designed siRNA targeted to 
the 3’- UTR of AR mRNA, the0role and function0of ARF876L could be assessed.0Overall,0it was 
found0that treatment with enzalutamide resulted in enrichment of ARF876L to AR-target genes, 
leading to0increased expression  of the AR target genes PSA and KLK2, as well as0increasing cell 
proliferation. Therefore, given the capability0of the model to recapitulate the antagonist to 
agonist switch observed in clinical samples, we sought0to understand the enzalutamide-induced 
transcriptional program0mediated via ARF876L that could indicate potential0distinctions between 
the0transcriptomes of CRPC-relevant AR isoforms and0hence provide important information0on 
subsequent0patient-tailored0treatments and biomarker identification. Hence, in this chapter, 
we conducted global gene analysis in our validated ARF876L- driven LNCaP cell line using an 
Illumina Bead CHIP-based micro-array. In all, we found that enzalutamide-activated ARF876L is able 
to drive a similar androgenic signature to that of endogenous receptor, while possessing the 
ability to preferentially upregulate a distinct subset of target genes outside of those controlled 
DHT-activated ARwt, including a GR-like gene signature. 
Preclinical and clinical studies have conclusively demonstrated that in most cases, acquired 
resistance to traditional ADT is the consequence of reactivation of the AR pathway. Critically, 
166 
 
increased selection pressure conferred by second-generation anti-androgens, such as 
enzalutamide, can also result in alternative resistant mechanisms, including GR-mediated AR 
mimicry (Balbas et al., 2013; Joseph et al., 2013; Korpal et al., 2013a). The functional involvement 
of the GR in resistance to enzalutamide was firstly documented by Arora et al. (2013) and Isikbay 
et al. (2014). Enhanced GR expression was observed in enzalutamide-resistant tumours in vivo 
and in tumour biopsies from enzalutamide-treated PC patients (Arora et al., 2013). By exploring 
AR and GR-signalling regulation in an LNCaP cell lines model derived from enzalutamide-resistant 
xenografts in vitro using ChIP-seq and gene expression profiling for both steroid receptors, it was 
reported that AR and GR have a distinct but significantly overlapping cistrome and transcriptome. 
In this chapter, by conducing global gene expression analysis in our validated ARF876L- driven 
LNCaP cell line, which is a model of the common mutation identified in enzalutamide-resistance, 
we discovered a 60% overlap between the ARF876L gene-set and the GR-regulated gene-set 
identified from the enzalutamide xenografts (Aurora et al., 2013). Specifically, we found 73 
ARF876L-upregulated genes overlapped with a 122 gene-containing GR signature (representing GR-
bound AR-target genes) and 43 matches to a GR-activated gene-set totalling 67 genes. In 
contrast, a DHT-upregulated gene-set in the LNCaP-Laz cell line derivative (O’Neill et al., 2015) 
was found to have considerably less overlap with the GR-bound and GR-activated signatures; 
with 36/122 and 15/67, respectively. Transcriptomic analysis of enzalutamide-activated ARF876L 
in LNCaP-ARF876L cells demonstrates considerable overlap with GR-targeted subset of AR targets, 
including STK39, MPK1, which has been previously found up-regulated via GR activation in 
glucocorticoid-dependent breast epithelial cells growth (Isikbay et al., 2014).  
Hence, we here propose two theories accounting for our observations in LNCaP-ARF876L: 
a. Up-regulation of endogenous GR enhances GR-target gene expression (due to 
compensation or selective pressure from acute enzalutamide exposure). 
b. Upon enzalutamide binding, ARF876L actively binds to GR-target gene response elements 
and mimics GR-signalling activation.  
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To investigate these proposed theories, LNCaP parental and LAPC4 cell lines were chosen to 
provide comparisons against the LNCaP-ARF876L derivative. By firstly examining GR expression in 
LNCaP-ARF876L, we found there was no increase in endogenous GR mRNA and protein expression 
(Figure 6.3) in response to enzalutamide. Furthermore, expression of the GR was undetectable 
by western analysis in both LNCaP and LNCaP-ARF876L derivatives suggesting that up-regulation of 
GR in the LNCaP-ARF876L cell line is an unlikely explanation for GR-target gene expression in 
response to the anti-androgen.  
As GR activation can be negatively regulated by direct AR binding to a cis-regulatory element 
upstream of the GR gene (Xie et al., 2015), we next went on to interrogate GR and AR function in 
LAPC4 cells. Indeed, we found that AR activation reduces GR expression in LAPC4 cells, while GR 
depletion up-regulates AR protein levels (Figure 6.4). This phenomenon was further supported 
by detecting occupancy of AR at GR cis-regulatory elements upon DHT stimulation. Importantly, 
we showed that in the LNCaP-ARF876L cell line, ectopic ARF876L is also recruited to the GR gene 
enhancer in the presences of enzalutamide which may help to maintain low GR levels in this cell 
line (Figure 6.5).  
 
Moreover, it was found that enzalutamide- and DHT-induced GR-target gene expression in the 
LNCaP-ARF876L cell line was largely distinct to parental LNCaP and LAPC4 cells supporting the 
concept that ARF876L has an altered target gene-set to that of endogenous AR T877A in LNCaP 
cells and wild-type AR in LAPC4 cells (Figure 6.6). In the presence of enzalutamide, over half of 
the tested genes increased in LNCaP-ARF876L cells whilst not in LNCaP. A smaller number of genes 
were elevated in LAPC4 in response to enzalutamide, including MPK1. We suspected that 
enzalutamide-induced elevation of genes in LAPC4 may be driven through activation of 
endogenous GR as a consequence of derepression of GR expression in response to AR 
inactivation. This notion was confirmed by knockdown of GR in LAPC4 which blocked 
enzalutamide-induction of MPK1 expression (Figure 6.7). It therefore seems that the second of 
the two predicted models may provide a more valid description of the observed elevated GR 
signature in the LNCaP-ARF876L cell line. 
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To further strengthen our comparative observations, functional clustering was performed using 
the Database for Annotation, Visualization and Integrated Discovery (DAVID) on enzalutamide-
induced core gene list. By applying Functional clustering using Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) pathway analysis (Appendix 6E), genes induced by enzalutamide in LNCaP-
ARF876L were mostly associated with metabolic pathways, protein trafficking, pathways in cancer, 
steroid and protein biosynthesis, focal adhesion, fatty acid metabolism and cell division. 
Furthermore, cluster comment function type analysis of ARF876L up-regulated genes (Appendix 
6F) revealed only 4.9% of genes are kinase-related signalling molecules; with only one kinase, 
SGK1 which is directly related to serum glucocorticoid regulation. More importantly, cells were 
not chronically treated with enzalutamide long-term, in fact no longer than 24 hours, prior to 
microarray analysis, hence generation of GR ligands by glucocorticoid synthesis-related enzymes 
and SGK1 would be an unlikely reason why GR-target genes are elevated in our LNCaP-ARF876L 
derivative. Moreover, expression of GR is undetectable in the LNCaP parental and ARF876L-
expressing derivative, even upon enzalutamide treatment indicating that although ligands may 
be generated, no GR will be available to drive gene expression in our model.  
The controversial roles of GR had been reported in several studies and no consensus had been 
drawn on whether GR acts as a driver or a facilitator for development of CRPC. By showing a 
substantial overlap in transcriptome, (Arora et al., 2013) proposed that GR is able to take over 
AR function. As a consequence, stimulation of GR activity can rescue cells from enzalutamide-
induced cell death. However, this is not in agreement with a later study by (Xie et al., 2015), which 
proposes that GR function is not positively correlated with aggressive phenotypes of prostate 
tumours. They also suggest that GR signalling is unable to replace AR in driving tumour 
progression in all prostate cancers, even though two steroid receptors share the ability to 
upregulate overlapping transcriptional targets. This is of interest, particularly given that not all 
enzalutamide-resistant LNCaP xenografts are GR positive or have GR overexpressed. Due to the 
complexity of GR function in PC and heterogeneity of CRPC progression, selective growth of cell 
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subpopulations that have elevated expression of AR mutants (such ARF876L) may be just one of 
many contributors for ultimate ADT resistance.   
 
For these reasons, we here propose an interesting observation that both ARF876L mutant activity 
and GR activation upon enzalutamide therapy are more likely driving a similar transcriptional 
gene-set which enables cellular survival and pro-proliferation rather than a genuinely distinct set 
of ‘ARF876L only ‘or ‘GR only’ target genes. It will be of interest to explore whether just one or a 
small number of downstream targets are responsible for resistance and also whether 
enzalutamide-driven ARF876L would activate transcription at the vast majority of the “GR unique” 
binding sites. We postulate that variables such as chromatin context, co-factors and other 
signalling events may be important. 
 
Recently, several studies described the BET-subfamily of bromodomain proteins, including BRD4, 
as a promising epigenetic target for the blockade of oncogenic drivers in pre-clinical models of 
CRPC. JQ1, a newly developed selective small molecule inhibitor that is designed to interfere with 
the function of bromodomain 1 of the BET family by preventing interaction with acetylated-lysine 
residues; principally on target histones H3 and H4 (Filippakopoulos et al., 2010). By competitively 
binding of the acetyl lysine recognition pocket of BRD4, JQ1 has demonstrated the down-
regulation effects of AR-driven oncogenic effects in vitro and in vivo models of advanced prostate 
cancer (Lochrin et al., 2014), although how efficacious it is against distinct mutational 
backgrounds of the AR remains ill-defined. Hence, JQ1 was applied in the LNCaP-ARF876L model to 
test whether inhibiting the BET protein family is a potentially efficacious method for attenuating 
the function of ARF876L in a model of enzalutamide resistance.   
 
JQ1 inhibits BRD4-AR interaction in DHT-stimulated LNCaP cells and removes RNA polymerase II 
from AR-target genes leading to down-regulation of gene transcription and subsequent 
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diminished AR signalling (Asangani et al., 2014). Similar to endogenous AR in LNCaP cells, analysis 
of ARF876L activity in response to varying concentrations of JQ1 showed down-regulation of DHT- 
and enzalutamide-induced expression of AR target genes PSA, KLK2 and TMPRSS2 (Figure 6.11). 
This corresponds with immunoblot analyses of PSA protein in LNCaP-ARF876L cells upon 
enzalutamide exposure which displays a dose-dependent decrease in PSA expression in response 
to JQ1 treatment (Figure 6.9). Phenotypically, interfering with the function of BET family 
members using JQ-1 in androgen-responsive PC cell lines (VCaP, LNCaP, and CWR22Rv1) induced 
dose-dependent cell cycle arrest (Lochrin et al., 2014). Consistent with these reports, in response 
to 48 hour treatment of JQ1, LNCaP-ARF876L cells exhibited anti-proliferative effects on 
enzalutamide-driven cell growth (Figure 6.10).  
 
Although the function of BRD4 has been widely implicated in the regulation of gene expression 
in various malignancies (Filippakopoulos et al., 2010), BRD4 inhibition displays selective 
regulation of gene expression in prostate cells. Consistent with this, in LNCaP-ARF876L cells, 
enzalutamide activated AR target gene expression in response to JQ-1 was varied with PSA and 
KLK2 being downregulated, while expression of FKBP5 and SGK1 were unchanged (Figure 6.11), 
suggesting regulation at these latter loci may be BET family-independent. This finding may be due 
to the involvement of other protein factors or cis-regulatory elements targeted by AR, but not 
bound by BET family members. Critically, there are other bromodomain proteins expressed in 
CRPC, including the HAT protein p300, which has been suggested to play a part in aberrant AR-
signalling in CRPC. Therefore, to extend and further explore applicability of our PC model, another 
bromodomain-targeting agent selective for p300 was applied to the LNCaP-ARF876L cell line to 
compare sensitivity to other PC cell lines. In addition to Compound G, a characterized HAT 
domain inhibitor of p300 was applied to the same cell line models to address if the enzalutamide-
activated ARF876L-driven cell line was sensitive to this other therapeutic agent.   
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By applying the two agents designed to individually target the bromodomain and HAT domain of 
p300, both Compound G and C646 down-regulated AR activity in LNCaP parental cells as 
indicated by reduced AR-target gene expression (Figure 6.14). In LNCaP-ARF876L derivative cells, 
DHT- and enzalutamide-activated gene expression was reduced in response to both compounds 
(Figure 6.16), including FKBP5 and SGK1.  
 
p300/CBP proteins are versatile transcriptional co-activators that can participate in gene 
regulation to control different physiological processes, including cell growth, proliferation and 
differentiation; all of which are important for cancer development. In fact, p300/CBP is an 
important cell cycle regulator (Moran, 1993) and is involved in controlling survival and invasion 
of prostate cancer cells (Santer et al., 2011). The induction of apoptosis in our prostate cancer 
cells model was confirmed by the use of C646 in our cell line (Figure 6.17). How effective these 
compounds and clinically-relevant derivatives will be in patients remains to be addressed, but 
our model has at least indicated that CRPC patients expressing ARF876L may be sensitive to agents 
within these drug classes.  
Interestingly, in our early stages of validating the role of ARF876L as a GR mimic, we noticed that 
the GR antagonist, mifepristone, possesses agonistic properties for AR stimulation. Compared to 
DMSO, 24 hours mifepristone treatment significantly induced AR-regulated gene expression 
(Figure 6.8). This is consistent with observations reported previously (Song et al., 2004) that 
mifepristone has a high binding affinity for AR and can function as an AR agonist. Mifepristone 
has also been shown to facilitate recruitment of p300 to cis-regulation of AR-target genes (Kang 
et al., 2004). Consistent with this, in our stable LNCaP-ARF876L cell line, we demonstrated that 
enzalutamide can drive ARF876L and p300/CBP co-enriching at GR/AR regulatory elements (Figure 
6.13). Mifepristone is currently used for CRPC patients in combination with ATD in a Phase II 
clinical trial (Phase II, NCT01867710, https://clinicaltrials.gov/). The mechanism of this antagonist 
in the background of ARF876L-driven enzalutamide-resistance, however, has not been established. 
Thus, it is vital to have clinically-relevant model depicting the mechanism of mifepristone 
combined with enzalutamide in the background of CRPC expressing the F876L mutant. We here 
172 
 
for the first time shown that mifepristone can drive ARF876L transcriptional activity and co-
recruitment with p300 to cis-regulatory elements in AR-target genes. Importantly, the inhibitor 
of the p300 bromodomain can attenuate the co-association of both factors from binding regions 
(Figure 6.13). 
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 Summary of key points and final conclusions 
In the clinic, the majority of patients that will receive next-generation anti-androgens are those 
with advanced PC. The development of these agents has been a positive step to towards 
improving patient healthcare, but their effectiveness is limited to approximately 50% of 
individuals and resistance to these agents remains a major issue. Critically, given that specific AR 
mutations are selected for during the first round of anti-androgen therapy, such as bicalutamide, 
it is of major clinical relevance to determine whether next-generation anti-androgens, such as 
enzalutamide, have efficacy in the background of pre-existing AR mutations.  
 
We are keen to implement next-generation precise genome editing using the CRISPR/Cas9 
method to to generate a PC model that endogenously expressed the clinically-relevant 
enzalutamide-activated ARF876L mutant which is urgently required for improving our 
understanding of the function of this aberrant receptor and to provide better models for drug 
development purposes. Hence, in Chapter 4, we firstly designed and verified sgRNA/Cas9 ‘on-
target activity’ of a specific CRISPR reagent at AR exon 8 in the LNCaP and CWR22Rv1 PC cell lines. 
Importantly, we optimized a systemic high throughput screening approach to enable detection 
of ‘knock-in’ mutants that did provide some evidence of precise editing in pooled cell 
populations, but these were never clonally expanded due to technical difficulties. Clearly, 
compared to the considerable ease of applying Cas9 for gene knock-out studies, relatively little 
is known about how to design a gRNA to make the desired precise gene-editing event more 
efficient. Multiple factors determine the success of any given CRISPR experiment, including the 
quantity of Cas9 proteins and guide RNA, chromatin accessibility of the targeting loci, and cellular 
response to CRISPR-induced DNA lesions. Most of these issues are beyond experimental controls. 
Of note, most of those factors remains little known when our project started. Although some of 
the developments enabling more efficient knock-in editing while project were progressing, such 
as using a double cut HDR donor (Zhang et al., 2017a), phosphorothioate linkages at oligo ends 
(Prykhozhij et al., 2018), additional studies with will be required to better understand locus-
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dependent differences in the efficiencies of HDR and Indel mutation induction in our experiment 
setting.  
 
With low level of CRISPR delivery efficiency and HDR frequency in both cell lines, it is likely that a 
larger number of colonies will need to be screened in order to create a clonal ARF876L–expressing 
cell line derivative. Given the time-schedule for this was outside of the parameters of the 
studentship, particularly with respect to fully validating the cell line once generated, an 
alternative strategy was utilised to generate a lesser, but still reasonably-physiological model 
system in the background of LNCaP cells that would also permit the interrogation of ARF876L 
function. To determine the impact of first- and second-generation antiandrogens enzalutamide 
on AR mutant transcriptional activity, we firstly employed a Luciferase reporter-based assay in 
AR negative PC3 cells to assess the anti-androgens ability to inhibit the ligand-induced 
transactivity of ARF876L, which is essential for the receptor function. Initially, we found that neither 
bicalutamide nor enzalutamide induced the AR-wildtype transactivity when administered alone 
and both inhibited the DHT-induced AR activity. Importantly, enzalutamide exhibited agonist-like 
properties on ARF876L when administered alone. In addition, we have demonstrated that 
bicalutamide effectively blocked  ARF876L transcriptional activity, suggesting the applicability and 
potential use in patients harbouring this mutation.  
 
Given the previous finding, we next developed an AR rescue/replacement LNCaP PC model that 
allows the stable expression of a0lentiviral delivered FLAG-tagged AR0mutant, whilst 
concurrently depleting endogenous AR0using a custom 3’UTR targeting siRNA. We confirmed 
that the 3’UTR targeted siRNA did not affect the expression of integrated ARF876L. Furthermore, 
we demonstrated that in response to enzalutamide, ARF876L was recruited to the promoters of 
AR-target genes and initiated active transcription, which resulted in increased cell proliferation. 
Overall, in Chapter 5, it was demonstrated that the cell line was a suitable model for defining the 
function of AR F876L and the resultant phenotype of the cells in response to enzalutamide. 
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To explore the effect of ARF876L further, a microarray was performed in Chapter 6 to investigate 
the enzalutamide-induced transcriptional program. Overall, it was determined that the 
enzalutamide/ ARF876L program was similar to that of the endogenous AR-induced program, 
although a select number of previously identified androgen-regulated genes were expressed at 
high levels in response to enzalutamide, including: TIPARP, FKBP5, NDRG1 and EAF2. Expression 
analysis of these genes across a panel of reported PC models identified a high overlap between 
the ARF876L gene-set and the GR-regulated gene-set identified from enzalutamide-resistant 
xenografts. Whilst it is understood that further target validation is required, given the initial 
remarkable parity between our generated LNCaP model and the patient derived xenograft, our 
work has shown that the ARF876L mutant drives a distinct transcriptional programme to the 
endogenous AR in LNCaP cells and may mimic GR activity. In addition, based on the findings 
presented here, screening of patients CTCs for AR mutation may help to provide relevant data 
elevating the issue of dosing patients with mifepristone. 
 
 
Simply replacing a single direct AR-targeted inhibitor with another may provide temporary 
benefit for CRPC patients.  It is, however, inevitable that resistance will ensue via reactivation of 
AR function in most cases; AR mutation(s) being a likely candidate for anti-AR drug resistance. 
Importantly, consistent with other mechanisms related to anti-androgen resistance, 
development of enzalutamide resistance seems to be very heterogeneous. Hence, identification 
of novel targets will likely lead to therapies which are not solely limited to AR inhibition. To that 
end, in chapter 6, we focused on targeting co-regulators of AR, and here provides evidence for 
considering BET-protein family inhibition as a rational therapeutic approach inactivating ARF876L-
mediated transcriptional signalling in enzalutamide-resistant disease.  
 
In summary, our well-defined LNCaP_ARF876L cell line model has provided a comprehensive 
transcriptomics data-set to provide an insight into how an enzalutamide-activated AR mutant can 
drive a distinct gene-set in advanced prostate cancer. Certainly, employing ChIP-seq in the LNCaP-
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ARF876L cell line would help increase the understanding of the ectopic AR in this model. Moreover, 
by more thoroughly investigating AR mutant regulated-transcriptomic alterations, we may 
potentially identify ARF876L-specific biomarkers and additional targets for therapy that are driven 
by this AR isoform. 
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 Appendix  
8.1  Appendix 4A  
Appendix 4A- RFLP analysis HDR-mediated designed ssODN insertion within desired regions. 
RFLP results from selected 10 clones derived from 22Rv1 cell following co-delivery 
Cas9/sgRNA196. Primers used to amplify the genomic DNA were indicated in 4.2.2. (A) Lane 1: 
marker; P-parental cell line (non-editing cell line), lane 2–10: PCR amplicon digestion with Sall. 
Lane11: parental cell line digested with Xbal using as positive control for PCR amplification. (B) 
Indigestion PCR amplicon for parental cells and all selected cell colonies.  (C) Positive control for 
Sall enzyme.  Appendix data. Donor oligo sequence. 
 
8.2  Appendix 4B  
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Appendix 4B- (A) the subsequent Surveyor assay failed to detect any heteroduplexes in 22Rv1 
and LNCaP upon delivery sgRNA196 and repair templates. (B) The successful detection of Cas9-
medicated DSB at AR exon 8 upon co-delivery Cas9/sgRNA196 and repair template prior subject 
for Sanger sequencing.  
 
8.3  Appendix 4C 
1.AR ex8 wt (5' to 3'):  
ggctagcagaggccacctccttgtcaaccctgtttttctccctcttattgttccctacagattgcgagagagctgCatcagttcActtt
tgacctgctaatcaagtcacacatggtgagcgtCgactttccggaaatgatggcagagatcatctctgtgcaagtgcccaagatcc
tttctgggaaagtcaagcccatcta 
2.AR ex8 F876L:  
ggctagcagaggccacctccttgtcaaccctgtttttctccctcttattgttccctacagattgcgagagagctgCatcagCtcActt
ttgacctgctaatcaagtcacacatggtgagcgtCgactttccggaaatgatggcagagatcatctctgtgcaagtgcccaagatc
ctttctgggaaagtcaagcccatcta 
 
8.4 Appendix 5A 
Appendix 5A - The gene expression of AR targets in LNCaP parental cells (A) and selected colonies 
(B,D,E and F). (C) FLAG_tag expression in LNCaP and all initially selected viral transduced colonies. 
Clone 3 (c3) were closed for all rest study in this report.  
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8.5 Appendix 5B 
Appendix 5B – Chromatin loading of ARF876L at enhancer (A) and promoter (B) region of PSA cis-
regulatory regions upon DHT and enzalutamide treatment.  
 
8.6 Appendix 6A  
SYMBOL fold change (≥ 1.5folds) 
RASD1 32.46582806 
ORM1 31.65248495 
TIPARP 25.59354801 
SPRYD5 20.65925549 
FKBP5 20.10147541 
ORM2 17.03976723 
LOC399939 13.86534555 
SLC2A3 13.38139968 
NDRG1 12.28636673 
LOC729384 11.30273904 
SLC16A6 10.82408116 
TRIM48 10.49241718 
SLC45A3 9.880929334 
NCAPD3 9.385527129 
RHOU 9.374939536 
LOC340970 9.10688876 
LOC100134006 9.096026021 
FAM105A 8.983921488 
A                                                        B
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ACSL3 8.908421843 
EAF2 7.681759891 
TMPRSS2 7.44336537 
ERRFI1 7.217316686 
TARP 6.984953005 
SGK 6.972653696 
WIPI1 6.962302447 
LPAR3 6.893218905 
UGT2B28 6.730692167 
PAK1IP1 6.613388834 
KLK3 6.099503364 
VPS33B 5.955763303 
CENPN 5.947516105 
HPGD 5.936439549 
NKX3-1 5.587800399 
ANKRD37 5.528673935 
SGK1 5.505949329 
TUBA3D 5.059784869 
SRD5A1 4.983396745 
TSKU 4.886237079 
EDG7 4.823899124 
LOC440040 4.767708218 
FADS1 4.731175911 
LOC729768 4.725744329 
LRIG1 4.649793033 
RDH10 4.508463937 
ELL2 4.463940043 
DNAJB9 4.399720477 
ANKRD22 4.309204184 
LOC100131392 4.223836585 
RHOB 4.213336184 
F2RL1 4.211141187 
SIPA1L2 4.192121174 
FOXD4 4.108924893 
SORD 4.050709572 
ELOVL5 4.033916579 
SMS 3.98329017 
LOC642590 3.969213448 
AMACR 3.867712519 
RALY 3.863060745 
HMOX1 3.862319555 
VCL 3.840420439 
PYGB 3.826745543 
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STK39 3.782399211 
LOC646347 3.764439984 
STEAP4 3.718466125 
ACAD8 3.686247301 
PDLIM1 3.671298689 
ALDH1A3 3.594320959 
DBI 3.525431262 
TBC1D8 3.516385962 
PHACTR2 3.5066654 
PTPRM 3.50325931 
FRAG1 3.501796213 
LIMS1 3.440357419 
CAP2 3.404908107 
KCTD3 3.398465006 
ERN1 3.395797715 
LGMN 3.386133462 
UGT2B11 3.351075752 
KLK4 3.284496196 
SHRM 3.277356388 
SCAP 3.260152064 
ST3GAL4 3.247992893 
PACSIN2 3.196350167 
HIPK2 3.190454522 
FOXD4L1 3.184907688 
MYL12A 3.182856348 
TPM1 3.164654049 
LOC642362 3.155550679 
PMEPA1 3.146617665 
CNN2 3.142556971 
TSC22D1 3.137491887 
FKSG30 3.133345354 
THYN1 3.106696823 
PIAS1 3.096587627 
TUBA3E 3.088542112 
TRIM53 3.084855509 
SLC35F2 3.060698575 
HIF1A 3.060081611 
ZNF812 3.045436356 
KRT8 3.040270899 
HOMER2 3.038311293 
MYADM 2.966163837 
ATAD2 2.963673145 
MTMR9 2.958865361 
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GLUD1 2.943545165 
NSDHL 2.940164372 
NFIB 2.937618509 
LIFR 2.932838635 
CBWD5 2.925040559 
MOCOS 2.921729127 
H2AFZ 2.910795265 
LOC647954 2.898392741 
C1orf116 2.886012837 
LOC644743 2.852031693 
KIAA0194 2.83507588 
KCNMA1 2.832942493 
SLC41A1 2.827354599 
PGM3 2.825839889 
NAMPT 2.810599778 
ABHD2 2.795477366 
LOC440459 2.777761391 
SERP1 2.769681073 
POTEF 2.758219279 
CBWD3 2.751112122 
GFM1 2.73877868 
KLF6 2.733690491 
LAMC1 2.725328194 
ZNF189 2.722072029 
TNFRSF10B 2.717939597 
LOC402221 2.702347777 
CREB3L2 2.699229607 
GADD45G 2.685094198 
LOC653111 2.658926379 
PARVA 2.651284924 
HMGCS1 2.649659721 
UGDH 2.645803126 
NAT1 2.644594813 
ANG 2.638283615 
KRT19 2.6283823 
VIL2 2.616765401 
BBX 2.607356779 
LOC728969 2.605812658 
FASN 2.599757089 
LRRFIP2 2.587589528 
PRAGMIN 2.581434548 
HK2 2.577106952 
CCDC15 2.569746418 
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SC4MOL 2.559341356 
LOC646567 2.547481705 
SSR1 2.53727477 
LOC647349 2.535491691 
NPPC 2.519697685 
LRRC16 2.496981275 
MAP7D1 2.489500299 
ZBTB16 2.488926793 
IDI1 2.487718815 
FADS2 2.478673091 
C17orf79 2.475135214 
NFKBIA 2.473432776 
EDEM1 2.471113211 
LDLR 2.462980576 
ACTB 2.462160188 
AZGP1 2.452833383 
HERPUD1 2.446288161 
MCCC2 2.434240278 
MERTK 2.429433064 
NAGK 2.42906471 
SELS 2.426632446 
DHCR7 2.424469326 
ENDOD1 2.413780913 
ZDHHC9 2.397573962 
PRC1 2.396918242 
WWC1 2.395785063 
SNAI2 2.393726355 
C1orf149 2.389370615 
RAB4A 2.384175367 
LOC100129882 2.383720194 
EZR 2.375416022 
BCL6 2.375047452 
PGC 2.345985212 
COL6A1 2.333083099 
SRP19 2.330254897 
LOC646723 2.328153725 
LOC493869 2.325143903 
FAM105B 2.324747111 
MPHOSPH9 2.320839267 
ABCC4 2.319165832 
C1orf122 2.318250788 
UCK2 2.316726538 
AGR2 2.316017525 
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KDELR2 2.31374666 
LOC653381 2.300296829 
RPRC1 2.292216013 
PWP1 2.289978299 
YTHDF1 2.289022625 
PDIA5 2.277916326 
CRISPLD2 2.277819733 
AP3S1 2.270819614 
LOC113386 2.270237948 
MRFAP1 2.266724877 
MLPH 2.263374898 
PPP2CB 2.258021588 
LOC654244 2.255940772 
CAPZB 2.25501421 
ANXA2 2.252064241 
GMPPA 2.24937978 
ARMET 2.245590027 
GPT2 2.241922264 
ATP1A1 2.239320929 
GADD45B 2.238913666 
MPZL1 2.237002043 
SEC11C 2.23650265 
GARS 2.233264817 
LCOR 2.232379181 
KRT18P13 2.223474353 
GBE1 2.220273376 
FNDC3B 2.219833092 
MAFB 2.218027905 
MFSD6 2.217549273 
C2orf30 2.217269796 
LOC728877 2.215770224 
PRDX6 2.203510986 
C12orf44 2.201428886 
LPIN1 2.191742494 
CPEB4 2.183868374 
HIST1H4H 2.173751814 
SLC38A2 2.172315556 
CBLL1 2.167006146 
TMED9 2.16403229 
ATF3 2.154943341 
HBEGF 2.144639177 
SHROOM3 2.141437032 
CEBPD 2.138652089 
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CDR2 2.135769054 
GTF3C6 2.134688606 
OSTC 2.134573361 
UBE2G1 2.133032672 
PEX10 2.131248453 
PECI 2.126402285 
CYR61 2.125761003 
GFPT1 2.125489348 
IMPDH1 2.124971069 
RGPD8 2.124694565 
SEC24D 2.116674573 
AXUD1 2.115678381 
LONRF1 2.113700547 
LOC93622 2.113490465 
UCHL3 2.111974321 
LOC644563 2.106435322 
CLPTM1L 2.102722768 
PNMA1 2.102087265 
C9orf119 2.101977837 
TXNDC17 2.094314639 
MAP7 2.092166145 
DHCR24 2.092156247 
KLHL36 2.086965685 
C19orf10 2.078191767 
FOXO3 2.077987398 
FLJ40504 2.063774215 
TMEM87A 2.06294443 
CUL4B 2.061298262 
LONP2 2.059472874 
RER1 2.059208853 
PRKAB2 2.058514338 
AKAP13 2.057913607 
STT3A 2.057697273 
LOC401074 2.05013027 
ACSL1 2.049681932 
F5 2.048284245 
C19orf48 2.048023204 
LOC149501 2.047177726 
CLDN12 2.046184358 
VPS37B 2.039366383 
HIBCH 2.037141009 
AHNAK 2.032773459 
SURF4 2.032674602 
186 
 
UAP1 2.03018191 
ITPR3 2.027270159 
GUCY1A3 2.027115186 
NANS 2.026225135 
CITED2 2.024619742 
FRAP1 2.024273503 
KLF15 2.021629996 
SEC23B 2.019249598 
PACS1 2.017537057 
PTRH2 2.017431843 
PSMA6 2.015545159 
TUFT1 2.013911581 
VLDLR 2.012818997 
LOC643431 2.01144139 
LIN7B 2.011227865 
NEDD4L 2.010775392 
TMED7 2.010098485 
FBXO31 2.009444435 
WDR1 2.002637359 
UOX 2.002078449 
EGLN2 2.001417872 
MALT1 1.996578616 
MEAF6 1.995188154 
ITGAV 1.995143635 
KRT73 1.994452798 
FICD 1.994303247 
ZFP36 1.994174443 
SLC1A5 1.993989837 
C2orf76 1.992724862 
TSPAN13 1.988576411 
ABCD3 1.987898446 
SASH1 1.986529952 
C16orf61 1.986144148 
LRRC8A 1.985833192 
PSMD8 1.98183067 
TARS 1.980271423 
GMPPB 1.980227601 
CLIC4 1.978663068 
SLC38A1 1.977550646 
GDPD5 1.976578329 
STAU2 1.97446557 
LOC100130308 1.971868198 
SAT1 1.96982955 
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CALU 1.967480183 
BRP44 1.965840056 
ZNF259 1.965638428 
LOC100129781 1.962124822 
TCEAL3 1.961302834 
EVL 1.960045559 
ODC1 1.959320993 
PNLIP 1.95786479 
ZNF350 1.955910648 
CRELD2 1.955676421 
ZNF613 1.953920497 
BNIP3 1.952429917 
TNFRSF12A 1.949645566 
EFNA1 1.94945211 
C17orf48 1.948420243 
C3orf58 1.947821281 
MIPEP 1.946838936 
SPCS3 1.946826592 
EEF2K 1.945355418 
CMAS 1.943654946 
TRIB3 1.941624474 
INSIG1 1.939747764 
H1F0 1.939666031 
MED31 1.939292705 
MGC18216 1.938386122 
ZFHX3 1.936312733 
ADM2 1.936306876 
HERC3 1.933047784 
B4GALT1 1.932575764 
NDFIP2 1.932050538 
TMED5 1.926640238 
SLC33A1 1.925967957 
KIF22 1.923782033 
SRPRB 1.920763647 
MTP18 1.9200851 
TXNDC11 1.918727961 
KCNG1 1.917912852 
TNFAIP8 1.917236341 
SPDEF 1.917216021 
SNX25 1.910905603 
THOC5 1.908845615 
SHC1 1.906267323 
TUBA3C 1.904317611 
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NUDT18 1.904285966 
SCNN1G 1.901936023 
C5orf13 1.898286003 
RBM24 1.895587096 
ZNF419 1.893210049 
SLC29A2 1.888803155 
MPHOSPH10 1.88420219 
ACADM 1.883365714 
SSR2 1.875810377 
RAB32 1.873272813 
DAPK3 1.872048515 
SEC61B 1.869508162 
STARD3NL 1.869488741 
MINPP1 1.867694694 
C12orf65 1.863441701 
FKBP11 1.860155172 
S100P 1.85826271 
TBX15 1.854798983 
DNM2 1.853059692 
NDEL1 1.852933994 
LOC648682 1.850174384 
STAMBPL1 1.847746345 
ALDH3A2 1.845468816 
KRT8P9 1.84180985 
HMGCR 1.840503978 
CDC25A 1.838125138 
PQLC1 1.833604787 
C1orf21 1.83300722 
ITGB1 1.832863837 
TMEM49 1.83178751 
CYTSA 1.830262493 
GSTT2 1.828247686 
DNAJC10 1.827231485 
SPINK5L3 1.827204611 
C9orf152 1.826754859 
CA12 1.82518767 
WDR41 1.824150069 
ARRDC1 1.820228892 
PDLIM5 1.819930368 
PPP1CB 1.819579925 
C9orf91 1.818783343 
CHKA 1.818236657 
SC5DL 1.81796958 
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GRPEL2 1.817939624 
SSR3 1.817749482 
DYNLL2 1.817301754 
MICAL1 1.814785778 
DNASE2B 1.81328698 
PCTP 1.811752531 
ATOH8 1.811527603 
SND1 1.811363346 
MCFD2 1.808806404 
ELOVL1 1.807137831 
CROT 1.806421965 
PPFIBP2 1.804856662 
FBXW2 1.804034067 
B2M 1.801820063 
FAM103A1 1.800593916 
ACAT2 1.800539097 
MORF4L2 1.800394318 
WDYHV1 1.799659362 
GALNTL4 1.798674738 
GOT1 1.797768825 
SLC6A3 1.79715782 
ARF4 1.79272829 
GNMT 1.791935906 
RRBP1 1.791540703 
ZC3H12A 1.791360065 
CEBPG 1.790910785 
GOT2 1.789644048 
AMY1C 1.78881432 
LOC652864 1.787719505 
SOCS2 1.783642948 
RBM45 1.781839916 
CHAC1 1.780514704 
CAMSAP1L1 1.779136516 
RBM47 1.778855147 
LYPLAL1 1.777539759 
GHR 1.77750969 
C17orf58 1.775565626 
CBX4 1.772016782 
RHBDF1 1.769723229 
SLC2A1 1.762661335 
FLJ20254 1.760912622 
DEFB32 1.760371239 
ZCCHC9 1.76032898 
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RNASE4 1.760217731 
MORC4 1.758047982 
CCDC53 1.757877617 
PTGER4 1.753047878 
PPAPDC1B 1.752889895 
LOC642282 1.745974336 
GSTT2B 1.745591717 
TMEM2 1.745433203 
P704P 1.745374105 
MGAT1 1.745039611 
MAP1LC3B 1.745005969 
IMPA2 1.744267344 
FAM129B 1.74415981 
LOC641825 1.743536329 
NSUN2 1.743152214 
LOX 1.742734775 
LOC653566 1.74068496 
FERMT2 1.737133381 
MAP2K1IP1 1.736874478 
KIAA1191 1.733863893 
USO1 1.733063958 
LOC652481 1.732868441 
ENTPD6 1.73129225 
LOC650518 1.731003563 
HADH 1.730117378 
GOLGA5 1.729105387 
SH3GLB1 1.72835671 
UBE2E1 1.727734696 
RIT1 1.723576572 
RPN1 1.719510638 
ASIP 1.718949524 
C7orf68 1.717541775 
SLC25A13 1.716542132 
SLC7A1 1.716219743 
LOC151579 1.716201468 
IFRD1 1.714768402 
FDFT1 1.714418052 
TACC2 1.714281842 
EML1 1.713849427 
RRAS 1.713305419 
ZYX 1.712680231 
RALBP1 1.712064976 
PPAPDC2 1.711774474 
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TRAPPC2P1 1.711607243 
DNM1L 1.709437061 
CAP1 1.709013405 
PASK 1.707112358 
ARCN1 1.707086205 
CSK 1.705875083 
PDXDC1 1.704406795 
TSC22D3 1.704138229 
LOC641785 1.702549473 
PFKFB4 1.70115465 
GALK2 1.699664029 
RNF14 1.698860411 
SYVN1 1.698692976 
C15orf23 1.698202466 
DUSP14 1.697525625 
CTBS 1.696306591 
LOC644936 1.696252323 
NRAS 1.695686655 
CDK2AP2 1.694717506 
DERL2 1.69446009 
P4HA1 1.692654054 
SEC13 1.691064627 
PDIA6 1.6874959 
ITPRIP 1.684278069 
CKAP2 1.68363619 
FAM107B 1.682128525 
MED8 1.680310352 
ANXA5 1.679094155 
CEBPB 1.678703091 
ELF1 1.677543961 
TIMM23 1.677347139 
EPDR1 1.675502562 
TMED10 1.675152366 
CLDN7 1.6717393 
KIAA2010 1.670196366 
CYP2U1 1.668438996 
C4orf34 1.66813073 
EPHX2 1.66810156 
DDIT3 1.666646198 
RHOG 1.665390052 
GCAT 1.665030841 
LOC399965 1.664463011 
TSPYL2 1.663112455 
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LOC344595 1.661003988 
DKFZp761P0423 1.660679588 
FBXO38 1.660254307 
NT5DC3 1.660138353 
FLJ43663 1.659609039 
ZNF518B 1.658681766 
SPSB1 1.657164332 
TMEM214 1.656350093 
COPB1 1.656289555 
M160 1.654035255 
SAR1B 1.652821941 
LRRC16A 1.652652245 
ANKFY1 1.650094396 
AK3L1 1.649947211 
CCDC6 1.649760978 
KRT10 1.649270913 
SH3TC1 1.648932291 
RAB11FIP1 1.647926802 
PEA15 1.647803514 
GPR89C 1.647774224 
PMM2 1.647553243 
SQLE 1.646826768 
NAPA 1.646027099 
EFNA5 1.645151328 
JUN 1.643178555 
STK40 1.642871051 
ATP6V1G1 1.642636484 
LSS 1.641935513 
ERO1L 1.637729899 
TMED2 1.637449771 
ALDH6A1 1.636193685 
EBP 1.635518744 
FAM18B 1.634086698 
OCRL 1.633231979 
PRSS27 1.632473059 
SEPP1 1.632154086 
MGAT2 1.631030873 
SLC30A7 1.630890803 
SF3B5 1.630760194 
EDEM2 1.630669878 
PPA1 1.626648901 
HEG1 1.62653223 
COPG 1.625853671 
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TCEB1 1.625230196 
LOC730820 1.624635878 
TBC1D16 1.624447529 
FAM174B 1.622968741 
PXMP3 1.622881252 
FBXO8 1.621077946 
GNG5 1.619707447 
PIK3C2A 1.618344839 
DISP1 1.617945546 
DNAJB14 1.617046866 
SLC35F5 1.616170794 
PDE9A 1.615053761 
SLC5A6 1.614689245 
UBFD1 1.614458221 
PAWR 1.614337077 
LDHA 1.611843578 
PPP1R13B 1.611374352 
RAB5A 1.611314744 
C6orf81 1.610162733 
PAPSS1 1.609386522 
WDFY2 1.608674247 
LOC643031 1.607580066 
WDR13 1.606466103 
ZFAND3 1.605295356 
C6orf85 1.604560521 
ABCC1 1.603872768 
RAB2A 1.603433961 
NRIP1 1.603273478 
KLK2 1.603228123 
LOC100132418 1.601875501 
SLC10A7 1.601823364 
CTNNAL1 1.601797919 
TRPM4 1.599758006 
ARID5B 1.599544108 
PACSIN1 1.599027883 
PICALM 1.598961989 
NBPF20 1.598829417 
NOSTRIN 1.598431404 
COPS3 1.597763177 
IFNGR1 1.597664221 
ATP6V0E1 1.595372012 
USP10 1.593116428 
SLC30A5 1.592197961 
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ABHD3 1.592068237 
BCL7C 1.589118772 
SLC10A3 1.589015553 
CLGN 1.587773932 
RHOBTB2 1.586121854 
BMPR1A 1.585242799 
MTHFD2 1.584793603 
SELK 1.584395762 
SEC24C 1.584125134 
PTPN21 1.583989127 
SEC16A 1.583124385 
PRDX4 1.582175492 
PRRC1 1.580955208 
LOC100130886 1.579374115 
NUDT9 1.578761622 
EHF 1.578555204 
LOC649260 1.578474227 
NBPF10 1.57843718 
FZD5 1.577607093 
TRIM24 1.577101273 
TMEM41B 1.574451181 
TMEFF2 1.574415085 
CHPT1 1.573571396 
DNAL1 1.572387866 
ELOF1 1.57161304 
LOC399748 1.569253232 
LPP 1.568606018 
ERGIC2 1.56767875 
SPCS2 1.567606167 
ZDHHC6 1.567294922 
YARS 1.566481739 
BIRC2 1.56613927 
ARL1 1.565580191 
HK1 1.565222408 
SBDSP 1.564288048 
PREB 1.56404063 
IQUB 1.563310881 
MIR635 1.561752828 
BET1 1.561586532 
ZBTB10 1.561318763 
PRKCA 1.560915989 
PDHX 1.560567837 
UFM1 1.559763902 
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FAM69A 1.559141841 
LOC652773 1.558823242 
FGFRL1 1.558390342 
LOC728037 1.5577326 
FAM119B 1.554433688 
CHFR 1.553518295 
STC2 1.553380573 
PDIA4 1.552778312 
GPR89A 1.552396241 
LOC100128163 1.549165449 
LOC730432 1.548603905 
GK5 1.547987288 
TUBB2A 1.547041775 
ANAPC13 1.5459588 
FAM104A 1.544880601 
ZFAND2A 1.543453039 
RRAS2 1.542078519 
CBWD7 1.541368374 
RASSF1 1.540939862 
LOC145853 1.540644126 
VPS26B 1.540527493 
COMMD1 1.538524443 
GDF15 1.538052962 
PTPLB 1.537970875 
P4HB 1.537563908 
SDF2L1 1.537041606 
MARS 1.535462522 
SLC20A1 1.535440619 
EXOSC3 1.535333927 
C7orf54 1.534877331 
BAG3 1.533405685 
GOLGA2 1.531500077 
GBF1 1.531106428 
TMEM8 1.530708829 
KLF9 1.530696607 
MRPS23 1.53020676 
INTS6 1.529586994 
DUSP1 1.529084383 
ORMDL1 1.529054747 
ACBD3 1.529008587 
GLB1L2 1.528438466 
SEC61G 1.527930007 
POP1 1.526942959 
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DIAPH1 1.526939965 
MON2 1.526785008 
NCKAP1 1.526624096 
COPB2 1.523830595 
C17orf91 1.523817858 
DIS3L2 1.522464454 
FGD4 1.52242998 
ADAM9 1.522163507 
TMEM14C 1.521658008 
LOC730167 1.52092052 
MYH9 1.520508508 
CHN2 1.519163426 
ACAA1 1.519109858 
SLC31A2 1.518781327 
STX5 1.518386245 
SLC35A2 1.517892321 
ATF4 1.517788136 
FLJ31568 1.516933936 
IMPAD1 1.51511742 
IGF2R 1.51502983 
USP38 1.51455947 
SEC31A 1.514052344 
TAX1BP3 1.513716385 
MYCBP2 1.513581963 
KCTD9 1.512432401 
NBL1 1.510922402 
OSBPL5 1.510737336 
MSX1 1.509650815 
PLOD1 1.509484916 
AFF4 1.509232759 
XPNPEP1 1.509187996 
MBOAT2 1.508600708 
TRIM5 1.508364126 
GADD45A 1.50754233 
WBP5 1.506682955 
RAB3B 1.506417088 
SSX2IP 1.50616148 
LOC644935 1.506084664 
HSP90B1 1.505929466 
C20orf24 1.505409903 
NPC1 1.503981294 
WNT7B 1.503969785 
GPR89B 1.503488974 
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C13orf1 1.501725579 
SRP54 1.500995482 
LOC731486 1.500101981 
 
Appendix 6A - The core list of 615 genes () found to upregulated following treatment with 10uM 
enzalutamide for 24 hours in LNCaP ARF876L cells. 
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siT877A+enz 
(fold changes) 
siF876L+enz 
(fold changes) 
ALDH1A3 3.594320959 2.376500018 
C1orf116 2.886012837 2.150905059 
FAM174B 1.622968741 1.56364679 
HOMER2 3.038311293 2.649381728 
KLK3 6.099503364 3.834462507 
ABCC4 2.319165832 2.381164319 
C19orf48 2.048023204 2.028027081 
CENPN 5.947516105 5.121067906 
CROT 1.806421965 1.480716744 
EAF2 7.681759891 3.029340986 
KLK2 1.603228123 1.651087138 
PASK 1.707112358 1.61097063 
TMEFF2 1.574415085 1.527812302 
TMPRSS2 7.44336537 3.282562937 
TUBA3D 5.059784869 2.652713618 
NKX3-1 5.587800399 3.692878564 
PDIA5 2.277916326 1.666417604 
PMEPA1 3.146617665 3.907311686 
SLC45A3 9.880929334 6.903293974 
TUBB2A 1.547041775 0.947094024 
CLGN 1.587773932 1.315333876 
DHCR24 2.092156247 1.725000581 
ELOVL5 4.033916579 4.394735082 
KLK4 3.284496196 2.285950381 
MCCC2 2.434240278 1.944002581 
ZBTB16 2.488926793 1.751295224 
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Appendix 6B- a gene list of overlap between the enzalutamide-activated ARF876L expression 
signatures lists and DHT-activated LNCaP-LacZ. And the comparison of enzalutamide-induced 
gene fold changes of siT877A and siF876L arm.  
 
 
8.8 Appendix 6C  
GR signature 
probe sets (Dex 
1.6 fold 
FDR<.05) 
match to 
enz-
F876L(1.5 
fold 
FDR<.05) 
no match 
to DHT-
laz_ARwt  
(1.5 fold 
FDR<.05) 
siT877A+enz 
(fold changes) 
siF876L+enz 
(fold changes) 
ABCC4  
 
  
ABHD2  No match 2.795477366 1.612163415 
ACTA2 No match  No match   
ALDH1A3  
 3.594320959 2.376500018 
ATAD2  
 2.963673145 2.175572197 
AZGP1  
 2.452833383 1.97820866 
BAMBI No match  No match   
BCL6  No match 2.375047452 1.643139556 
BRDT No match  No match   
C11ORF92 No match  No match   
C17ORF48  
 1.948420243 1.269424632 
C19ORF48  
 2.048023204 2.028027081 
C1ORF116  
 2.886012837 2.150905059 
C1ORF149  No match 2.389370615 1.71292531 
C6ORF85  No match 1.604560521 1.090379649 
C7ORF63 No match  No match   
C9ORF152  
 1.826754859 2.156986874 
CEBPD  No match 2.138652089 1.493144838 
CGNL1 No match  No match   
CHKA  No match 1.818236657 1.404357595 
CRY2 No match  No match   
DBC1 No match  No match   
DDIT4 No match  No match   
EDG7  
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EEF2K  No match 1.945355418 1.344368441 
ELL2  
 
  
EMP1 No match  No match   
ERRFI1  
 7.217316686 3.254157864 
F2RL1  No match 4.211141187 3.079385851 
FAM105A  
 8.983921488 6.036153385 
FAM49A No match  No match   
FKBP5  
 20.10147541 11.39907853 
FLJ22795 No match  
No match 
  
FOXO3  
No match 
2.077987398 1.343095774 
GADD45B  
No match 
2.238913666 1.019830169 
GHR  No match 1.77750969 0.960160949 
HERC5 No match     
HMOX2 No match     
HOMER2  
 3.038311293 2.649381728 
HS.99472 No match  No match   
HSD11B2 No match  No match   
IL6R No match  No match   
KBTBD11 No match  No match   
KIAA0040 No match  No match   
KIAA1370 No match  No match   
KLF15  
 2.021629996 1.311756743 
KLF5 No match  No match   
KLF9  No match 1.530696607 1.185931738 
KLK3  
 6.099503364 3.834462507 
KLK4  
 3.284496196 2.285950381 
KRT80 No match  No match   
LIN7B  
 2.011227865 1.367801001 
LINCR No match  No match   
LOC100008588 No match  No match   
LOC100130886  No match 1.579374115 1.39026578 
LOC100131392  No match 4.223836585 2.817441331 
LOC100134006  No match 9.096026021 4.929293362 
LOC340970  No match 9.10688876 4.808123208 
LOC346702 No match  No match   
LOC399939  No match 13.86534555 7.790827452 
LOC440040  No match 4.767708218 2.932487647 
LOC648509 No match  No match   
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LOC728431 No match  No match   
LPAR3  
 6.893218905 3.437555432 
MAP3K8 No match  No match   
MBOAT2  No match 1.508600708 1.519063365 
MEAF6  No match 1.995188154 1.277304872 
MGC87042 No match  No match   
MT1X No match     
MTMR9  
 2.958865361 2.141094855 
NDRG1  
 12.28636673 5.270634396 
NEDD4L  
 2.010775392 1.356407928 
NFKBIA  
 2.473432776 1.636273891 
NKX3-1  
 5.587800399 3.692878564 
NPC1  No match 1.503981294 0.931045497 
NRP1 No match  No match   
PDE9A  No match   
PER1 No match  No match   
PGC  No match 2.345985212 1.614127152 
PGLYRP2 No match  No match   
PHLDA1 No match  No match   
PLGLB1 No match  No match   
PNLIP  No match 1.95786479 1.173735831 
PPAP2A No match     
PRKCD No match  No match   
PRR15L No match  No match   
PSD No match  No match   
RASD1  No match 32.46582806 6.442470968 
RDH10  No match 4.508463937 1.50798382 
RGS2 No match  No match   
RHOB  No match 4.213336184 1.525477243 
RHOU  
 9.374939536 3.643489707 
RND3 No match  No match   
RNF160 No match  No match   
S100P  No match 1.85826271 1.691618798 
SCNN1G  No match 1.901936023 1.112999245 
SGK  No match 6.972653696 7.420656532 
SGK1  No match 5.505949329 5.999534669 
SIPA1L2  No match 4.192121174 1.899412025 
SLC25A18 No match  No match   
SLC26A3 No match  No match   
SLC2A12 No match     
SLC31A2  No match 1.518781327 1.271786442 
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SLC45A3  
 9.880929334 6.903293974 
SNAI2  No match 2.393726355 1.597350433 
SPRYD5  No match 20.65925549 10.88982128 
SPSB1  No match 1.657164332 1.18322278 
STEAP2 No match  No match   
STK39  
 3.782399211 3.053446473 
SYTL2 No match  No match   
TBC1D8  No match 3.516385962 2.245574986 
TMPRSS2  
 7.44336537 3.282562937 
TRIM48  
 10.49241718 5.886973648 
TSKU  No match 4.886237079 2.921684327 
TUBA3C  No match 1.904317611 1.252270758 
TUBA3D  
 5.059784869 2.652713618 
TUBA3E  No match 3.088542112 1.795690803 
ZBTB16  
 2.488926793 1.751295224 
ZC3H12A  No match 1.791360065 1.047353712 
ZMIZ1 No match  No match   
ZNF812  
 3.045436356 1.373163328 
 
Appendix 6C – A list of the 73 enz-induced genes found upregulated in siUTR2 transfected LNCaP-
ARF876L cells relative vehicle control (n=3). Highlighted in green are the genes which were also 
found upregulated in GR signature probe sets >1.6 fold by Dex (FDR<.05). And the comparison of 
enzalutamide-induced gene fold changes of siT877A and siF876L arm.  
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GR selective 
gene set 
no match to 
enz-
F876L(1.5 
fold FDR<.05) 
no match to 
DHT-laz_ARwt  
(1.5 fold 
FDR<.05) 
siT877A+enz 
(fold 
changes) 
siF876L+enz 
(fold 
changes) 
ABHD2  No match 2.795477 1.612163 
ACTA2 No match  No match   
ATAD2  
 2.963673 2.175572 
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AZGP1  
 2.452833 1.978209 
BCL6  No match 2.375047 1.64314 
C1ORF149  No match 2.389371 1.712925 
C6ORF85  No match 1.604561 1.09038 
C7ORF63 No match  No match   
C9ORF152  
 1.826755 2.156987 
CEBPD  No match 2.138652 1.493145 
CGNL1 No match  No match   
CHKA  No match 1.818237 1.404358 
CRY2 No match  No match   
DBC1 No match  No match   
DDIT4 No match  No match   
EEF2K  No match 1.945355 1.344368 
EMP1 No match  No match   
ERRFI1  
 7.217317 3.254158 
FKBP5  
 20.10148 11.39908 
FLJ22795 No match  No match   
FOXO3  No match 2.077987 1.343096 
GADD45B  No match 2.238914 1.01983 
GHR  No match 1.77751 0.960161 
HERC5 No match     
HOMER2  
 3.03831129 2.64938173 
HSD11B2 No match  No match   
KBTBD11 No match  No match   
KIAA0040 No match  No match   
KLF15  
 2.02163 1.311757 
KLF9  No match 1.530697 1.185932 
KRT80 No match  No match   
LIN7B  
 2.011228 1.367801 
LOC100130886  No match 1.579374 1.390266 
LOC100131392  No match 4.223837 2.817441 
LOC100134006  No match 9.096026 4.929293 
LOC340970  No match 9.106889 4.808123 
LOC399939  No match 13.86535 7.790827 
LOC440040  No match 4.767708 2.932488 
LOC728431 No match  No match   
MEAF6  No match 1.995188 1.277305 
MT1X No match     
NPC1  No match 1.503981 0.931045 
NRP1 No match  No match   
PGC  No match 2.345985 1.614127 
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PGLYRP2 No match  No match   
PHLDA1 No match  No match   
PNLIP  No match 1.957865 1.173736 
PPAP2A No match     
PRKCD No match  No match   
PRR15L No match  No match   
RGS2 No match  No match   
RHOB  No match 4.213336 1.525477 
S100P  No match 1.858263 1.691619 
SCNN1G  No match 1.901936 1.112999 
SGK  No match 6.972654 7.420657 
SGK1  No match 5.505949 5.999535 
SLC25A18 No match  No match   
SPRYD5  No match 20.65926 10.88982 
SPSB1  No match 1.657164 1.183223 
STK39  
 3.782399 3.053446 
TRIM48  
 10.49242 5.886974 
TUBA3C  No match 1.904318 1.252271 
TUBA3D  
 5.05978487 2.65271362 
TUBA3E  No match 3.088542 1.795691 
ZBTB16  
 2.48892679 1.75129522 
ZMIZ1 No match  No match   
ZNF812  No match 3.045436 1.373163 
 
Appendix 6D – A list of the 43 enzalutamide-regulated genes found to be upregulated in siUTR2 
transfected LNCaP-ARF876L cells following treatment for 24 hours relative vehicle control (n=3). 
Highlighted in green are the genes which were also found upregulated in GR selective gene set. 
And the comparison of enzalutamide-induced gene fold changes of siT877A and siF876L arm.  
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8.10 Appendix 6E  
Appendix 6E-Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis summary of 
enz-ARF876L driven core gene list. 
8.11 Appendix 6F  
 
Appendix 6F-Functional Annotation Chart of enz-ARF876L driven core gene list. 
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